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SUMMARY 
The aminocoumarin antibiotics novobiocin (nov) and clorobiocin (clo) are potent 
inhibitors of bacterial DNA gyrase produced by different Streptomyces strains. Since 
they are closely related in structure, and their biosynthetic gene clusters have been 
cloned and sequenced, they represent interesting starting compounds for the 
development of new antibacterial agents by genetic engineering. However, the 
functional analysis of biosynthetic genes and the availability of genetic tools for 
manipulation of producer strains are pre-requisites for such approaches. 
Clorobiocin is more potent than novobiocin. It differs from the latter, clinically 
approved drug in the substitution pattern at C-8´ of the aminocoumarin moiety, 
carrying a chlorine atom instead of a methyl group , and in the presence of a 5-
methylpyrrole-2-carboxyl moiety instead of a carbamoyl group at 3´´-OH of the 
deoxysugar unit. One aim of this thesis was the production of hybrid antibiotics, 
combining structural features of these two compounds. By gene inactivation, clo-hal 
was identified as the gene of the halogenase responsible for the introduction of the 
chlorine atom of clorobiocin. Inactivation of cloZ did not affect clorobiocin formation, 
showing that this ORF is not involved in the halogenation, nor is it essential for 
clorobiocin biosynthesis under the present culture conditions. 
Expression of the methyltransferase gene novO in the clo-hal- mutant of the 
clorobiocin producer S. roseochromogenes led to the very efficient formation of a 
clorobiocin analog with –CH3 instead of –Cl at C-8´ (= novclobiocin 102). However, 
earlier attempts to generate a hybrid antibiotic with a chlorine atom at C-8´ and a 
carbamoyl group at 3´´-OH (novclobiocin 114) by conventional gene inactivation/gene 
expression experiments in the novobiocin producer S. spheroides had remained 
unsuccessful (Pojer and Heide, unpublished results), due to difficulties in the genetic 
manipulation of this natural producer. In order to circumvent this problem, the entire 
biosynthetic gene cluster of novobiocin was now expressed in S. coelicolor and S. 
lividans which are well characterized and easy to manipulate. By the same method, 
the clorobiocin cluster was also heterologously expressed. For this purpose, cosmids 
containing the integration functions  of the Streptomyces phage fC31 and the 
complete novobiocin or clorobiocin clusters were introduced into the heterologous 
 SUMMARY  2
hosts, respectively.  S. coelicolor M512 derivatives produced at least five times more 
of the respective antibiotic than S. lividans TK24 and further investigations were 
carried out using the former strain as host.  
Inactivation of the methyltransferase gene novO could be rapidly achieved in the 
cosmid by l-Red-mediated recombination in Escherichia coli. Subsequent integration 
of the novO- cosmid into the S. coelicolor genome, followed by co-expression of clo-
hal, readily allowed the production of the desired hybrid antibiotic novclobiocin 114. 
BhaA, responsible for 3-chlorination of the b-hydroxy-tyrosyl moieties of the 
glycopeptide antibiotic balhimycin, was unable to replace Clo-hal, suggesting that the 
two halogenases have different substrate specificities. 
Furthermore, shortening of the cosmids’ inserts proved, for the first time, that the 
DNA regions from cloE to gyrBR and from novE to gyrBR contain all genes which are 
essential for clorobiocin and novobiocin production, respectively. 
Comparison of the antibacterial activity of clorobiocin and novobiocin analogues with 
–Cl, –H or –CH3 a t  C-8´ showed that substitution with either –CH3 or –Cl was 
important for biological activity.  –CH3 or –Cl led to comparable activity, whereas –H 
led to a strong loss in activity. 
Moreover, functional proof for the role of NovG as a positive regulator of novobiocin 
biosynthesis was provided by genetic and biochemical approaches. Using the 
method described above, DnovG mutants were created. These DnovG mutants 
produced only 2% of the novobiocin amount formed by the S. coelicolor strains 
carrying the intact novobiocin cluster. The production could be restored by 
introducing an intact copy of novG into the mutant. The introduction of novG on a 
multicopy plasmid into the strain carrying the intact novobiocin cluster led to almost 
three-fold overproduction of the antibiotic, suggesting that novobiocin biosynthesis is 
limited by the availability of NovG protein. Furthermore, purified N-terminal His6 
tagged NovG showed specific DNA-binding activity for the novG-novH and for the 
cloG-cloY intergenic regions of the novobiocin and clorobiocin biosynthetic gene 
cluster, respectively. By comparing the DNA sequences of the fragments binding 
NovG, conserved inverted repeats were found in both fragments, similar to those 
identified as the binding sites for StrR, the well-studied pathway-specific 
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transcriptional activator of streptomycin biosynthesis. The consensus sequence for 
the StrR and the putative NovG binding sites is GTTCRACTG(N)11CRGTYGAAC. 
Therefore, NovG and StrR apparently belong to the same family of DNA-binding 
regulatory proteins. 
Furthermore, inactivation of novE by gene replacement using PCR targeting proved 
that novE does not have an essential catalytic role in novobiocin biosynthesis, since 
some novobiocin was still produced by the mutants. This gene is likely to have a 
regulatory function, as a 25–fold drop in productivity was observed in the mutants. 
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ZUSAMMENFASSUNG 
Die Aminocoumarinantibiotika Novobiocin (nov) und Clorobiocin (clo) sind potente 
Gyrasehemmer, die von unterschiedlichen Streptomyces-Stämmen gebildet werden. 
Da sie strukturell eng verwandt sind und ihre Biosynthese-Gencluster kloniert und 
sequenziert wurden, stellen sie interessante  Ausgangssubstanzen für die 
Entwicklung neuer Wirkstoffe durch genetische Manipulation der Produzenten dar. 
Der Funktionsnachweis der Gene und die genetische Manipulierbarkeit von 
Produzenten sind jedoch Voraussetzungen dafür . 
Clorobiocin ist potenter als Novobiocin. Es unterscheidet sich vom klinisch 
untersuchten Novobiocin durch die Substitution an C-8´ des Aminocoumarinrings (–
Cl anstatt von –CH3), und durch Anwesenheit einer 5-Methylpyrrol-2-carboxyl Einheit 
anstatt einer Carbamoylgruppe an 3´´-OH des Desoxyzuckers. Ein Ziel dieser 
Dissertation war die Produktion von Hybrid-Antibiotika, in denen die strukturellen 
Eigenschaften dieser beiden Stoffe kombiniert sind. Durch Geninaktivierung wurde 
clo-hal als das Gen nachgewiesen, das für die Halogenierung von Clorobiocin 
zuständig ist. Die Inaktivierung von cloZ hatte keinen Einfluss auf die Clorobiocin-
Produktion. Dies zeigte, dass cloZ nicht an der Halogenierung beteiligt ist sowie nicht 
essentiell für die Clorobiocin-Biosynthese unter den verwendeten Kulturbedingungen 
ist. 
Die Expression des Methyltransferasegens novO in der clo-hal- Mutante des 
Clorobiocinproduzenten S. roseochromogenes führte zur effi zienten Bildung eines 
Clorobiocin-Analogon mit –CH3 anstatt von –Cl an C-8´ (= novclobiocin 102). Jedoch 
waren frühere Versuche zur Herstellung des mit einem Chloratom an C-8´ und einer 
Carbamoylgruppe an 3´´-OH (= novclobiocin 114) versehenen Hybridantibiotikums im 
natürlichen Novobiocinproduzenten S. spheroides gescheitert (Pojer und Heide, 
unveröffentlichte Daten), weil dieser Stamm genetisch nur schwer zu manipulieren ist. 
Um dieses Problem zu umgehen, wurde das komplette Novobiocin-Cluster nun in 
den gut bekannten und einfach zu manipulierenden S. coelicolor und S. lividans 
Stämmen exprimiert. In gleicher Weise wurde auch das Clorobiocin-Cluster heterolog 
exprimiert. Dafür wurden Cosmide, die die Integrationsfunktionen des Streptomyces-
Phagen fC31 sowie das komplette Novobiocin- bzw. Clorobiocin-Cluster beinhalten, 
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jeweils in die heterologen Wirte eingebracht. S. coelicolor M512 Stämme 
produzierten mindestens fünfmal mehr des entsprechenden Antibiotikums als S. 
lividans TK24. Deshalb wurden die folgenden Untersuchungen in S. coelicolor M512 
durchgeführt.  
Die Inaktivierung von novO wurde im Cosmid mittels l-Red-vermittelter 
Rekombination in Escherichia coli erzielt. Anschließende Integration des novO- 
Cosmids in das S. coelicolor Genom und Expression von clo-hal (in einem 
replikativen Expressionsplasmid) erlaubten rasch die Produktion des gewünschten 
Hybrid-Antibiotikums Novclobiocin 114. Die Halogenase BhaA ist für die 3-
Chlorierung der b-Hydroxy-tyrosyl Einheiten des Glykopeptid-Antibiotikums 
Balhimycin verantwortlich. BhaA war nicht in der Lage, Clo-hal funktionell zu ersetzen. 
Dies spricht dafür, dass die zwei Halogenasen unterschiedliche Substratspezifität 
besitzen. 
Außerdem konnte durch die Verkürzung der Cosmid-Inserts zum ersten Mal 
nachgewiesen werden, dass die DNA-Regionen von cloE bis gyrBR bzw. von novE 
bis gyrBR alle für die Clorobiocin- bzw. Novobiocin-Produktion essentiellen Gene 
beinhalten. 
Der Vergleich der antibakteriellen Aktivität von Clorobiocin- und Novobiocin-Analoga 
mit –Cl, –H oder –CH3 an C-8´ zeigte, dass Substitution mit –CH3 bzw. –Cl in beiden 
Fällen wichtig für die biologische Aktivität war. Während –CH3 bzw. –Cl zu 
vergleichbarer Aktivität führten, verursachte –H einen starken Aktivitätsverlust. 
Zudem wurde mittels genetischer und biochemischer Methoden bewiesen, dass 
NovG ein positiver Regulator der Novobiocin-Biosynthese ist. S. coelicolor Stämme 
mit einem novG-defekten Novobiocincluster  wurden hergestellt. Diese DnovG 
Mutanten produzierten nur noch 2% Novobiocin im Vergleich zum Stamm mit dem 
intakten Cluster. Die Produktion konnte durch Expression einer intakten Kopie von 
novG wiederhergestellt werden. Die Einführung von novG in einem Multicopy-
Plasmid in den S. coelicolor Stamm mit dem intakten Novobiocin-Cluster führte zu 
fast dreifacher Überproduktion des Antibiotikums. Dies deutet darauf hin, dass die 
Novobiocin-Biosynthese durch die Verfügbarkeit von NovG-Protein begrenzt wird. 
Außerdem zeigte gereinigtes NovG-Protein mit einem N-terminalen His6-Tag 
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spezifische DNA-bindende Aktivität für die novG-novH bzw. cloG-cloY 
intergenetischen Regionen des Novobiocin- bzw. Clorobiocin-Clusters. Durch 
Vergleich der DNA-Sequenzen dieser Fragmente wurden konservierte  
palindromische Sequenzen in beiden Fragmenten gefunden. Diese palindromischen 
Sequenzen sind ähnlich zu den für StrR identifizierten Bindungsstellen im 
Streptomycin-Cluster. Die Consensus-Sequenz für die StrR- und für die putative 
NovG-Bindungsstelle ist GTTCRACTG(N)11CRGTYGAAC. Daher  gehören NovG 
und StrR wahrscheinlich zur gleichen Familie von DNA-bindenden, regulatorischen 
Proteinen. 
Außerdem bewies die Inaktivierung von novE mittels Genaustausch durch PCR-
Targeting, dass novE keine essentielle katalytische Funktion in der Novobiocin-
Biosynthese hat, da Novobiocin immer noch gebildet wird. Eine regulatorische Rolle  
kann für dieses Gen wegen der 25-fachen Produktivitätsverringerung in der Mutante 
vermutet werden. 
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I. INTRODUCTION 
I.1. The search for new antibiotics: an overview of genetic 
approaches 
Antibiotic resistance has developed to every class of antibiotics, both natural and 
synthetic, over the course of one year to more than a decade after the first clinical 
use (see Table I.1). For example, virtually all gram-positive infections were 
susceptible to penicillin in the 1940s, but in hospitals today, the vast majority of 
infections caused by important bacterial agents like Staphylococcus aureus are 
penicillin-resistant, and up to 50% are resistant to methicillin. Also vancomycin, the 
principal alternative treatment for methicillin-resistant infections, has been overcome 
by some of the most frequent infection agents in hospitals. Resistance, then, has 
proven not to be a matter of  “if”, but a matter of “when” (Palumbi, 2001; Walsh, 2003). 
Therefore, there is a constant need for the development of new antibacterial drugs in 
order to reduce the impact of resistance in antibacterial therapy, as emphasized by 
the World Health Organization (2001). 
TABLE I.1: Dates of deployment of representative antibiotics, and the 
evolution of resistance. (Source (Palumbi, 2001)) 
Antibiotic Year 
deployed 
Resistance 
observed 
Sulfonamides 1930s 1940s 
Penicillin 1943 1946 
Streptomycin 1943 1959 
Chloramphenicol 1947 1959 
Tetracycline 1948 1953 
Erythromycin 1952 1988 
Vancomycin 1956 1988 
Methicillin 1960 1961 
Ampicillin 1961 1973 
Cephalosporins 1960s late 1960s  
Natural products play a dominant role in the discovery of new drugs. This is 
particularly evident in the areas of cancer and infectious diseases, where 62% and 
78% of these drugs, respectively, were shown to be of natural origin, based on the 
numbers of new drugs approved by regulatory agencies (e.g., the United States Food 
and Drug Administration, FDA) from 1981 to 2002 (Newman et al., 2003). 
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Structural modifications of these natural products are often necessary for 
improvements in efficacy and pharmacokinetics. Optimization of drug leads can be 
achieved using modern organic chemistry. Yet, introduction of structural changes by 
chemical synthesis is not always easy, especially if the compound’s scaffold is very 
complex (Wohlleben and Pelzer, 2002). 
In 1985, Hopwood et al. (1985) reported for the first time the production of “hybrid” 
antibiotics by genetic engineering of Streptomyces strains, i.e. through the transfer of 
biosynthetic genes between strains producing different members of the same class of 
antibiotics in order to combine structural features of both compounds. 
In the meantime, different authors, e.g. (Kunnari et al., 2000; Madduri et al., 1998; 
Yanai et al., 2004; Zhao et al., 1999), have demonstrated that rational and directed 
generation of structurally modified antibiotics can be achieved by metabolic 
engineering of biosynthetic pathways, i.e. by the modification of specific biochemical 
reactions or the introduction of new ones using recombinant DNA technology 
(Stephanopoulos, 1999). 
Another approach to create new compounds, which has been applied especially for 
polyketides and nonribosomal peptides, is the so-called combinatorial biosynthesis, 
namely the shuffling of biosynthetic genes with related functions but different 
specificities via genetic engineering to create combinatorial libraries of novel natural 
product-like molecules (Cane et al., 1998; Khosla, 1998; McDaniel et al., 1999; 
Walsh, 2002). 
The last few years have shown that the manipulation of the genes which encode the 
enzymes in the biosynthetic pathways represents a promising alternative approach 
for redesign of antibiotic structures to create new activities and overcome bacterial 
resistance to existing drugs (Walsh, 2002). 
The functional analysis of biosynthetic genes is, however, a pre-requisite for such 
approaches. Moreover, a principal limitation is the challenge associated with 
developing suitable protocols for the genetic manipulation of natural producers. The 
expression of biosynthetic genes in heterologous hosts which are genetically more 
amenable can be used to circumvent this problem (Eppelmann et al., 2001; Sánchez 
et al., 2002; Tang et al., 2000). 
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I.2. Streptomyces – the largest antibiotic-producing genus 
Streptomycetes are among the most numerous and ubiquitous soil bacteria, where 
they play a central role in carbon recycling. Unusually for bacteria, streptomycetes 
exhibit complex multi-cellular development: a branching, filamentous vegetative 
growth gives rise to aerial hyphae bearing long chains of reproductive spores 
(Bentley et al., 2002; Kieser et al., 2000). 
They belong to the order Actinomycetales, which includes, besides a large number of 
antibiotic-producing species, also major pathogens like Mycobacterium tuberculosis, 
M. leprae and Corynebacterium diphtheriae (reviewed in (Embley and Stackebrandt, 
1994)). 
Streptomycetes produces over two thirds of the clinically useful antibiotics of natural 
origin (Kieser et al., 2000). The history of antibiotics derived from this genus begins 
with the discovery of streptothricin, in 1942. It was streptomycin, however, discovered 
two years later that triggered systematic screening of antibiotics from Streptomyces. 
Between 1955 and 1962, about 80% of the antibiotics discovered originated from 
actinomycetes, among which the major contributor was Streptomyces (Watve et al., 
2001). 
S. coelicolor A3(2) is genetically the best known representative of the genus. This 
strain is able to produce four known antibiotics, i.e. the tri-pyrroles prodiginines, the 
polyketide actinorhodin, the acidic lipopeptide calcium-dependent antibiotic (CDA) 
and the unusual exomethylene cyclopentanone methylenomycin. The biosynthetic 
gene clusters for the first three are found in the chromosome and for the latter, in 
plasmid SCP1. 
The complete genome sequence of strain M145, which is a prototrophic derivative of 
strain A3(2) lacking its two plasmids (SCP1, linear, 365 kb; and SCP2, circular, 31 kb) 
has been reported (Bentley et al., 2002). The single chromosome of 8.7 Mb is linear 
with a centrally located origin of replication and a G+C content of 72%. Interestingly, 
the distribution of different types of genes reveals a central core, comprising 
approximately half the chromosome and a pair of chromosome arms. Nearly all 
genes likely to be unconditionally essential are located in the core. Non-essential 
functions, such as secondary metabolites, lie in the arms (Bentley et al., 2002). 
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Comparison of the S. coelicolor genome with those of two pathogenic actinomycetes, 
Mycobacterium tuberculosis and Corynebacterium diphtheriae, indicated a conserved 
gene arrangement between the whole genomes of the pathogens and just the core of 
the S. coelicolor chromosome. This suggested descent of the core from a common 
actinomycete ancestor, with the arms being acquired subsequently by horizontal 
gene transfer (Bentley et al., 2002; Hopwood, 2003). 
The complete genome of S. avermitilis, which produces the anti-parasitic agent 
avermectin, has also been sequenced recently (Ikeda et al., 2003). Its genome (linear, 
9 Mb, G+C content of 70.7%) shows a similar division between core and arm regions 
and provides further support for the idea that the arms have a separate origin from 
the core and an adaptive function (Hopwood, 2003; Ikeda et al., 2003). 
In the context of biotechnology, the most interesting finding in the two Streptomyces 
genomes is the abundance of genes that would encode enzymes for secondary 
metabolism. Before the genome was sequenced, three antibiotics and a spore 
pigment were known to be encoded in the S. coelicolor chromosome, but the 
sequence revealed 24 clusters for secondary metabolites. For S. avermitilis, 30 such 
clusters, nearly all encoding different compounds in the two species, were described 
(Hopwood, 2003). 
Thus, there is increasing evidence that the full capacity for secondary metabolite 
production in soil microorganisms is not expressed under typical conditions used for 
antibiotic screening in the laboratory. Furthermore, only a small portion of microbes 
are culturable by present methods, indicating that a large number of pathways still 
awaits discovery in the actinomycetes. This lends encouraging support to use genetic 
approaches to antibiotic discovery, like heterologous expression of biosynthetic gene 
clusters in culturable and genetic manipulable strains and combinatorial biosynthesis 
or metabolic engineering as methods to increase the natural diversity (Hopwood, 
2003; Walsh, 2003). 
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I.3. Aminocoumarin antibiotics 
The aminocoumarin antibiotics novobiocin, clorobiocin (=chlorobiocin), and 
coumermycin A1 (Fig. I.1) are potent inhibitors of bacterial DNA gyrase produced by 
different Streptomyces strains (Lewis et al., 1996b; Maxwell, 1993; Maxwell, 1997). 
Novobiocin was first reported in the middle of 1950s (called then streptonivicin) 
(Hoeksema et al., 1955; Smith et al., 1956),  whereas coumermycin and clorobiocin 
were found between the 1960s and the 1970s (Kawaguchi et al., 1965; Ninet et al., 
1972). In the literature, two producers of novobiocin are described, i.e. S. spheroides 
NCIMB 11891 (Steffensky et al., 2000b) and S. niveus (Smith et al., 1956). However, 
Lanoot et al. (2002) have proposed that these two strains are synonyms of S. 
caeruleus LMG 19399T. Clorobiocin is produced by S. hygroscopicus, S. 
albocinerescens and S. roseochromogenes var. oscitans (Mancy et al., 1974; Ninet 
et al., 1972). Coumermycin A1 is obtained from several Streptomyces strains, i.e. S. 
rishiriensis, S. hazeliensis var. hazeliensis, S. spinichromogenes and S. 
spinicoumarensis (Berger and Batcho, 1978). So far, two further aminocoumarin 
antibiotics, simocyclinones of the D class (Schimana et al., 2000) and rubradirin 
(Sohng et al., 1997), have been discovered which are also produced by different 
Streptomyces strains. 
I.3.1.  Chemical structure 
The characteristic structural moiety of the aminocoumarin antibiotics is a 3-amino-
4,7-dihydroxycoumarin unit (= Ring B), which is attached to a deoxysugar (= Ring C) 
at position 7´, and to an acyl component at position 3´  (Fig. I.1). Novobiocin and 
clorobiocin carry the same acyl substituent, 3-dimethylallyl-4-hydroxybenzoyl moiety 
(= Ring A). In contrast, the acyl component in coumermycin A1 is a 3-methylpyrrole-
2,4-dicarboxylic acid. To both carboxyl groups, the same aminocoumarin-deoxysugar 
moiety is attached, making the molecule nearly, but not completely symmetrical in 
structure. The 3´ -´OH group of the deoxysugar is acylated, in novobiocin with a 
carbamoyl group, in the other two with a 5-methylpyrrole-2-carboxylic acid. 
Clorobiocin, as indicated by its name, carries a chlorine atom at position 8´ of the 
aminocoumarin unit, whereas novobiocin and coumermycin A1 show a methyl group 
at the corresponding positions. 
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Fig. I.1: Structure of the aminocoumarin antibiotics. 
The simocyclinones of the D class and rubradirin have in common with the “classical” 
aminocoumarins described above only the aminocoumarin ring, which is substituted 
at position 8 in simocyclinone D8 with a chlorine atom, just as in clorobiocin (Fig. I.1). 
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I.3.2.  Mechanism of action and clinical application 
The molecular basis of action of novobiocin, clorobiocin and coumermycin A1 has 
been examined by Maxwell (1993; 1999), by Lewis et al. (1996b) and more recently 
by Maxwell and Lawson (2003). These drugs are very potent inhibitors of bacterial 
DNA gyrase. Their equilibrium dissociation constants are in the 10 nM range, i.e. two 
orders of magnitude lower than those of modern fluorochinolones. Their affinity for 
gyrase is therefore considerably higher than that of fluorochinolones. 
Gyrase is a type II topoisomerase, which consists of two subunits, GyrA and GyrB, 
with the active enzyme being an A2B2 complex.  DNA topoisomerases (enzymes 
which control the topological state of DNA) are found in all cell types and are 
essential for cell viability, since they are implicated in DNA transcription and 
replication. Gyrase is found in all bacteria but not in eukaryotes and is therefore a 
good target for antibacterial agents. It has the unique ability to introduce negative 
supercoils into closed circular DNA, playing a role in the maintenance of the level of 
intracellular DNA supercoiling and removing supercoils that build up ahead of and 
behind transcription and replication complexes. The supercoiling reaction involves 
the wrapping of DNA around the A2B2 complex, cleavage of this DNA in both strands 
and passage of a segment of DNA through this double-stranded break. Resealing of 
the break results in the introduction of two negative supercoils. Catalytic supercoiling 
requires the hydrolysis of ATP to complete enzyme turnover. GyrA is involved in DNA 
breakage-resealing reactions (N-terminus) and DNA wrapping (C-terminus), whereas 
GyrB catalyses ATP hydrolysis (N-terminus, 43 kDa domain) and interacts with GyrA 
and DNA (C-terminus). 
Novobiocin, clorobiocin and coumermycin A1 are competitive inhibitors of the ATPase 
reaction catalysed by GyrB. In comparison, quinolones inhibit gyrase-catalysed 
supercoiling by disrupting the DNA breakage-reunion reaction on GyrA. X-ray 
crystallographic studies using the 24 kDa N-terminal subdomain of Escherichia coli 
GyrB showed that the complexes between novobiocin (Lewis et al., 1996a) or 
clorobiocin (Tsai et al., 1997) and the protein involve hydrophobic interactions and a 
network of hydrogen bonds. Key hydrogen bonds include those between Arg136 and 
the coumarin ring, Asp73 and the 3´´-acyl group on the deoxysugar, and Asn46 and 
the 2´´-hydroxyl group on the deoxysugar (Fig. I. 2). The drugs do not occupy the 
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same binding pocket as ATP, but the sites for the two ligands overlap: the 
deoxysugar moiety overlaps the binding site for the adenine ring of ATP. 
 
a b
 
Fig. I.2: Interaction between Escherichia coli GyrB and novobiocin (a) as well as between 
GyrB and clorobiocin (b), adapted from (Maxwell and Lawson, 2003). 
 
Coumermycin A1 has been shown to stabilize a dimmer form of the 43 kDa N-
terminal fragment of GyrB. This is consistent with the pseudo-dimeric structure of 
coumermycin (Fig. I.1) (Maxwell and Lawson, 2003). 
Analysis of aminocoumarin-resistant bacterial strains from several species has 
identified point mutations that map to the 24 kDa N-terminal subdomain of GyrB. The 
most prevalent of these are mutations of an arginine residue (Arg136 in E. coli GyrB). 
GyrB proteins that bear mutations at Arg136 show low supercoiling and ATPase 
activities. It is likely that other mutations in GyrB would also confer coumarin 
resistance but would lead to inactive protein, i.e. they would not be selected in a 
bacterial screen (Maxwell, 1999). 
Recently, Hardy and Cozzarelli (2003) proposed that topoisomerase IV  (topo IV), 
another essential bacterial type II topoisomerase, is a secondary target of novobiocin. 
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The primary function of topo IV is the ATP-dependent decatenation of daughter 
chromosomes following DNA replication. The topo IV  of E. coli has a similar structure 
as gyrase: two ParC and two ParE subunits which form a C2E2 complex. In a similar 
way, ParC is responsible for DNA breakage and reunion, and ParE contains the ATP-
binding site. The authors concluded, by mutational experiments in the ParE subunit, 
that novobiocin likely inhibits topo IV  by the same mechanism as DNA gyrase is 
inhibited. 
Novobiocin (Albamycin®, Pharmacia & Upjohn) was licensed in the USA for the 
treatment of human infections with multi-resistant gram-positive bacteria such as 
Staphylococcus aureus and S. epidermidis. Its efficacy has been demonstrated in 
preclinical and clinical trials (Raad et al., 1995; Raad et al., 1998; Walsh et al., 1993). 
However, due to some adverse reactions (principally urticaria and dermatitis), their 
poor solubility in water, and their low activity against Gram-negative bacteria 
(resulting from poor permeability) , clinical use of these antibiotics remains restricted 
(Maxwell, 1993). Clorobiocin and coumermycin have not been used clinically.  
Therefore it is of interest to test whether new, structurally modified aminocoumarin 
antibiotics may be able to overcome the limitations of the known compounds 
(Maxwell and Lawson, 2003). 
In addition, novobiocin and its derivatives have also been investigated as potential 
anticancer drugs. Novobiocin acts synergistically with etoposide and could be used in 
combination therapies to overcome drug resistance. The increase in etoposide 
cytotoxicity produced by novobiocin was not due to the combined effects of these 
agents on topoisomerase II, but to inhibition by novobiocin of etoposide efflux (Rappa 
et al., 1992; Rappa et al., 2000a; Rappa et al., 2000b). Furthermore, novobiocin, 
clorobiocin and coumermycin A1 were shown to interact with eukaryotic heat shock 
protein 90 (Hsp90), which plays a key role in the stability and function of multiple cell-
signalling molecules, e.g. several oncogenic tyrosine and serine-threonine kinases, 
being expressed at two- to ten-fold higher levels in tumour cells than in their normal 
counterparts. Hsp90 is therefore considered to be a novel molecular target for 
anticancer therapeutics. Aminocoumarins markedly reduced cellular levels of 
oncogenic kinases in vitro and in vivo (mice) by interacting with Hsp90 (Marcu et al., 
2000). Recently, novobiocin was found to increase CD38 expression on cells of 
myeloid leukaemia lines. Human myelogenous leukaemia cells are unable to 
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differentiate to functional mature cells. This arrest in maturation is accompanied by 
uncontrolled cell proliferation. Novobiocin showed anti-proliferative properties and the 
ability to induce myeloid leukaemia cell lines to differentiate along the monocytic 
path. The latter was concluded by measuring the expression of a range of 
differentiation markers, like the surface antigen CD38 in the cell lines (Thiele et al., 
2002). 
I.3.3.  Structure-activity relationships  
Hooper et al. (1982) have investigated aminocoumarin antibiotics and their 
analogues for their inhibitory activity towards E. coli DNA gyrase in vitro and for their 
antibacterial activity against E. coli cells. Important for activity was the 
aminocoumarin moiety linked to the substituted deoxysugar; lack of the pyrrole or 
carbamoyl substituent resulted in loss of inhibitory activity. Reusser and Dolak (1986) 
have also reported the novenamine, i.e. aminocoumarin moiety plus substituted 
deoxysugar, to represent the minimal structural entity of novobiocin necessary to 
interact with DNA gyrase. This is in accordance with X-ray data (see above). The 
aminocoumarin or the deoxysugar alone were inactive in antibacterial and anti-
gyrase activities (Althaus et al., 1988; Hooper et al., 1982; Reusser and Dolak, 1986). 
Coumermycin A1 was the most active compound (Hooper et al., 1982). As mentioned 
above, the pseudo-dimeric structure of coumermycin may be responsible for such 
effect (Maxwell and Lawson, 2003). Besides, of many aryl and alkyl substituents 
tested, the prenylated benzoic acid moiety of novobiocin and clorobiocin, i.e. Ring A, 
was the most effective  (Hooper et al., 1982). This was also confirmed by a recent 
study (Galm et al., 2004b). Ring A was supposed to be unimportant in DNA gyrase 
interactions and to only facilitate the absorption of aminocoumarin compounds (Lewis 
et al., 1996a), which, however, was disproved by recent studies (Galm et al., 2004b; 
Lafitte et al., 2002). 
Clorobiocin has been reported to show a higher inhibition of Escherichia coli gyrase 
and bacterial growth than novobiocin (Hooper et al., 1982), and to bind more 
efficiently to isolated gyrase (Lafitte et al., 2002; Lewis et al., 1996a; Tsai et al., 1997). 
Most authors have attributed the higher activity of clorobiocin primarily to the pyrrole 
moiety at C-3´´ (Berger and Batcho, 1978; Tsai et al., 1997). Interestingly, however, 
clorobiocic acid, the aglycon of clorobiocin, but not novobiocic acid, was found to 
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inhibit both DNA synthesis in vivo and gyrase activity in vitro (Althaus et al., 1988; 
Reusser and Dolak, 1986), suggesting that the chlorine atom makes an important 
contribution to the biological activity of this molecule. 
I.3.4.  Biosynthesis and identification of the biosynthetic gene clusters  
The biosynthesis of novobiocin was firstly studied by feeding experiments in the 
1960s and 1970s. Birch et al.  (1962) proved that the deoxysugar is derived from 
intact glucose. Bunton et al. (1963) showed that tyrosine is the precursor of both the 
aminocoumarin moiety and the acyl component Ring A, and concluded by feeding of 
[carboxyl-18O] labelled tyrosine that the ring oxygen of the aminocoumarin moiety 
comes from the carboxyl group of tyrosine . However, it has been shown recently by 
Holzenkämpfer and Zeeck (2002) that the ring oxygen of the aminocoumarin moiety 
of simocyclinone D8 is derived from molecular oxygen, not from the carboxyl group of 
tyrosine. The amino group in position 3´ of the coumarin unit was found to be derived 
from the nitrogen of tyrosine (Calvert et al., 1972). Feeding experiments with 13C-
glucose provided evidence for the biosynthesis of the dimethylallyl moiety of 
novobiocin via the non-mevalonate (= methyl-erythritol-phosphate) pathway (Li et al., 
1998). Feeding of 14C-labelled L-proline to a coumermycin producer led to the  
incorporation of radioactivity into the pyrrole groups of coumermycin A1 (Scannell and 
Kong, 1969). However, the degradation method used in this experiment did not allow 
distinction between the central and the two terminal pyrrole moieties of this 
compound. 
In 2000, cloning and sequencing of the novobiocin (nov) biosynthetic gene cluster 
from S. spheroides NCIMB 11981 provided the basis for molecular biological 
investigations of aminocoumarin antibiotics biosynthesis (Steffensky et al., 2000b). 
Subsequently, the biosynthetic gene cluster for coumermycin A1 (cou) from S. 
rishiriensis DSM 40489 (Wang et al., 2000) and for clorobiocin (clo) from S. 
roseochromogenes var. oscitans DS 12.976 (Pojer et al., 2002) were also identified. 
Comparison of the three gene clusters revealed a strikingly stringent correspondence 
between the structures of the antibiotics and the organization of the biosynthetic 
genes (Fig. I.3). The order of the genes coding for each structural moiety are 
perfectly identical for the three clusters. 
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Fig. I.3: The biosynthetic gene clusters of novobiocin (nov), clorobiocin (clo) and 
coumermycin A1 (cou). Accession numbers: novobiocin cluster AF170880, clorobiocin cluster 
AF329398, coumermycin cluster AF235050 (Li and Heide, 2004). 
 
Downstream of novE/cloE/couE, the three clusters show very high similarity between 
each other, whereas upstream of these genes, the genomic sequences of the three 
organisms are completely different, containing different genes which may code for 
primary metabolic enzymes as shown by database comparison analysis. Therefore, it 
has been suggested but not proven that novE, cloE and couE may represent the left 
borders of the clusters, respectively (Eustáquio et al., 2003b; Pojer et al., 2002). 
Likewise, the aminocoumarin resistance genes gyrBR and parYR may delineate the 
right border of these clusters (Schmutz et al., 2003a). 
A gyrBR gene, coding for a resistant GyrB subunit, is found in all three clusters, as 
expected since the producers must obviously protect their gyrases from the inhibitory 
effect of aminocoumarins during antibiotic production. Furthermore, the clorobiocin 
and the coumermycin A1 but not the novobiocin clusters were shown to contain an 
additional similar gene, parYR. Expression of gyrBR and parYR in S. lividans resulted 
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in resistance against aminocoumarin antibiotics, proving that the function of these 
genes consists in confer resistance to aminocoumarins  (Schmutz et al., 2003a). 
Recently, Schmutz et al. (2004) have overexpressed and purified the encoded 
proteins, as well as GyrA and ParX subunits. The complex of GyrA and GyrB R was 
found to catalyse ATP-dependent supercoiling of DNA, i.e. to function as a gyrase, 
whereas the complex of ParX and ParYR catalysed ATP-dependent decatenation and 
relaxation, i.e. the functions of topo IV. This finding gives additional support to the 
hypothesis that topo IV is a secondary biological target of aminocoumarins (see 
above). The high affinity of coumermycin and clorobiocin to both their primary and 
secondary targets may explain the need of the antibiotic producers to create a 
resistance mechanism protecting both targets. In addition, this is believed to 
represent the first topo IV identified in actinobacteria. As explained above, topo IV is 
found in most bacteria and consists of a (ParC)2(ParE)2 complex. However, some 
members of the class of actinobacteria, like species of the genus Corynebacterium 
and Mycobacterium, contain only genes for gyrase, which seems to carry out the 
functions of both gyrase and topo IV. Recently, however, the complete genome 
sequence of S. coelicolor showed that this organism contains in addition to genes 
coding for gyrase subunits, two genes for another type II topoisomerase. These 
genes, annotated as “putative gyrase subunit A” (SCO5822) and “subunit B” 
(SCO5836), were called parX and parY by our group, respectively, since in a 
sequence comparison with type II topoisomerases from Gram-positive organisms, 
these genes could neither be classified as gyrase nor as topo IV  (Schmutz et al., 
2004). 
The hypothetical biosynthetic pathway of aminocoumarin antibiotics is presented in 
Fig. I.4, exemplified for clorobiocin. 
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Fig. I.4: Hypothetical biosynthetic pathway of clorobiocin. 
It is not clear at which exact step during the biosynthesis halogenation takes place. 
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Chen and Walsh (2001) have investigated the biosynthesis of the aminocoumarin 
unit of novobiocin by biochemical methods. The authors demonstrated that within this 
pathway, the enzyme NovH activates tyrosine by thioester formation with the 4’-
phosphopantetheinyl cofactor, and subsequently the cytochrome P450 enzyme NovI 
hydroxylates the activated tyrosine in the b-position (Fig. I.4). It was proposed that 
NovJ and NovK may act together in the oxidation of b-hydroxytyrosine to b-
ketotyrosine, however, no evidences were provided. The same functions may be 
expected for cloHIJK and couHIJK, which show very high homology with each other 
and with novHIJK. 
Holzenkämpfer and Zeeck (2002) recently suggested that the ring oxygen of the 
aminocoumarin moiety of simocyclinone of the D class (Fig. I.1), which is similar to 
the aminocoumarin moiety of novobiocin, clorobiocin and coumermycin A1, is 
introduced by the action of a monooxygenase. Chen and Walsh (2001) speculated 
that the product of novC, which is situated 5 kb upstream of novHIJK in the 
novobiocin cluster, may encode this monooxygenase. However, no homologue to 
novC is present in the clorobiocin or coumermycin clusters, casting doubts on this 
suggestion (Eustáquio et al., 2003b; Pojer et al., 2002). It remains to be shown, 
which gene codes for this monooxygenase, and whether such an enzyme is indeed 
involved in the aminocoumarin ring formation. 
novL has been shown to encode an amide synthetase, linking the substituted 
benzoyl moiety (= Ring A) of novobiocin to the amino group of the aminocoumarin 
ring (Steffensky et al., 2000a). The same function is expected for cloL. couL encodes 
an unusual amide synthetase, which catalyses the formation of both amide bonds of 
coumermycin A1 (Fig. I.1), i.e. between the central pyrrole moiety and the two 
aminocoumarins  (Schmutz et al., 2003b). 
Pojer et al. (2002; 2003b; 2003a) have elucidated the biosynthesis of Ring A by 
biochemical and genetic studies. Gene inactivation experiments showed that cloR 
and cloQ are essential for Ring A biosynthesis (Pojer et al., 2002; Pojer et al., 2003b). 
The precursor of this substituted benzoyl moiety is 4-hydroxy-phenylpyruvate (Pojer 
et al., 2003b), rather than L-tyrosine, as reported by Bunton et al. (1963).  CloQ is a 
prenyltransferase, which prenylates 4-hydroxy-phenylpyruvate  (Pojer et al., 2003b). 
CloR, a bifunctional non-heme iron oxygenase, catalyses the conversion of 3-
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dimethylallyl-4-hydroxyphenylpyruvate to Ring A in two consecutive oxidative 
decarboxylation steps, with 3-dimethylallyl-4-hydroxymandelic acid as intermediate  
(Pojer et al., 2003a). The same functions may be postulated for the corresponding 
genes of the novobiocin gene cluster, i.e. novQR. NovF and CloF show sequence 
similarity to prephenate dehydrogenases and are likely to supply 4-hydroxy-
phenylpyruvate for the biosynthesis of Ring A. No orthologue of nov/cloF is found in 
the coumermycin cluster, consistent with the structure of this antibiotic (Eustáquio et 
al., 2003b). 
Inactivation of couN3 and couN4 showed the involvement of these genes in the 
biosynthesis of the terminal pyrrole-2-carboxylic acid moieties of coumermycin A1, 
which were known to be derived from pyrrole (see above), and proved, for the first 
time, that the central 3-methylpyrrole-2,4-dicarboxylic acid unit of coumermycin is 
formed by a biosynthetic pathway that differs from that used to assemble the terminal 
pyrrole moieties (Xu et al., 2002), indicating the need of additional genes which may 
be responsible for this pathway. couR1-R6 are found in the coumermycin cluster at 
the same relative position as nov/cloQR in the novobiocin and clorobiocin clusters, 
respectively. It was speculated that couR1-R4 could be involved in the biosynthesis 
of the central pyrrole unit of coumermycin A1 (Wang et al., 2000). However, no 
experimental evidence is available yet. couR5, a putative transporter gene, confers 
moderate levels of resistance against novobiocin and coumermycin A1 when 
heterologously expressed in S. lividans, suggesting that it may be involved in 
antibiotic transport (Schmutz et al., 2003a). CouR6 has a putative helix-turn-helix 
(HTH) motif in its N-terminal region, which is characteristic of bacterial regulatory 
proteins, and shows sequence similarity to transcriptional regulators of the LysR-type. 
Five ORFs are found at the right end of all three gene clusters, i.e. novSTUVW, 
cloSTUVW and couSTUVW, respectively. Based upon their homology to known 
genes of deoxysugar biosynthesis, they were assigned to the first five steps required 
for the biosynthesis of the deoxysugar moiety (Pojer et al., 2002; Steffensky et al., 
2000b; Wang et al., 2000). A functional proof for this hypothesis was provided by an 
inactivation experiment with novT, since novT- mutants accumulated the aglycon 
novobiocic acid (Steffensky et al., 2000b). 
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NovM catalyses the formation of the glycosidic bond between the deoxysugar and 
the aminocoumarin ring. The aglycone novobiocic acid and TDP-L-noviose were 
shown to be the preferred substrates (Freel Meyers et al., 2003). CloM and CouM 
may have the same function. 
novN codes for the carbamoyltransferase responsible for the introduction of the 
carbamoyl group of novobiocin (Freel Meyers et al., 2004; Xu et al., 2004). At the 
corresponding position in the clorobiocin and coumermycin A1 clusters, the genes 
clo/couN1-N7 are found. Clo/CouN3-N5 are involved in the biosynthesis of the 
pyrrole-2-carboxyl moiety from proline (Thomas et al., 2002; Xu et al., 2002), 
whereas Clo/CouN2 are the acyltransferases involved in the attachment of this 
moiety to the deoxysugar of clorobiocin and coumermycin. Since only pyrrole-2-
carboxylic acid, but not its 5-methyl derivative was found in cloN2-defective mutants, 
the methylation of the pyrrole unit must occur only after its transfer to the deoxysugar 
moiety (Xu et al., 2003). An inactivation experiment provided evidence that CloN6 
catalyzes the 5-methylation of the pyrrole group  of clorobiocin (Westrich et al., 2003). 
The same function may be assigned to CouN6. The functions of clo/couN1 and 
clo/couN7 remain to be elucidated. 
Gene inactivation experiments showed that couO encodes a C-methyltransferase 
responsible for the transfer of the methyl group to C-8´ of the aminocoumarin ring, 
and couP an O-methyltransferase for methylation of 4´´-OH of the deoxysugar (Li et 
al., 2002). Homologues of couP are found in the clorobiocin and novobiocin clusters 
(cloP and novP, respectively). However, no gene homologous to novO and couO 
exists in the clorobiocin cluster. Instead, the gene clo-hal, which shows sequence 
similarity to FADH2-dependent halogenases, is located in the same relative position. 
In addition, the clorobiocin cluster also contains the ORF cloZ, which shows no 
sequence similarity to known genes. For all genes of the clorobiocin cluster, with the 
exception of clo-hal and cloZ, homologues exist in the novobiocin and/or 
coumermycin cluster. Since the halogen atom represents the only structural 
characteristic of clorobiocin absent from both novobiocin and coumermycin, it can be 
questioned whether cloZ, together with clo-hal, may play a role in the halogenation of 
clorobiocin. 
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Besides the genes above, the gene clusters of clorobiocin and coumermycin, but not 
of novobiocin, contain cloY and couY, respectively, of which the functions are still 
unknown. 
I.4. Regulation of antibiotic production 
Considerable efforts are directed towards understanding how streptomycetes 
synthesize antibiotics, in order to manipulate the gene clusters and produce novel 
compounds with improved properties. In addition, the identification and 
characterization of regulatory genes is crucial for the rational engineering of strains 
with enhanced antibiotic production. 
Biosynthesis of secondary metabolites by Streptomyces is a complex process 
involving several levels of regulation. In this respect, two phylogenetically distant 
species have received the most extensive attention so far: S. coelicolor A3(2) and S. 
griseus. The former because of its early development as an excellent genetic system, 
which allowed the analysis of morphological differentiation and secondary 
metabolites formation, and the latter because it provided the first well-studied 
bacterial example of extra cellular signalling  by an hormone-like acylated lactone (the 
g-butyrolactone A-factor) (Chater and Horinouchi, 2003). In both cases, pleiotropic 
regulatory genes affect antibiotic biosynthesis by influencing the expression of 
pathway-specific regulatory genes, which are usually clustered with the structural 
biosynthetic genes (Chater and Bibb, 1997). 
In S. griseus, StrR has been characterized as a pathway-specific regulatory protein. It 
activates the expression of streptomycin biosynthetic genes by binding to DNA loci 
which are characterized by an inverted repeat with the consensus sequence 
GTTCGActG(N)11CagTcGAAc and which are located upstream of respective  
promoter regions (Retzlaff and Distler, 1995). StrR has a putative helix-turn-helix 
(HTH) motif in the central region of its primary structure (Retzlaff and Distler, 1995), 
which is typical for a family of bacterial and phage DNA-binding proteins  (Pabo and 
Sauer, 1992). 
Analysis of ActII-ORF4 from S. coelicolor (Arias et al., 1999; Wietzorrek and Bibb, 
1997) and of DnrI from S. peucetius (Sheldon et al., 2002; Wietzorrek and Bibb, 1997)  
revealed another family of Streptomyces antibiotic regulatory proteins , termed 
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SARPs. They show in their  predicted secondary structure a OmpR-like DNA-binding 
domain with a different structure than the  typical HTH motif (Sheldon et al., 2002; 
Wietzorrek and Bibb, 1997). These proteins activate transcription of target genes by 
binding to direct (rather than inverted) heptameric repeats with the consensus 
sequence TCGAGCG/C located close to the transcriptional start sites (Arias et al., 
1999; Sheldon et al., 2002; Wietzorrek and Bibb, 1997). 
Furthermore, other types of pathway-specific regulatory genes have been identified 
from different Streptomyces strains, like srmR of the spiramycin cluster in S. 
ambofaciens, the predicted product of which shows no significant sequence similarity 
to any other known regulatory protein, mmyR of the methylenomycin cluster in S. 
coelicolor, representing the first negative pathway-specific regulator of antibiotic 
production identified, and response regulator genes of putative two-component 
systems like dnrN of the daunorubicin cluster in S. peucetius and redZ of the 
undecylprodigiosin cluster in S. coelicolor (Chater and Bibb, 1997). 
Extensive investigation of the biosynthetic pathways of the aminocoumarin antibiotics 
(see above)  as well as the generation of novel antibiotics by metabolic engineering  
(this thesis (Eustáquio et al., 2003a; Eustáquio et al., 2004)), chemo-enzymatic 
synthesis (Xu et al., 2004) and precursor-directed biosynthesis (Galm et al., 2004a) 
have been carried out.  
In contrast, little is known about how aminocoumarin antibiotic production is regulated. 
Two candidate genes may be involved in the regulation of aminocoumarin antibiotic 
biosynthesis, i.e. nov/clo/couG and nov/clo/couE.  
NovG shows sequence similarity to StrR, the well-studied pathway-specific activator 
of streptomycin biosynthesis in S. griseus (see above). NovE shows sequence 
similarity only to an unknown protein, LmbU, of the lincomycin biosynthetic gene 
cluster. Lincomycin, like the aminocoumarin moiety of novobiocin, is formed from 
tyrosine, but the reaction sequence is unknown. Peschke et al. (1995) speculated 
that lmbU may encode a regulatory protein, but a catalytic function for LmbU could 
not be excluded. 
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I.5. Aims of this study 
The principal aims of this study were: 
1. To provide experimental evidence for the function of the genes involved in the 
chlorination and methylation reactions at position 8 of the aminocoumarin rings 
of the antibiotics clorobiocin and novobiocin, respectively. 
2. To generate structural analogues of clorobiocin and novobiocin for an 
investigation of the structure-activity relationships. 
3. To produce these antibiotics in a heterologous host, by transfer of the 
biosynthetic gene clusters to a different organism. 
4. To investigate the regulation of novobiocin biosynthesis and to develop 
methods to increase its productivity by genetic means. 
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Fig. I.5: Structures of the aminocoumarin antibiotics clorobiocin and novobiocin and of the 
hybrid antibiotics novclobiocin 102 and 114, which should be generated by metabolic 
engineering of the biosynthetic gene clusters. 
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The first aim of the present study was to provide functional proof for the role of the 
putative halogenase gene clo-hal and of the gene cloZ in clorobiocin biosynthesis by 
gene inactivation. 
The aminocoumarin antibiotic clorobiocin and the glycopeptide antibiotic balhimycin 
both contain 3-chloro-b-hydroxy-tyrosyl moieties, and the biosynthesis of these 
moieties show striking similarities. However, for both antibiotics it is not clear at which 
step of biosynthesis the halogenation reaction takes place (Eustáquio et al., 2003a; 
Puk et al., 2002; Süssmuth and Wohlleben, 2004). In order to gain more insights 
about the substrate specifity of the halogenases Clo-hal of clorobiocin biosynthesis 
and BhaA of balhimycin biosynthesis, it was therefore examined whether bhaA could 
functionally replace clo-hal. 
Clorobiocin (Fig. I.5) has been reported to show a stronger inhibition of Escherichia 
coli gyrase and of bacterial growth than novobiocin (Hooper et al., 1982), and to bind 
more tightly to isolated gyrase (Lafitte et al., 2002; Lewis et al., 1996a; Tsai et al., 
1997). The relative contribution of the 5-methylpyrrole -2-carboxyl moiety at 3´´-OH of 
clorobiocin and of the chlorine atom at C-8´ to this effect is not known (Berger and 
Batcho, 1978; Eustáquio et al., 2003a; Tsai et al., 1997). Hybrid antibiotics combining 
structural features of these two compounds (Fig. I.5) and derivatives lacking the 
substitution at C-8´ should allow an investigation of these structure-activity 
relationships. Generation of novclobiocin 102 (Fig. I.5) should be attempted by 
inactivation of clo-hal in the clorobiocin producer S. roseochromogenes and 
heterologous expression of the putative C-methyltransferase gene novO from the 
novobiocin producer S. spheroides in the clo-hal- mutant. 
On the other hand, earlier attempts to express the halogenase clo-hal in a novO- 
mutant of the natural novobiocin producer S. spheroides in order to generate 
novclobiocin 114 had remained unsuccessful (Pojer and Heide, unpublished results). 
S. spheroides is very difficult to manipulate genetically (Hussain and Ritchie, 1991), 
and this may have been the cause for the failure of the experiment.  
In Escherichia coli, rapid methods for gene inactivation are available, including a 
recently developed technique which uses the l-Red recombination system (Datsenko 
and Wanner, 2000). In streptomycetes, genetic manipulation is more difficult. 
Reasonably efficient methods are established for Streptomyces coelicolor, the best-
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characterized species of its genus and for S. lividans, a close relative of S. coelicolor 
(Bentley et al., 2002; Kieser et al., 2000). In contrast, the development of suitable 
protocols for the genetic manipulation of Streptomyces strains which produce useful 
antibiotics is time-consuming and often, e.g. for the novobiocin producer S. 
spheroides, gives unsatisfactory results. 
In the present study it was therefore attempted to circumvent the problem of genetic 
manipulation in S. spheroides by heterologous expression of the entire biosynthetic 
gene cluster of novobiocin in S. coelicolor and S. lividans. The successful 
heterologous expression of this biosynthetic cluster should also provide, for the first 
time, proof that all genes which are essential for novobiocin biosynthesis are included 
in this single cluster. For the same purpose, heterologous expression of the 
clorobiocin cluster was also attempted. For these experiments, cosmids containing 
the integration system of the Streptomyces phage fC31 and the complete novobiocin 
or clorobiocin clus ters should be introduced into the heterologous hosts. Prior to 
heterologous expression, the DNA sequence of the cosmids’ inserts should be easily 
modified in E. coli, allowing, e.g., the production of the desired novclobiocin 114. 
It had been suggested that the genes novE/cloE and gyrBR/parYR represent the 
borders of the novobiocin and clorobiocin clusters, respectively. Removal of the DNA 
regions outside of these borders should be attempted, in order to provide 
experimental evidence that they are non-essential for biosynthesis. 
The last part of this study concerned investigations of regulatory processes. The 
identification of genes that regulate antibiotic production in streptomycetes can help 
to rationally engineer novel strains which show higher productivity. 
Therefore, the role of novG as a regulator of novobiocin biosynthesis was 
investigated by genetic and biochemical approaches. It was also examined whether 
overexpression of novG can be used to increase novobiocin production. Furthermore, 
in order to gain insights into the role of the putative regulatory gene novE, a novE- 
mutant was generated and examined. 
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II. MATERIALS AND METHODS 
II.1. Chemicals 
Chemicals and components of the media used in this thesis are listed in Table II.1.  
TABLE II.1: Chemicals and media components 
Supplier Chemical / Media component 
Amersham Biosciences, Freiburg, 
Germany 
Agarose 
Aventis, Bad Soden, Germany Clorobiocin 
Bacto-Difco, Heidelberg, Germany Agar 
Casaminoacids 
Corn starch (soluble) 
Malt extract 
Nutrient agar 
Peptone  
Tryptic soy broth 
Tryptone  
Yeast extract 
Calbiochem-Novabiochem, Bad 
Soden, Germany 
L-Proline 
Thiostrepton 
Fluka, Ulm, Germany Apramycin 
Novobiocin 
FMC BioProducts, Rockland, USA NuSieve® GTG® Agarose 
Merck, Darmstadt, Germany Chloramphenicol 
EDTA  
Ethanol 
Glucose   
Meat extract 
ß-Mercaptoethanol 
Methanol  
Phosphorus pentoxide 
Uvasol® methanol-d4 
Roth, Karlsruhe, Germany Ammonium persulphate (APS) 
5-Bromo-4-chlor-3-indolyl-ß-D-
galactopyranoside (X-Gal) 
Carbenicillin 
1,4-Dithiothreitol (DTT) 
Glacial acetic acid 
Glycine 
Isopropanol 
Isopropyl-ß-thiogalactoside (IPTG) 
 II. MATERIALS AND METHODS 30 
Maleic acid 
Phenol/Chloroform/Isoamylalkohol(25:24:1) 
Polyethyleneglycol (PEG) 1000 
Rotiphorese® Gel 30 (30% acrylamid, 0.8% 
bisacrylamide) 
Sodium dodecyl sulphate (SDS) 
N,N,N´,N´-Tetramethylethylenediamine 
(TEMED) 
Tris-(hydroxymethyl)-aminomethane-maleate 
(Tris-maleate) 
N-Tris-(Hydroxymethyl)-methyl-2-aminoethane 
sulfonic acid (TES) 
Serva, Heidelberg, Germany Coomassie Brilliant Blue R250 
N-Lauroylsarcosine (Na-Salt, 35%) 
Sigma-Aldrich, Deisenhofen, 
Germany 
Bromophenol blue  
Dimethyl formamide (DMF) 
Dimethyl sulfoxide (DMSO) 
Distillers grains and solubles 
Ethyleneglycol 
Imidazol 
Kanamycin  
Polyoxyethlenesorbitan monolaurate (Tween 
20) 
Tetracycline 
Tris base 
Südzucker, Mannheim, Germany Sucrose  
 
II.2. Materials for Chromatography 
The liquid chromatography media were obtained as dry beads, suspensions or 
commercial columns. The storage of the media or columns was carried out according 
to the manufacturers’ instructions. 
TABLE II.2: Liquid chromatography media 
Supplier Medium 
Amersham Biosciences, Freiburg, 
Germany 
Sephadex® LH-20 (dry beads) 
Sephadex®  G-25 NAP-10 (commercial column) 
C+S Chromatographie Service, 
Düren, Germany 
Multosphere® RP 18-5 (commercial colum, 5 
µm, 250×4 mm) 
Multosphere® 100 RP 18-5 (commercial colum, 
5 µm, 250×20 mm) 
Qiagen, Hilden, Germany Ni-NTA Agarose (Suspension) 
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II.3. Enzymes and kits 
TABLE II.3: Enzymes and kits 
Supplier Enzymes and kits 
Amersham Biosciences, Freiburg, 
Germany 
Low Molecular Weight Calibration Kit for SDS-
Electrophoresis 
Restriction endonucleases 
T4 DNA Ligase 
Fluka, Ulm, Germany Lysozyme (76 000 U/mg) 
GibcoBRL Life Technologies, 
Karlsruhe, Germany 
1 kb DNA Ladder 
High Molecular Weight DNA Marker 
Macherey-Nagel, Düren, Germany Nucleobond® AX100 
NucleoSpin® Extract 2 in 1 
New England Biolabs, Schwalbach, 
Germany 
Restriction endonucleases 
100 bp DNA Ladder 
Plant Bioscience Limited, Norwich, 
UK 
REDIRECT© technology: PCR-targeting 
system in Streptomyces coelicolor 
Promega, Madison, WI, USA Taq DNA polymerase 
Pfu DNA polymerase 
Qiagen, Hilden, Germany RNase A 
Roche, Mannheim, Germany DIG Gel Shift Kit, 2nd Generation 
DIG-High Prime DNA Labelling and Detection 
Starter Kit II 
DNA Molecular Weight Marker VII, DIG-
Labelled 
Expand High Fidelity PCR System  
GC-Rich PCR System Kit 
Strategene, Taufkirchen, Germany Restriction endonucleases 
 
II.4. Media, buffers and solutions  
II.4.1. Media for bacterial cultivation 
The media used in this study were as follows. Unless otherwise stated, the media 
were prepared with distilled water and autoclaved for 20 min at 121 °C (15 psi). To 
obtain solid media, 2% (w/v) agar was added before autoclaving. If necessary, sterile 
supplementary components like antibiotics and other heat-labile substances were 
added in the sterile media at time of use. The media were stored at RT or at 4 °C. 
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II.4.1.1. Cultivation of E. coli 
LB (Luria-Bertani) Medium (Sambrook and Russell, 2001) 
NaCl                                10.0 g 
Tryptone                          10.0 g 
Yeast extract                     5.0 g 
Dissolve the ingredients in about 900 ml water, adjust the pH to 7.0, and 
adjust the volume to  1 litre with water. Sterilize by autoclaving. 
 
SOB Medium 
Tryptone                          20.0 g 
Yeast extract                     5.0 g 
NaCl                                  0.5 g 
 
Dissolve the ingredients in about 900 ml water, adjust the pH to 7.0, and 
adjust the volume to 1 litre with water. Sterilize by autoclaving. Add 10 ml 
of a sterile solution of 1 M MgCl2. 
II.4.1.2. Cultivation of Streptomyces 
YMG (Yeast-Malt-Glucose) Medium 
Yeast extract                     4.0 g 
Malt extract                     10.0 g 
Glucose                             4.0 g 
Dissolve the ingredients in about 900 ml water, adjust the pH to 7.3, and 
add water to make up to 1 litre. Sterilize by autoclaving. 
TSB (Tryptone Soya Broth) Medium (Kieser et al., 2000) 
Tryptone Soya Broth  30.0 g 
 
Dissolve the ingredient in up to 1 litre water, and sterilize by autoclaving. 
YEME (Yeast Extract – Malt Extract) Medium (Kieser et al., 2000)  
Yeast extract   3.0 g 
Peptone    5.0 g 
Malt extract   3.0 g 
Glucose            10.0 g 
Sucrose             340 g 
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Dissolve the ingredients in up to 1 litre water. Sterilize by autoclaving. Add 
5 ml of a sterile solution of 1 M MgCl2. 
 
MS (Mannitol Soya flour) Agar (Kieser et al., 2000)  
Mannitol    20.0 g 
Soya flour   20.0 g 
Agar    20.0 g 
 
Dissolve the mannitol in up to  1 litre tap water and pour 100 ml into 300 ml 
Erlenmeyer flasks each containing 2 g agar and 2 g soya flour. Sterilize by 
autoclaving twice (115 ºC, 15 min) with gentle shaking between the two 
runs.  
Note: This medium is appropriate for S. coelicolor, S. lividans and S. 
spheroides sporulation, but not for S. roseochromogenes. 
 
DNA (Difco Nutrient Agar) (Kieser et al., 2000)  
Difco Nutrient Agar  4.6 g 
 
Place the ingredient into 300 ml Erlenmeyer flasks and add 200 ml water. 
Sterilize by autoclaving. 
Note: S. coelicolor, S. lividans, S. roseochromogenes and S. spheroides do 
not sporulate on this medium. 
 
Grundy starch agar 
Soluble starch                     5.0 g 
(NH4)2HPO4                        1.0 g 
KCl                                      0.2 g 
Mg2Cl · 6H2O                      0.2 g 
 
Dissolve the ingredients in about 900 ml water, and adjust the pH to 7.3. 
Adjust the volume with water to 1 litre and add 15 g Agar. Sterilize by 
autoclaving. Use high petry dishes (9 cm), in which 50 ml agar can be 
poured; otherwise they will dry out during the long incubation period which 
is necessary for S. roseochromogenes var. oscitans sporulation. 
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Note: For sporulation of S. roseochromogenes, mix 2-3 ml 2-day-old YMG-
culture with 1 g sterile powdered soil and plate the mixture on two grundy 
starch agar plates. Let dry for about 30 min under the laminar flow, and 
incubate at 28 ºC for four to six weeks till sporulation is observed (the 
spores have a light pinkish colour). 
II.4.1.3. Clorobiocin production medium 
Corn starch medium (pre-culture medium) (Mancy et al., 1974) 
Corn starch    10.0 g 
Peptone    10.0 g 
Meat extract     5.0 g 
 
Dissolve the ingredients in about 900 ml water, adjust the pH to 7.0, and 
add water to make up to 1 litre. Sterilize by autoclaving. 
 
Distillers solubles medium (production medium) (Mancy et al., 1974) 
Solution A     Distillers solubles              48.0 g 
Glucose                            12.0 g 
Cobalt chloride                  24 mg 
Dissolve the ingredients in about 800 ml water, adjust the pH to 7.8, add 
6.0 g calcium carbonate and then add water to make up to 887 ml. 
Solution B      Ammonium sulphate        32.0 g 
Dissolve in 200 ml water and autoclave. 
Solution C      Glucose                            75.0 g 
Dissolve in 300 ml water and autoclave. 
After autoclaving, add 13 ml solution B and 100 ml solution C to solution A. 
II.4.1.4. Novobiocin production medium 
CDM medium (Kominek, 1972) 
tri-sodium citrate  × 2H20  6.0 g 
L-proline                               6.0 g 
K2HPO4 × 3H2O    2.0 g 
(NH4)2SO4    1.5 g 
NaCl     5.0 g 
MgSO4 × 7H2O            2.05 g 
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CaCl2 × 2H2O    0.4 g 
ZnSO4 × 7H2O    0.1 g 
Glucose (30% (w/v))   100 ml 
 
Dissolve the ingredients till NaCl in water, adjus t the pH to 7.2, dissolve the 
remaining ingredients except the glucose solution, and add water to make 
up to 900 ml. Sterilize by autoclaving. Add the sterile glucose solution. 
II.4.1.5. Protoplast transformation of Streptomyces 
CRM medium 
Sucrose                              103.0 g 
Tryptic soy broth                  20.0 g 
MgCl2 · 6H2O                       10.12 g 
Yeast extract                        10.0 g 
 
Dissolve in about 900 ml water, adjust the pH to 7.0 and adjust the volume 
to 1 litre. Sterilize by autoclaving. To 100 ml sterile medium, add 1 ml 
CaCl2 (1 M) and a final concentration of 0.75% glycine (for S. 
roseochromogenes). 
YEME medium with glycine (Kieser et al., 2000) 
For preparation of protoplasts of S. coelicolor and S. lividans, 25 ml 
Glycine 20% (w/v) are added to 1 litre YEME medium (s. II.4.1.2); 0.5% 
final concentration. 
Trace elements solution 
ZnCl2    40 mg 
FeCl3 · 6H2O           200 mg 
CuCl2 · 2H2O   10 mg 
MnCl2 · 4H2O   10 mg 
Na2B4O6 · 10H2O  10 mg 
(NH4)6Mo7O24 · 4H2O  10 mg 
 
Dissolve in 1 litre distilled water and autoclave. 
R2YE Medium (Kieser et al., 2000) 
Sucrose            103.0 g 
K2SO4    0.25 g 
MgCl2 · 6H2O           10.12 g 
Glucose    10.0 g 
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Casaminoacids     0.1 g 
Trace elements solution 2.0 ml 
Yeast extract     5.0 g 
TES    5.73 g 
Agar (plates)   23.0 g 
 
Dissolve in water to a final volume of 1 litre and sterilize by autoclaving. To 
prepare soft agar, 6 g Agar instead of 23 g, were added.  
After autoclaving, add: 
KH2PO4 (0.5%)   10 ml 
CaCl2 · 2H2O (5 M)    4 ml 
L-Proline (20% (w/v))  15 ml 
NaOH (1M)     7 ml 
R3 soft agar 
Sucrose          171.0 g 
Glucose            10.0 g 
Peptone    4.0 g 
KCl    0.5 g 
CaCl2 · 2H2O   2.2 g 
MgCl2 · 6H2O   8.1 g 
Agar    8.0 g 
 
Dissolve in water to a final volume of 1 litre and autoclave. After that, add: 
KH2PO4 (0.5%)                      40 ml 
TES (0.25 M, pH 7.2)           100 ml 
Soft nutrient agar (Kieser et al., 2000) 
Nutrient broth                            8 g 
Agar                                          5 g 
 
Dissolve in water to a final volume of 1 litre and autoclave. 
 
II.4.2. Antibiotic solutions 
Antibiotics were dissolved in appropriate solvents as stock solutions and kept at -20 
°C. The aqueous solutions were sterilized by passing through a 0.22 µm filter. The 
solutions in ethanol and DMSO were autosterile. For antibiotic selection, the required 
antibiotics were added to the cooled media (RT to 60 °C) in appropriate 
concentration. 
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TABLE II.4: Solutions of antibiotics 
Concentration in 
Antibiotic 
stock solution (mg/ml) media (µg/ml) 
Solvent 
Apramycin 50 15-50a H2O 
Carbenicillin 50-100 50-100 H2O 
Chloramphenicol 25-50 25-50 ethanol 
Kanamycin 50 15-50a H2O 
Tetracycline 12 12 ethanol 
Thiostrepton 50 15-50a DMSO 
a15 µg/ml in liquid and 50 µg/ml in solid media for selection of Streptomyces 
strains; otherwise, 50 µg/ml. 
 
II.4.3. Buffers and solutions 
Unless otherwise stated, the buffers and solutions were prepared with distilled water, 
autoclaved and stored at room temperature (RT). 
II.4.3.1. Buffers and Solutions for DNA isolation 
TABLE II.5: Buffers and solutions for plasmid and cosmid isolation from E.coli 
Buffer Components Final concentration Preparation 
Solution 
MP1 
Tris-HCl 
EDTA 
RNase A 
50 mM 
10 mM 
100 µg/ml 
Adjust the pH to 8.0. Add 
RNase A just before use. 
Solution 
MP2 
NaOH 
SDS 
0.2 M 
1% (w/v) 
 
Solution 
MP3 
KAc·3H2O 3 M Adjust the pH to 4.8. Store at 4  
°C.  
 
TABLE II.6: Buffers and solutions for plasmid isolation from Streptomyces  
Buffer Components Final concentration Preparation 
Solution 
MP1GL 
Glucose 
Tris-HCl 
EDTA 
RNase A 
Lysozyme 
50 mM 
25 mM 
10 mM 
100 µg/ml 
2-4 mg/ml 
Adjust the pH to 8.0. Add 
RNase A and lysozyme just 
before use. 
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Solution 
MP2 
NaOH 
SDS 
0.2 M 
1% (w/v) 
 
Solution 
MP3 
KAc·3H2O 5 M Adjust the pH to 4.8. Store at 4  
°C. 
 
TABLE II.7: Buffers for isolation of genomic DNA from Streptomyces 
Buffer Components Final concntration Preparation 
TSE buffer Sucrose 
Tris-HCl 
EDTA 
RNase A 
Lysozyme 
10.3% 
25 mM 
25 mM 
100 µg/ml 
3 mg/ml 
Adjust the pH to 8.0. Add 
RNase A and lysozyme just 
before use. 
2´Kirby mix SDS 
Sodium 4-
aminosalicilate 
2 M Tris-HCl 
pH 8 
equilibrated 
phenol pH 8.0 
2 g 
12 g 
 
5 ml 
 
6 ml 
Dissolve the SDS and the 
sodium 4-aminosalicilate in up 
to 89 ml distilled water, add 
the Tris-HCl buffer and the 
phenol. Do not autoclave. 
Store protected from light at 4 
ºC. 
 
TE buffer Tris-HCl 
EDTA 
10 mM 
1 mM 
Adjust the pH to 7.5.  
 
II.4.3.2. Buffers for DNA gel electrophoresis 
TABLE II.8: Buffers for DNA gel electrophoresis 
Buffer/solution Components Final 
concentration 
Preparation 
50×TAE Tris base 
EDTA 
Glacial acetic acid  
2 M 
0.05 M 
57.1 ml/l 
Adjust the pH to 8.0 
with glacial acetic 
acid. 
Load buffer Glycerol  
Bromophenol blue 
30% (w/v) 
0.25% (w/v) 
Store at 4 °C 
Ethidium bromide 
solution for staining 
the agarose gel 
Ethidium bromide 1 µg/ml  
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II.4.3.3. Buffers and solutions for Southern blot analysis 
TABLE II.9: Buffers and solutions for Southern blot analysis 
Buffer/solution Components Final 
concentration 
Preparation 
Denaturing 
solution 
NaOH 
NaCl 
0.5 M 
1.5 M 
 
Neutralizing 
buffer 
Tris-HCl 
NaCl 
0.5 M 
3 M 
Adjust the pH to 7.5. 
20×SSC buffer Trisodium citrate 
NaCl 
0.3 M 
3 M 
Adjust the pH to 7.0 
Pre-hybridizing 
solution 
Creamed milk powder 
SDS (10% (w/v) in H2O)  
N-lauroylsarcosine (35% 
(w/v) in H2O) 
3% 
0.02% 
0.1% 
Add to 5×SSC buffer 
before use.  
Hybridizing 
solution 
Creamed milk powder 
SDS (10% (w/v) in H2O)  
N-lauroylsarcosine (35% 
(w/v) in H2O) 
1.5% 
0.02% 
0.1% 
Add to 5×SSC buffer 
before use. Add 
appropriate probe (5-
25 ng/ml) 
2×Washing 
buffer 
SDS (10% (w/v) in H2O)  
 
0.1% Add to 2×SSC buffer 
before use.  
0.5×Washing 
buffer 
SDS (10% (w/v) in H2O)  
 
0.1% Add to 0.5×SSC 
buffer before use.  
Maleic acid 
buffer 
Maleic acid  
NaCl 
0.1 M 
0.15 M 
Adjust the pH to 7.5  
Tween® wash 
buffer 
Tween® 20 0.3% Add to the maleic 
acid buffer before 
use. 
Blocking solution Creamed milk powder 3% Add to the maleic 
acid buffer just 
before use 
Detection buffer Tris-HCl 
NaCl 
0.1 M 
0.1 M 
Adjust the pH to 9.5 
Antibody solution Blocking solution  
Anti-DIG-AP-conjugate 
40 ml 
4 µl 
Mix just before use. 
Stripping solution 
for blot 
NaOH 
SDS (10% (w/v) in H2O) 
0.2 M 
0.1% 
 
 
II.4.3.4. Solutions for blue/white selection of E. coli 
The storage was carried out at -20°C. 
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TABLE II.10: Stock solutions for blue/white selection. 
Solution Composition Per plate 
IPTG 80 mg/ml in distilled water, sterilize by filtering  15 µl 
X-Gal 20 mg/ml in DMF, autosterile 60 µl 
 
II.4.3.5. Buffers for preparation of protoplasts and transformation of 
Streptomyces 
The following sterile solutions were prepared separately. To obtain P-buffer and T-
buffer, they were mixed according to the description and stored at -20°C. 
TABLE II.11: Buffers for preparation of protoplasts and transformation of 
Streptomyces 
Buffer Components Amount (ml) 
P(protoplast)-buffer 
(Kieser et al., 2000) 
Sucrose (12% (w/v) in H2O) 
MgCl2 · 6H2O (1M) 
K2SO4 (140 mM) 
Trace elements solution  
KH2PO4 (40 mM) 
CaCl2 · 2H2O (250 mM) 
TES (0.25M, pH 7.2) 
85.5 
1.0 
1.0 
0.2 
1.0 
1.0 
10.0 
T(transformation)-
buffer (Kieser et al., 
2000) 
Sucrose (25% (w/v) in H2O) 
Trace elements solution 
K2SO4 (140 mM) 
KH2PO4 (40 mM) 
MgCl2 · 6H2O (1 M) 
CaCl2 · 2H2O (5 M) 
Tris-maleate (0.5 M, pH 8.0) 
For S. coelicolor, S. lividans, S. 
spheroides, and S. rishiriensis, add 
PEG 1000 (50% (w/v) in H2O); 
or for S. roseochromogenes, add 
PEG 1000 (68% (w/v) in H2O) 
 
1.0 
0.03 
0.1 
0.1 
0.1 
1.0 
1.0 
 
 
5.0 
 
6.6 
adjust the volume with 
distilled water to 10 ml. 
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II.4.3.6. Buffers for protein purification by nickel affinity chromatography 
The buffers for protein purification were prepared with distilled water, autoclaved and 
stored at 4 °C. If required, lysozyme, imidazol and DTT were added just before use. 
TABLE II.12: Buffers for protein purification 
Buffer Components Amount 
Lysis buffer NaH2PO4/Na2HPO4 
NaCl 
Lysozyme 
Imidazol 
50 mM (pH 8.0) 
300 mM 
2 mg/ml 
10 mM 
Wash buffer NaH2PO4/Na2HPO4 
NaCl 
Imidazol 
50 mM (pH 8.0) 
300 mM 
20-50 mM 
Elution buffer NaH2PO4/Na2HPO4 
NaCl 
Imidazol 
50 mM (pH 8.0) 
300 mM 
250 mM 
Storage buffer Tris-HCl 
Glycerol 
DTT 
25 mM (pH 7.5) 
10% (w/v) 
2 mM 
 
II.4.3.7. Buffers and solutions for protein gel electrophoresis (SDS-PAGE) 
and for Coomassie staining 
All the buffers and solutions were prepared according to the user manual for protein 
gel electrophoresis of Bio-Rad (Bio-Rad, München, Germany).  
TABLE II.13: Buffers and solutions for SDS-PAGE and Coomassie staining 
Buffer/solution Components Amount Preparation 
Stacking gel 
(4%) 
Distilled water 
0.5 M Tris-HCl (pH 6.8) 
10% (w/v) SDS 
Rotiphorese® Gel 30 
10% (w/v) APS 
TEMED 
6.1 ml 
2.5 ml 
0.1 ml 
1.3 ml 
0.05 ml 
0.01 ml 
Combine all the 
components, except 
APS and TEMED; degas 
under vacuum for about 
15 min. Add APS and 
TEMED just before 
pouring the gel. 
Resolving gel 
(12%) 
Distilled water 
1.5 M Tris-HCl (pH 8.8) 
10% (w/v) SDS 
Rotiphorese® Gel 30 
10% (w/v) APS 
TEMED 
3.35 ml 
2.5 ml 
0.1 ml 
4.0 ml 
0.05 ml 
0.005 ml 
(See above). 
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Sample buffer Distilled water 
0.5 M Tris-HCl (pH 6.8) 
Glycerol 
SDS (10% (w/v) in H2O) 
Bromophenol blue (0.5% 
(w/v) in H2O) 
3.55 ml 
1.25 ml 
2.5 ml 
2.0 ml 
0.2 ml 
Add 5 µl ß-mercapto-
ethanol to 95 µl sample 
buffer prior to each use. 
Store at 4 °C. 
10×running 
buffer 
Tris base 
Glycine 
SDS 
30.0 g 
144.0 g 
10.0 g 
Dissolve in distilled 
water to a final volume 
of 1 litre. Store at 4  °C. 
Fixing buffer Distilled water 
Acetic acid 
Methanol 
70% (w/v) 
10% (w/v) 
20% (w/v) 
Store at RT. 
Coomassie 
Brilliant Blue G-
250 solution 
Coomassie Brilliant Blue 
G-250 
Distilled water 
Acetic acid 
Methanol 
0.25% (w/v) 
 
45% (w/v) 
10% (w/v) 
45% (w/v) 
Store at RT. 
Bleaching 
solution for 
SDS-PAGE 
Distilled water 
Acetic acid 
Methanol 
45% (w/v) 
10% (w/v) 
45% (w/v) 
Store at RT. 
 
II.4.3.8. Buffers and solutions for gel mobility-shift assay 
The buffers for gel mobility-shift assay were stored at RT. 
TABLE II.14: Buffers and solutions for gel mobility-shift assay 
Solution Components Amount Preparation 
5×TBE buffer Tris base 
Boric acid 
EDTA (0.5 M, pH 8.0) 
54.0 g 
27.5 g 
20 ml 
Dissolve all 
components in 1 l 
distilled water, adjust 
to pH 8.0, and 
autoclave. 
Native 
polyacrylamid gel 
(6%) 
5×TBE 
Distilled water 
10% (w/v) APS 
TEMED 
1 ml 
9 ml 
0.1 ml 
0.01 ml 
 
Combine all the 
components, except 
APS and TEMED; 
degas under 
vacuum for about 15 
min. Add APS and 
TEMED just before 
pouring the gel (85 x 
75 x 0.75 mm). 
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5×assay buffer Tris-HCl (pH 7.5) 
Glycerol 
DTT 
62.5 mM 
25% (w/v) 
4 mM 
Dissolve Tris base 
and glycerol in 
distilled water and 
adjust to pH 7.5. 
Autoclave. Add DTT 
from a 200 mM 
solution prior to each 
use. 
 
II.5. Plasmids, bacterial strains, primers and probes 
II.5.1. Vectors, cosmids and plasmids 
TABLE II.14: Vectors, cosmids and plasmids 
Name Description Source or 
reference 
Vector 
pBluescript SK(-) Cloning vector, lacZa, ColE1-origin, f1(-)-origin, 
AmpR 
Stratagene 
pBSKT pBluescript SK(+) derivative, lacZa, ColE1-
origin, non-replicative in Streptomyces, AmpR, 
ThioR 
 (Lombó et al., 
1997) 
pcDNA 2.1 Cloning vector, lacZa, ColE1-origin, f1-origin, 
AmpR 
Invitrogen 
pEM4 E. coli - Streptomyces shuttle vector, lacZa, 
ermE* promoter, AmpR, ThioR 
 (Quirós et al., 
1998) 
pGEM-T Linearized vector with T-overhang for direct 
cloning of PCR fragments with A-overhang, 
lacZa, ori, f1-origin,  AmpR 
Promega 
pIJ82 pSET152-derivative, lacZa, pUC-origin, oriT 
(RK2), int and attP of fC31, HygR 
Mike Butler 
(John Innes 
Centre, 
Norwich, UK) 
pKC1132 lacZa, pUC-origin, non-replicative in 
Streptomyces, oriT, ApraR 
 (Bierman et 
al., 1992) 
pLitmus28 Cloning vector, lacZa, ColE1-origin, M13-origin, 
AmpR 
New England 
Biolabs 
pRSET B Expression vector for E. coli, pUC-origin, T7 
promotor, N-terminal 6×His-tag, AmpR 
Invitrogen 
pSL1180 Cloning vector, blue/white selection not possible, 
pUC-origin, M13-origin, AmpR 
Amersham 
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pSPORT1 Cloning vector, lacZa, ori, AmpR Invitrogen 
pUWL 201 E. coli - Streptomyces shuttle vector, ermE* 
promoter, AmpR, ThioR 
 (Doumith et 
al., 2000) 
pWHM3 E. coli-Streptomyces shuttle vector, lacZa, 
AmpR, ThioR 
 (Vara et al., 
1989) 
Cosmid 
Cosmid 9-6G SuperCos1-based cosmid containing the 
novobiocin biosynthetic gene cluster, AmpR, 
KanR 
 (Steffensky et 
al., 2000b) 
Cosmid 10-9C SuperCos1-based cosmid containing the 
novobiocin biosynthetic gene cluster, AmpR, 
KanR 
 (Steffensky et 
al., 2000b)  
Cosmid nov-BG1 From cosmid 10-9C, bla gene replaced by 
cassette from pIJ787 (oriT, tet, attP, int fC31), 
KanR. See Fig. III.6 
Bertolt Gust 
(Eustáquio et 
al., 2004) 
Cosmid K1F2 SuperCos1-based cosmid containing the 
clorobiocin biosynthetic gene cluster without the 
resistance genes gyrBR and parYR (sequence 
AF 329398), AmpR, KanR. 
 (Pojer et al., 
2002) 
Cosmid D1A8 SuperCos1-based cosmid containing the 
clorobiocin biosynthetic gene cluster with the 
resistance gene gyrBR, AmpR, KanR 
 (Pojer et al., 
2002) 
Cosmid clo-BG1 From cosmid D1A8, bla gene replaced by 
cassette from pIJ787 (oriT, tet, attP, int fC31), 
KanR. See Fig. III.7 
Bertolt Gust 
(Eustáquio et 
al., 2005) 
Plasmid 
pcha 1.6 kb BamHI-XbaI fragment (clo-hal) amplified 
by PCR from cosmid K1F2 into the same sites of 
pSETbhaA (clo-hal instead of bhaA), ApraR 
Florence Pojer, 
unpublished 
pIJ787 SuperCos1-derivative, bla gene replaced by a 
cassette containing oriT, tet, attP, int fC31, 
KanR 
Bertolt Gust 
(Eustáquio et 
al., 2004) 
pMS32 1.78 kb BamHI fragment of cosmid 9-6G in 
pBluescript SK(-), containing (T7) the end of 
novC, novD, and the beginning of novE (T3), 
AmpR 
Marion 
Steffensky’s 
Thesis 
pMS33 1.43 kb BamHI-EcoRI fragment of cosmid 9-6G 
in pBluescript SK(-),containing (T3) the end of 
novF, and novG (T7), AmpR 
Marion 
Steffensky’s 
Thesis 
pMS61 3.84 kb BglII fragment of cosmid 9-6G in 
pLitmus28, containing (T3) novO, novP, novQ, 
and the beginning of novR (T7), AmpR 
Marion 
Steffensky’s 
Thesis 
pMS62 5.58 kb BglII fragment of cosmid 9-6G in the 
BamHI site of pBC SK(-), containing the end of 
novS, novT-W, and the start of gyrBR, AmpR 
Marion 
Steffensky’s 
Thesis 
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pMS63 11.83 kb NotI-HindIII fragment of cosmid 9-6G in 
pBlueskript SK(-), containing (T3) ORF21 to 
novG (T7), AmpR 
Marion 
Steffensky’s 
Thesis 
pSETbhaA ermE* promoter and bhaA gene (halogenase 
from balhimycin cluster) in pSET152, ApraR 
 (Puk et al., 
2002) 
pTLO1 0.7 kb HindIII-XhoI fragment (novO and natural 
RBS) amplified by PCR from cosmid 9-6G into 
the same sites of pGEM7Zf(-), AmpR 
Thomas Luft 
(Eustáquio et 
al., 2003a) 
pTLO5 0.7 kb HindIII-XbaI fragment (novO and natural 
RBS) from pTLO1 into the same sites of 
pUWL201, AmpR, ThioR 
Thomas Luft 
(Eustáquio et 
al., 2003a) 
pUG019 pBlueskript SK(-)-derivative containing an 
apramycin resistance (aac(3)IV) cassette 
flanked by XbaI and SpeI restriction sites, AmpR 
Ute Galm 
(Eustáquio et 
al., 2004) 
pZW10 12.748 kb BglII fragment (position 15 530 (T7) to 
28 278 (T3) of AF235050) in the BamHI site of 
pBluescript SK(-), AmpR 
 (Wang et al., 
2000) 
pZW11 14.255 kb BglII fragment (position 1 275 (T7) to 
15 530 (T3) of AF235050) in the BamHI site of 
pBluescript SK(-), AmpR 
 (Wang et al., 
2000) 
 
TABLE II.15: Plasmids and cosmids produced in this study 
Name Description 
Plasmid 
pAE1 1 266 bp ApaI-XhoI fragment (position 9 705 – 10 971 of AF235050) 
from pZW11 into the same sites of pSL1180, containing couN2 
pAE2 1 360 bp XhoI-ApaI fragment (position 3 655 – 5 015 of AF235050) 
from pZW11 into the same sites of pSL1180, containing  the end of 
couI and beginning of couJ 
pAE3 1.44 kb HindIII-EcoRI fragment of pAE2 into the same sites of 
pBluescript SK(-) 
pAE4 1.48 kb EcoRI fragment (position 5 533 – 7 017 of AF235050) from 
pZW11 in the same site of pAE3 
pAE5 2.93 kb HindIII-XbaI fragment of pAE4 into the same sites of 
pKC1132. Construct for in frame inactivation of couJ 
pAE6 2.93 kb HindIII-XbaI fragment of pAE4 into the same sites of pBSKT. 
Construct for in frame inactivation of couJ 
pAE7 209 bp EcoRI-SalI fragment of pMS33 (position 7 613 – 7 821, 
AF170880) in the same sites of pBluescript SK(-), containing the 
NovG binding site (novH) 
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pAE8 1.43 kb BamHI-EcoRI fragment of pMS33 (novG, position 6 393 – 7 
821, AF170880) in the same sites of pWHM3, containing 336 bp 
before the putative start codon of novG 
pAE9 235 bp NotI-Mlu I fragment of cosmid K1F2 (position 12 654 – 12 888, 
AF329398) in the same sites of pSPORT1, containing the NovG 
binding site (cloY) 
pAE-B1 1.6 kb BamHI-XbaI fragment (bhaA) from pSETbhaA into the same 
sites of pSPORT1 
pAE-B2 1.6 kb EcoRI-BamHI fragment (bhaA) from pAE-B1 into the same 
sites of pEM4 
pAE-B3 1.6 kb BamHI-XbaI fragment (bhaA) from pAE-B1 into the same sites 
of pUWL201 
pAE-E1 1 037 bp SalI fragment (position 4 571 – 5 608 of AF170880) from 
pMS63 into the XhoI site of pLitmus28, containing novE, the end of 
novD and beginning of novF 
pAE-E2 1 kb XbaI-BglII fragment from pAE-E1 (novE) into the XbaI-BamHI 
sites of pSPORT1 
pAE-E4_1 1 kb EcoRI fragment from pAE-E2 (novE) into the same site of 
pWHM3 (against the lacZa orientation) 
pAE-E4_3 1 kb EcoRI fragment from pAE-E2 (novE) into the same site of 
pWHM3 (same orientation as lacZa) 
pAE-E5_1 1 kb XbaI-SpeI fragment from pAE-E1 (novE) into the XbaI site of 
pIJ82 (same orientation as lacZa) 
pAE-E5_2 1 kb XbaI-SpeI fragment from pAE-E1 (novE) into the XbaI site of 
pIJ82 (against the lacZa orientation) 
pAE-G1 1.19 kb AatII-EcoRI fragment (novG, position 6 628 – 7 821, 
AF170880) of pMS33 in the same sites of pLitmus28, containing 103 
bp before the putative start codon of novG 
pAE-G2_1 1.20 kb XbaI-SpeI fragment of pAE-G1 (novG) in the XbaI site of 
pWHM3 (against lacZa orientation) 
pAE-G2_2 1.20 kb XbaI-SpeI fragment of pAE-G1 (novG) in the XbaI site of 
pWHM3 (same orientation as lacZa) 
pAE-G4 1 kb PCR fragment (novG, amplified using cosmid nov-BG1 as 
template and primers PnovG_f and PnovG_r) in pGEM-T  
pAE-G5 0.96 kb BamHI-HindIII fragment from pAE-G4 into the same sites of 
pRSET B. Construct for expression of novG from S. spheroides in E. 
coli 
pAE-ha1 1 010 bp PstI-XbaI fragment (position 27 100 – 28 110 of AF329398) 
amplified by PCR (primers Pha1 and Pha2) from cosmid K1F2 into 
the same sites of pcDNA2.1, containing the end of cloN7, und 
beginning of clo-hal 
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pAE-ha2 1 004 bp XbaI-HindIII fragment (position 29 613 – 30 617 of 
AF329398) amplified by PCR (primers Pha3 and Pha4) from cosmid 
K1F2 into the same sites of pBSKT, containing the end of clo-hal and 
beginning of cloP 
pAE-ha3 1 052 bp SacI-XbaI fragment from pAE-ha1 into the same sites of 
pAE-ha2. Construct for in frame inactivation of clo-hal 
pAE-ha4 2 014 bp PstI-HindIII fragment from pAE-ha3 into the same sites of 
pKC1132. Construct for in frame inactivation of clo-hal 
pAE-ha5 1.6 kb BamHI-XbaI fragment (clo-hal and natural RBS) from pcha into 
the same sites of pSPORT1 
pAE-ha6 1.6 kb EcoRI-BamHI fragment (clo-hal and natural RBS) from pAE-
ha5 into the same sites of pEM4 
pAE-ha7 1.6 kb BamHI-XbaI fragment (clo-hal and natural RBS) from pAE-ha5 
into the same sites of pUWL201 
pAE-K1 1 045 bp SacI-XbaI fragment (position 16 394 – 17 439 of AF329398) 
amplified by PCR (primers PK1 and PK2) from cosmid K1F2 into the 
same sites of pcDNA2.1, containing the end of cloI, all cloJ, and 
beginning of cloK 
pAE-K2 992 bp XbaI-PstI fragment (position 17 994 – 18 986 of AF329398) 
amplified by PCR (primers PK3 and PK4) from cosmid K1F2 into the 
same sites of pSPORT1, containing the end of cloK and beginning of 
cloL 
pAE-K3 1 045 bp SacI-XbaI fragment from pAE-K1 into the sames sites of 
pAE-K2 
pAE-R1 
(=pLcouR1-6) 
7 976 bp EcoRI-HindIII fragment (position 17 745 – 25 721 of AF 
235050) from pZW10 into the same sites of pLitmus28, containing 
the end of couP and couR1-couR6 
pAE-R2 
(=pScouR1-6) 
8.0 kb XbaI-BglII fragment from pAE-R1 into the XbaI-BamHI sites of 
pSPORT1, containing the end of couP and couR1-couR6 
pAE-R3 
(=pEMcouR1-
6) 
8.0 kb EcoRI fragment from pAE-R2 into the same site of pEM4, 
containing the end of couP and couR1-couR6 downstream of the 
ermE* promoter 
pAE-Z1 1 018 bp HindIII-PstI fragment (position 38 450 – 39 468 of 
AF329398) amplified by PCR (primers PZ1 and PZ2) from cosmid 
K1F2 into the same sites of pBluescript SK(-), containing the end of 
cloV, all cloW and beginning of cloZ 
pAE-Z2 1 015 bp PstI-XbaI fragment (position 40 146 – 41 161 of AF329398) 
amplified by PCR (primers PK3 and PK4) from cosmid K1F2 into the 
same sites of pBSKT, containing the end of cloZ and beginning of 
gyrBR 
pAE-Z3 1 018 bp HindIII-PstI fragment from pAE-Z1 into the same sites of 
pAE-Z2. Construct for in frame inactivation of cloZ 
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pAE-Z4 2 033 bp HindIII-XbaI fragment from pAE-Z3 into the same sites of 
pKC1132. Construct for in frame inactivation of cloZ 
Cosmid 
D1A8-h-773 
(= H10) 
From D1A8, clo-hal replaced by the apramycin resistance cassette 
from pIJ773 
D1A8-Z-773 
(= Z3) 
From D1A8, cloZ replaced by the apramycin resistance cassette from 
pIJ773 
10-9C-E-773 
(= E1) 
From 10-9C, novE replaced by the apramycin resistance cassette 
from pIJ773 
clo-AE1 From clo-BG1, DNA sequence upstream of cloE was replaced by the 
apramycin resistance cassette from pUG019 
clo-AE2 From clo-AE1, cassette excised by restriction and religation; the 
insert of clo-AE2 comprises the genes from cloE to gyrBR, i.e. DNA 
sequence from position 9 200 to 40 573 in Gene Bank entry 
AF329398, and from position 1 to 2 238 in Gene Bank entry 
AY136281. The insert of clo-AE2 starts 148 bp upstream of the 
translational start codon of cloE (Fig. III.7) 
nov-AE1 From nov-BG1, DNA sequence downstream of gyrBR was replaced 
by the apramycin resistance cassette from pUG019 
nov-AE2 From nov-AE1, cassette excised by restriction and religation 
nov-AE3 From nov-AE2, DNA sequence upstream of novE was replaced by 
the apramycin cassette from pUG019 
nov-AE4 From nov-AE3, cassette excised by restriction and religation; the 
insert of nov-AE4 comprises the genes from novE to gyrBR, i.e. DNA 
sequence from position 4 628 to 25 617 in Gene Bank entry 
AF170880, and from position 1 to 2 490 in Gene Bank entry 
AF205854. The insert of nov-AE4 starts 180 bp upstream of the 
translational start codon of novE (Fig. III.6) 
nov-AE5 From nov-AE2, DNA sequence downstream of ORF20 was replaced 
by the apramycin resistance cassette from pUG019 
nov-AE6 From nov-AE5, cassette excised by restriction and religation; the 
insert of nov-AE6 comprises the genes from ORF20 to gyrBR, i.e. 
DNA sequence from position 5 619 to 6 339 in Gene Bank entry 
AY227005, all sequence from Gene Bank entry AF170880 (1 – 25 
617), and from position 1 to 2 490 in Gene Bank entry AF205854 
(Fig. III.6) 
nov-AE7 From nov-BG1, novO replaced by the apramycin resistance cassette 
from pUG019 
nov-AE8 From nov-AE7, cassette excised by restriction and religation; DnovO 
cosmid (Fig. III.10) 
nov-AE9 From nov-BG1, novG replaced by the apramycin resistance cassette 
from pUG019 
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nov-AE10 From nov-AE9, cassette excised by restriction and religation; DnovG 
cosmid (Fig. III.15) 
 
 
II.5.2. PCR primers used for construction of plasmids 
TABLE II.16: Primers used for construction of plasmids 
Name Sequence (5’-3’)a Restriction 
site 
Positions 
(Acession 
number) 
Plasmid 
PnovG_f TGGGGATCCCATGACCAACAG BamHI 6720-6740 
(AF170880) 
PnovG_r GATTCAAGCTTTTGAACGTCAGG HindIII 7704-7682 
(AF170880) 
pAE-G4 
Pha1 TACGAGATCCAAGCTGCAGGTC PstI 27083-27104 
(AF329398) 
Pha2 GTCATATTCTAGATTTTCGGACAC XbaI 28112-28099 
(AF329398) 
pAE-ha1 
Pha3 ACAGTGAGGATCTAGACCGAAGC XbaI 29603-29625 
(AF329398) 
Pha4 GTCCATTCGAAGCTTGGCGAGC HindIII 30630-30609 
(AF329398) 
pAE-ha2 
PK1 TTGCACGGGATGAGCTCACTGC SacI 16378-16399 
(AF329398) 
PK2 TTCGGTGTCTAGAAGGGCGACG XbaI 17450-17429 
(AF329398) 
pAE-K1 
PK3 GACGGAGTTTCTAGACGACGAGC XbaI 17984-18006 
(AF329398) 
PK4 CAGCACGCCAGGCAACACTGTG --- 19016-18995 
(AF329398) 
pAE-K2 
PZ1 AGGAGAAGCTTGCCGATCCCAA HindIII 38445-38467 
(AF329398) 
PZ2 CACGCTGCAGACCATCATCGAC PstI 39473-39452 
(AF329398) 
pAE-Z1 
PZ3 AGCGCAACTGCAGACGCGTGATG PstI 40135-40157 
(AF329398) 
PZ4 GTGGTCTAGAAGATGTCGCCGTC XbaI 41169-41147 
(AF329398) 
pAE-Z2 
aLetters shown in bold represent mutations inserted in the original sequence to give 
desired restriction sites (underlined). 
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II.5.3. Bacterial strains 
TABLE II.17: Bacterial strains of E. coli and Streptomyces 
Strain Relevant characteristics Source or 
reference 
E. coli XL1Blue 
MRF’ 
General cloning host (recA1 endA1 gyrA96 
thi-1 hsdR17 supE44 relA1 lac [F´ proAB 
laclqZDM15 Tn10 (TetR)]), TetR 
Stratagene 
E. coli ET 12567 Strain triply defective in DNA methylation 
(dam- dcm- hsdM-), TetR, CmR 
 (MacNeil et al., 
1992) 
E. coli 
BL21(DE3)pLysS 
Host for the heterologous expression of 
His6 tagged NovG (F- ompT hsdSB(rB-mB-) 
gal dcm (DE3)pLysS), CmR 
Invitrogen 
 
S. coelicolor M512 DredD DactII-ORF4 SCP1- SCP2- (no 
production of actinorhodin, 
undecylprodigiosin, and methylenomycin) 
 (Floriano and 
Bibb, 1996) 
S. coelicolor (clo-
BG1) 
S. coelicolor M512 containing the 
clorobiocin cluste r and flanking DNA 
regions, KanR 
This thesis 
S. coelicolor (clo-
AE2) 
S. coelicolor M512 containing the 
clorobiocin cluster (from cloE to gyrBR), 
KanR 
This thesis 
S. coelicolor (nov-
BG1) 
S. coelicolor M512 containing the 
novobiocin cluster and flanking DNA 
regions, KanR 
This thesis 
S. coelicolor (nov-
AE4) 
S. coelicolor M512 containing the 
novobiocin cluster (from novE to gyrBR), 
KanR 
This thesis 
S. coelicolor (nov-
AE6) 
S. coelicolor M512 containing the 
novobiocin cluster (from ORF20 to gyrBR), 
KanR 
This thesis 
S. coelicolor (nov-
BG1)/pAE-G2_1 
KanR, ThioR This thesis 
S. coelicolor (nov-
BG1)/pAE-G2_2 
KanR, ThioR This thesis 
S. coelicolor (nov-
BG1)/pAE8 
KanR, ThioR This thesis 
S. coelicolor (nov-
BG1)/pWHM3 
KanR, ThioR This thesis 
S. coelicolor (nov-
AE10) 
S. coelicolor M512 containing a novG-
defective novobiocin cluster, KanR 
This thesis 
S. coelicolor (nov-
AE10)/pAE-G2_1 
KanR, ThioR This thesis 
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S. coelicolor (nov-
AE10)/pAE-G2_2 
KanR, ThioR This thesis 
S. coelicolor (nov-
AE10)/pAE8 
KanR, ThioR This thesis 
S. coelicolor (nov-
AE10)/pWHM3 
KanR, ThioR This thesis 
S. coelicolor (nov-
AE8) 
S. coelicolor M512 containing a novO-
defective novobiocin cluster, KanR 
This thesis 
S. coelicolor (nov-
AE8)/pTLO5 
KanR, ThioR This thesis 
S. coelicolor (nov-
AE8)/pAE-ha7 
KanR, ThioR This thesis 
S. coelicolor (nov-
AE8)/pAE-B3 
KanR, ThioR This thesis 
S. coelicolor (nov-
AE8)/pUWL201 
KanR, ThioR This thesis 
S. lividans TK24 str-6 SLP2- SLP3-  (Kieser et al., 
2000; Shima et al., 
1996) 
S. lividans (clo-BG1) S. lividans TK24 containing the clorobiocin 
cluster and flanking DNA regions, KanR 
This thesis 
S. lividans (nov-
BG1) 
S. lividans TK24 containing the novobiocin 
cluster and flanking DNA regions, KanR 
This thesis 
S. 
roseochromogenes 
var. oscitans DS 
12.976 
Wild-type, clorobiocin producer Aventis (Mancy et 
al., 1974) 
S. 
roseochromogenes 
AE-h2, AE-h10 and 
AE-h11 
Three independent clo-hal- mutants of S. 
roseochromogenes, ApraR 
This thesis 
S. 
roseochromogenes  
AE-h10/pAE-ha7 
clo-hal- mutant complemented with clo-hal, 
ApraR, ThioR 
This thesis 
S. 
roseochromogenes  
AE-h10/pTLO5 
clo-hal- mutant complemented with novO, 
ApraR, ThioR 
This thesis 
S. 
roseochromogenes  
AE-h10/pAE-B3 
clo-hal- mutant transformed with bhaA 
construct, ApraR, ThioR 
This thesis 
S. 
roseochromogenes  
AE-h10/pUWL201 
clo-hal- mutant transformed with empty 
vector pUWL201, ApraR, ThioR 
This thesis 
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S. 
roseochromogenes 
AE-Z4, AE-Z25, and 
AE-Z40 
Three independent cloZ- mutants of S. 
roseochromogenes, ApraR 
This thesis 
S. spheroides 
NCIMB 11897 
Wild-tpye, novobiocin producer The National 
Collection of 
Industrial, Food & 
Marine Bacteria, 
Ltd, Aberdeen 
Scottland 
S. spheroides AE-
E2, AE-E3, and AE-
E4 
Three independent novE- mutants of S. 
spheroides, ApraR 
This thesis 
 
II.5.4. Probes used in Southern blot analysis 
TABLE II.18: DIG-labelled probes  
Probes Description 
clo-hal 946 bp PvuII-XbaI fragment (position 27 164 – 28 110, 
AF329398) from plasmid pAE-ha1 
cloZ 1 027 bp BlnI-BamHI fragment (position 38 909 – 39 468 and 40 
146 – 40 614, AF329398) from plasmid pAE-Z3 
Cosmid clo-BG1 Cosmid clo-BG1 digested with PstI 
Cosmid E1 Cosmid E1 digested with BamHI 
Cosmid H10 Cosmid H10 digested with BamHI 
Cosmid nov-BG1 Cosmid nov-BG1 digested with PstI 
couJ 1.36 kb XhoI-ApaI fragment (position 3 657 – 5 015, AF235050) 
from plasmid pAE2 
novE 962 bp BamHI fragment (position 5 431 – 6 392, AF170880) from 
plasmid pMS63 
 
II.6. Culture conditions 
II.6.1. Cultivation of E. coli 
For cloning experiments, E. coli strains were grown overnight (16-18 h) in liquid or 
solid LB medium with appropriate antibiotic(s) at 37 °C (Sambrook and Russell, 
2001).  
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For NovG overexpression, the incubation temperature was 15 to 30 ºC. 
Permanent cultures of E. coli were prepared by mixing 600 µl of overnight culture 
with 400 µl of glycerol solution (50% (w/v) in distilled water) and stored at -70°C. 
II.6.2. Cultivation of Streptomyces 
II.6.2.1. General cultivation 
Streptomyces strains were routinely cultured in liquid or solid YMG medium. Liquid 
cultures were carried out in baffled Erlenmeyer flasks containing a stainless steel 
spring at 180-200 rpm and 28-30 °C for 2 to 3 days. For preparation of protoplasts, S. 
coelicolor and S. lividans were cultured in YEME medium containing  0.5% glycine; S. 
roseochromogenes, in CRM medium containing 0.75% glycine; and S. spheroides, in 
TSB medium containing 10% sucrose and 0.4% glycine . For isolation of genomic 
DNA, S. coelicolor, S. lividans and S. roseochromogenes were cultured in YEME 
medium; and S. spheroides in YMG medium. An appropriate concentration of 
antibiotic(s) was added, if required. 
II.6.2.2. Production of secondary metabolites 
For the production of clorobiocin and derivatives, 1 ml of a two-day-old YMG culture 
of wild-type or mutant strains of S. roseochromogenes was inoculated into 50 ml corn 
starch medium and grown at 33 °C and 210 rpm for 2 days. 5 ml of this pre-culture 
were inoculated into 500 ml baffled flasks containing 50 ml of production medium, 
Distillers solubles-medium. Cultivation was carried out at 33 °C and 210 rpm for 5 to 
8 days (adapted from (Mancy et al., 1974)). 
For the production of novobiocin and derivatives, about 108 spores or 1 ml of a two-
day-old YMG culture of wild-type or mutant strains of S. spheroides were inoculated 
into 50 ml CDM medium and grown at 28 °C and 180 rpm for 4 days. 1 ml of this pre-
culture was inoculated into 50 ml of CDM medium and grown for 3 to 10 days. 
S. coelicolor and S. lividans parental and mutant strains containing the clorobiocin 
cluster were cultured as described above for S. roseochromogenes. 
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S. coelicolor and S. lividans parental and mutant strains containing the complete or 
modified novobiocin cluster were cultured as described above for S. spheroides. No 
spore suspension of transformants containing muti-copy recombinant plasmids was 
made. In this case, it was observed that the higher productivity was achieved by 
carrying out the cultivation as follows: 1 ml cells from an YMG pre-culture were 
inoculated into 50 ml CDM production medium and cultured at 30 °C and 200 rpm for 
7 days; the cultivation in production medium was carried out without addition of 
antibiotics. 
II.6.2.3. Preparation of mycelia for storage and of spore suspensions of 
Streptomyces 
For preparation of mycelia for storage, 1 ml 2-day-old YMG culture was harvested by 
centrifugation and the cells were resuspended in 0.5 ml 20% glycerol. The storage 
was carried out at -70°C.  
To prepare spore suspensions, Streptomyces strains were spread on YMG agar (S. 
spheroides) or on MS agar (S. coelicolor and S. lividans) and incubated at 30 °C for 
about a week. S. roseochromogenes var. oscitans sporulates not always and if, only 
very slowly (Mancy et al., 1974). Its sporulation media normally contain starch and 
ammonium salts, like Grundy starch medium, which was used during this study.  2-3 
ml 2-day-old YMG culture of S. roseochromogenes strains were mixed with 1 g sterile 
powdered soil and plated on two Grundy starch agar plates. The plates were 
incubated at 28 ºC for four to six weeks (the spores have a light pinkish colour). 
 The plates (one to two plates for good sporulaters, four for more sparely sporulating 
strains) were grown till they were well sporulated. 4 ml of Tween® 20 (0.1% (w/v)) 
were added to each plate and the spores scraped off of the top of the plates and into 
suspension. The resulting spore suspension was poured into a falcon tube and 
vortexed vigorously (about 1 min). The spores were separated from the mycelium by 
passing the suspension through sterile cotton pluged in a disposable syringe. Spores 
were collected by centrifugation (2,100×g, 10 min, 4 °C), and resuspended in 1-3 ml 
of 20% glycerol. The spore suspensions were kept at -70 °C. 
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II.6.2.4. Sensitivity of S. rishiriensis, S. roseochromogenes and S. spheroides 
to different antibiotics 
The sensitivity of S. rishiriensis, S. roseochromogenes and  S. spheroides to 
kanamycin, neomycin, and a mixture of streptomycin (strep) and spectinomycin (spec) 
was tested by (1) platting 100 µl of a 2-day-old YMG culture on YMG agar plates 
containing increasing concentrations of the respective antibiotic; and (2) by a spot 
test, i.e. six spots were made by dropping suspensions containing 102 to 107 spores 
(or alternatively, dilutions of a liquid culture) on YMG agar plates containing 
increasing concentrations of the respective antibiotic. After incubation at 30 ºC for 
five days, the plates were evaluated (Table II.19). 
TABLE II.19: Sensitivity of S. rishiriensis, S. roseochromogenes and S. 
spheroides to different antibiotics 
S. rishiriensis 
Kanamycin (µg/ml) 0 20* 50 100 200 500 
CFU +++ 0 0 0 0 0 
 
Neomycin (µg/ml) 0 10 20 50* 100 200 
CFU +++ + + 0 0 0 
 
Strep/Spec (µg/ml) 0 5/100* 10/200 20/400   
CFU +++ 0 0 0   
 
S. roseochromogenes 
Kanamycin (µg/ml) 0 20* 50 100 200 500 
CFU +++ 0 0 0 0 0 
 
Neomycin (µg/ml) 0 10 20 50* 100 200 
CFU +++ 15 9 0 0 0 
 
S. spheroides 
Kanamycin (µg/ml) 0 20 50* 100 200 500 
CFU +++ 1 0 0 0 0 
 
Neomycin (µg/ml) 0 10* 20 50 100 200 
CFU +++ 0 0 0 0 0 
* Minimal antibiotic concentration, which inhibits growth completely. 
+++ Confluent growth. 
+ Growth observed by the spot test, CFU counting not possible. 
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II.7. Methods of molecular biology 
II.7.1. Purification, concentration and quantification of DNA 
Standard methods for DNA isolation and manipulation were performed as described 
elsewhere  (Kieser et al., 2000; Sambrook and Russell, 2001).  
Phenol/chloroform extraction and ion exchange column chromatography were used 
for purification of DNA. Ethanol or isopropanol precipitation was used for 
concentration.  
Quantification of DNA was carried out by using a GeneQuant photometer (Pharmacia, 
Freiburg, Germany) at 260 nm as well as by comparing the fluorescent intensity with 
DNA markers on agarose gels. 
II.7.2. Agarose gel electophoresis of DNA 
Gel electrophoresis with 0.8-1.5% (w/v) agarose was used to separate DNA 
fragments between 0.5 and 50 kb, and with 2-2.5% NuSieve®GTG® agarose to 
separate DNA fragments between 0.1 and 0.5 kb. The buffer system employed was 
1×TAE buffer (Table II.8).  After running the gels, they were stained with the 
fluorescent dye ethidium bromide, detected under the UV light at 312 nm and 
photographed by using Eagle Eye II System (Strategene, Heidelberg, Germany)  
(Sambrook and Russell, 2001). 
DNA fragments were isolated from agarose gels using a NucleoSpin® 2 in 1 
extraction kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s 
protocol. 
II.7.3. DNA manipulation with enzymes 
Restriction of DNA with endonucleases was carried out according to the 
manufacturer' instructions.  
DNA ligation was achieved by using T4-DNA ligase. The ligation preparation, 
containing 1U T4 DNA ligase, 1×ligation buffer and a 1:1 (mole ratio) mixture of insert 
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and linearized vector (about 100 ng) in a final volume of 10 µl, was incubated at RT 
for 2 h or at 16 °C or 4 °C overnight.    
II.7.4. DNA isolation 
II.7.4.1.  Isolation of plasmids from E. coli 
Mini-preps employing alkaline lysis were used to isolate recombinant plasmids from E. 
coli for routine screening. 3 ml LB-medium was inoculated with a single colony and 
grown overnight at 37 °C, 170 rpm. 2 ml of this culture were harvested by 
centrifugation (10,000×g, 4 °C, 1 min) and resuspended in 250 µl solution MP1 by 
vortexing. The suspension was mixed with 250 µl solution MP2 by inversion and 
incubated at RT for 1-5 min. 250 µl solution MP3 was added and the mixture was 
incubated on ice for 5 min. After centrifugation (20,000×g, 4 °C, 15 min), the 
supernatant was poured into a fresh microfuge tube. The DNA was precipitated by 
addition of 0.8-fold isopropanol and centrifugation (20,000×g, 4 °C, 30 min). The DNA 
pellet was washed with 500 µl 70% ethanol, air dried and resuspended in 50 µl 
distilled water or TE buffer. The mentioned solutions are listed in Table II.5. 
Preparative isolation of plasmids from E. coli was carried out with ion-exchange 
columns (Nucleobond® AX100, Macherey-Nagel, Düren, Germany) according to the 
manufacter´s protocol.  
II.7.4.2.  Isolation of plasmids from Streptomyces 
Isolation of plasmid DNA from Streptomyces strains was carried out by alkaline lysis 
and potassium acetate precipitation, adapted from procedure D (Kieser et al., 2000). 
2 ml of a 2-day-old culture in YEME or YMG medium were harvested by 
centrifugation (17,000×g, 4 °C, 1 min). After washing with 1ml of solution MP1, the 
cells were resuspended in 500 µl of solution MP1GL by vortexing. The suspension 
was incubated at 37 °C for 30-60 min, then mixed with 500 µl of solution MP2 by 
inversion and incubated at RT for 10 min. 400 µl solution MP3 and 40 µl Rotiphenol® 
were added and mixed by inversion. The mixture was incubated on ice for 5 min. 
After 20 min centrifugation (20,000×g, 4 °C), the supernatant was poured into a fresh 
microfuge tube and extracted twice with 300 µl Rotiphenol®. The DNA was 
precipitated by addition of 0.8-fold volume of isopropanol and centrifugation 
 II. MATERIALS AND METHODS 58 
(20,000×g, 4 °C, 20 min). The DNA pellet was washed with 500 µl 70% ethanol, air 
dried and resuspended in 20-50 µl distilled water or TE buffer. If required, the 
plasmid DNA isolated from Streptomyces was amplified in E. coli XL1 blue MRF´ 
before restriction analysis. The mentioned solutions are listed in Tables II.5 and II.6. 
II.7.4.3.  Isolation of genomic DNA from Streptomyces 
Genomic DNA was isolated from S. spheroides by lysozyme treatment and phenol-
chloroform extraction (Kieser et al., 2000).  2 ml of a 2-day-old culture in YMG 
medium were harvested by centrifugation (10,000×g, 4 °C, 1 min). The cells were 
washed with 1 ml TSE buffer and resuspended in 500 µl TSE buffer with lysozym (3 
mg/ml) and RNase A (100 µg/ml) by vortexing. The suspension was incubated for 30 
min at 37 °C and in between mixed well every ten minutes. 250 µl of 2% SDS 
solution were added and the mixture was incubated for 10 min at 60 °C, and for 10 
min at RT. The lysate was extracted three times with 250 µl Rotiphenol®. The third 
extraction was carried out with addition of 70 µl NaAc (pH 4.8). The aqueous phase 
was separated and genomic DNA was precipitated by addition of 0.8-1.0 volume of 
isopropanol and centrifugation (20,000×g, 4 °C, 30 min). The DNA pellet was washed 
with 500 µl 70% ethanol, air dried and resuspended in 50 µl TE buffer.  
Genomic DNA was isolated from S. coelicolor, S. lividans and S. roseochromogenes 
by the Kirby mix procedure (Kieser et al., 2000).  2 ml of a 2-day-old culture in YEME 
medium were harvested by centrifugation (17,000×g, 4 °C, 1 min). The cells were 
washed with 1 ml TSE buffer and resuspended in 500 µl TSE buffer with lysozym (3 
mg/ml) and RNase A (100 µg/ml) by vortexing. The suspension was incubated for 15 
min at 37 °C. 400 µl of 2×Kirby mix were added and the mixture was vortexed 
vigorously for 1 min. 800 µl phenol/chloroform/isoamyl alcohol were added and the 
mixture was vortexed vigorously for 15 s and centrifuged at 17,000×g and 4 °C for 10 
min. The supernatant was poured into a fresh microfuge tube and extracted a second 
time with addition of 70 µl “unbuffered” 3 M NaAc and 300 µl 
phenol/chloroform/isoamyl alcohol (1 min vigorous vortexing). The aqueous phase 
was separated and genomic DNA was precipitated by addition of 0.7-fold volume of 
isopropanol and centrifugation (20,000×g, 4 °C, 30 min). The DNA pellet was washed 
with 500 µl 70% ethanol, air dried and resuspended in 50 to 100 µl TE buffer. 
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II.7.5. DNA denaturation for ssDNA transformation in Streptomyces 
II.7.5.1. Alkaline treatment  
9 µl dsDNA in H2O was mixed with 2 µl 1 M NaOH and incubated for 10 min at 37 °C. 
The mixture was replaced on ice and the reaction was terminated with addition of 2 µl 
1 M HCl (Oh and Chater, 1997). 
 
II.7.6. PCR amplification 
II.7.6.1. General conditions  
PCR amplifications were carried out with the GeneAmp PCR System 2400 (Perkin-
Eimer, Weiterstadt, Germany). The amplification conditions  for PCR reactions  using 
the Expand High Fidelity PCR system (Roche) are given in Table II.20, and using the  
GC-Rich PCR system (Roche) in Table II.21.  
 
TABLE II.20: PCR reaction and amplification conditions using the Expand High 
Fidelity PCR system 
Substance Final concentration  Cyclus Temperature Time Cycles 
Reaction buffer 
(10´) 
1´  Hot start 94 °C 2 min 1 
DMSO  5% (v/v)  Denaturing 94 °C 45 s 
Template DNA about 100 ng  Annealing 50-60 °C 45 s 
dNTPs 0.2 mM each  Elongation 72 °C 90 s 
30 
Primer  50 pmol each  Final elongation 72 °C 5 min 1 
DNA-Polymerase 2.5 U  End 4 °C ¥ 1 
Add distilled water to make up to 50 ml      
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TABLE II.21: PCR reaction and amplification conditions using the GC-Rich PCR 
system  
Substance Final concentration  Cyclus Temperature Time Cycles 
GC-Rich PCR 
reaction buffer with 
DMSO (5´) 
1´  Hot start 95 °C 5 min 1 
 Denaturing 95 °C 90 s GC-Rich resolution 
solution (5 M) 
0.5 mM 
 Annealing 55-60 °C 90 s 
dNTP-Mix 0.2 mM each 
 Elongation 72 °C 45s/ 1 
kb 
30 
Primer 1 20 pmol  Final elongation 72 °C 5 min 1 
Primer 2 20 pmol  End 4 °C ¥ 1 
Template DNA about 100 ng      
GC-Rich PCR 
System enzyme 
mix 
2 U      
Add distilled water to make up to 100 ml      
 
For PCR amplification with Taq or Pfu  polymerase, the PCR mixture (50-100 µl) 
contained 50 pmol each primer, 100-300 ng template DNA, 0.2 mM each dNTP, 1× 
reaction buffer, 5% (v/v) DMSO and 2-3 U polymerase. Amplification conditions were 
according to the supplier’s instructions. 
In general, 5 to 10 µl of the PCR reaction were analysed by gel electrophoresis. 
 
II.7.6.2. Conditions for amplification of the apramycin resistance cassette 
from pIJ773 and from pUG019  
The conditions for amplification of the apramycin resistance cassette from pIJ773 
(REDIRECT© technology kit for PCR targeting (Gust et al., 2003)) using the Expand 
High Fidelity PCR system (Roche) are given in Table II.22. Template DNA was 
prepared by digesting about 10 µg of pIJ773 with EcoRI and HindIII, and by isolating 
the 1.4 kb cassette fragment from an agarose gel (Gust et al., 2003). 
 II. MATERIALS AND METHODS 61 
TABLE II.22: Conditions for amplification of the apramycin resistance cassette 
from pIJ773 
Substance Final concentration  Cyclus Temperature Time Cycles 
Reaction buffer 
(10´) 
1´  Hot start 94 °C 2 min 1 
DMSO  5% (v/v)  Denaturing 94 °C 45 s 
Template DNA about 100 ng  Annealing 50 °C 45 s 
dNTPs 0.2 mM each  Elongation 72 °C 90 s 
10 
Primer  50 pmol each  Denaturing 94 °C 45 s 
DNA-Polymerase 2.5 U  Annealing 55 °C 45 s 
Add distilled water to make up to 50 ml  Elongation 72 °C 90 s 
15 
   Final elongation 72 °C 5 min 1 
   End 4 °C ¥ 1 
For amplification of the apramycin resistance cassette from pUG019, the first 
annealing temperature was 45 ºC instead of 50 ºC and the second, 48 ºC instead of 
55 ºC; otherwise the conditions were the same as listed in Table II.22. Template DNA 
was prepared by digesting about 2 µg of pUG019 with EcoRI, HindIII and DraI (DraI 
cuts three times in the vector backbone, and it is used to guarantee the destruction of 
traces of cccDNA and  to avoid purification of the cassette by gel electrophoresis). 
After digestion, the mixture was purified and concentrated by isopropanol 
precipitation. 
 
II.7.7. Southern blot analysis 
Southern blot analysis was performed on Hybond-N membranes (Amersham) by 
using the DIG high prime DNA labelling and detection starter kit II (Roche). Buffers 
and solutions are given in Table II.9.  
Note: powder-free gloves were always worn to handle the used plastic or glass ware 
and the membrane (which should, if possible, only be handled with a pair of clean 
tweezers on the edges). Plastic and glass ware were thoroughly washed with distilled 
water before use. 
 II. MATERIALS AND METHODS 62 
II.7.7.1. Probe preparation 
Probe for Southern hybridization was prepared by the random priming method using 
the DIG high prime DNA labelling and detection starter Kit II (Roche) according to the 
user’s manual. The probes used in this thesis are listed in Table II.18. 
II.7.7.2. Southern blot preparation 
An agarose gel with DNA digested with appropriated enzymes and the DIG Molecular 
Weight Marker VII (Roche) was run. The gel was stained with ethidium bromide and 
photographed. The DNA was denaturized by soaking the gel in denaturing buffer for 
2´15 min, and then neutralized by soaking in neutralizing buffer for 2´15 min, with 
gentle agitation. Southern blot was carried out by capillary transfer using 20´SSC 
buffer. For this purpose, the gel was placed on pre-wetted (in 20´SSC buffer) filter 
paper and overlaid with pre-wetted (in 2´SSC buffer) Hybond-N nylon membrane and 
pre-wetted (in 20´SSC buffer) filter paper. About 7 cm paper towels and a 1 kg 
weight were stacked on the top. The transfer was carried out overnight. The 
membrane was then crosslinked with UV light (312 nm, 60 s on the front side and 30 
s on the backside) and washed with sterile, distilled water. The membrane was used 
immediately or stored at 4 ºC after air drying.  
II.7.7.3. Prehybridization and hybridization  
The membrane was incubated in prehybridization solution (20 ml/100 cm2) for 4 h at 
68 °C with gentle rotation. Appropiate probe was added to the hybridization solution 
(5-25 ng/ml). This was denaturized by heating (10 min in a boiling water bath), and 
immediately chilled in liquid nitrogen. The prehybridization solution was replaced by 
the hybridization solution containing the appropriate probe (about 7 ml/100 cm2) and 
incubated overnight at 68 °C.  
II.7.7.4. Detection 
The membrane was washed twice with 2´ washing buffer for 10 min at RT, and 
afterwards twice with 0.5´washing buffer at 68 °C for 20 min, with gentle rotation. 
After equilibration in maleic acid buffer for 5 min, the membrane was incubated with 
blocking solution for 30 min and then with antibody solution for 30 min. To remove 
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excess of antibody, the membrane was washed twice in Tween® washing buffer, 15 
min each at RT. Finally, the membrane was equilibrated in detection buffer for 5 min 
and immediately placed between two plastic sheets (which were sealed in two sides) 
with the backside of the membrane placed on one sheet, and the front side remaining 
free by lifting the second sheet. A 1:100 dilution of CSPD stock solution in detection 
buffer was dropped onto the membrane (0.5 ml/100cm2) and spread over it by letting 
down the second sheet. It was incubated at RT for 2-5 min protected from light. 
Excess of solution and air bubbles were removed by wiping the cover sheet with a 
clean paper tower. The membrane was exposed to a Hyperfilm ECL-X-ray film 
(Amersham Biosciences, Freiburg, Germany) at 37 °C for 30 min to 3 h, depending 
on the strength of the signal. The film was developed using standard methods. 
II.7.7.5. Removal of probe 
If necessary, probe was removed by washing the membrane twice with stripping 
solution for 15 min at 37 °C, followed by washing with 2´SSC solution for 30 min at 
RT. After that, the membrane could be used for further hybridization or stored in 
2´SSC solution at 4  °C. 
 
II.7.8. Introduction of DNA in E. coli  
The methods described in this section were modified from Sambrook and Russel 
(2001). 
II.7.8.1. CaCl2-mediated transformation 
Preparation of competent cells : 100 ml LB-medium was inoculated with 1 ml of an 
overnight culture of E. coli and cultivated at 37 °C, 170 rpm till the OD600 reached 0.6 
(2.5-4 h). The cells were harvested by centrifugation (3,000×g, 4 °C, 5 min), 
resuspended in 30 ml ice-cold 0.1 M MgCl2 and again centrifuged as above. The cell 
pellet was suspended in 20 ml ice-cold CaCl2 (0.1 M) and incubated on ice for 20 min. 
After centrifugation, the pellet was suspended in 5 ml of CaCl2 (0.1 M) solution 
containing 15% glycerol. Competent cells could be used immediately or dispensed in 
200-µl aliquots in 1.5-ml microfuge tubes, and stored at -70 °C.  
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Note: Resuspension of cells should not be done by vortexing. Therefore, it is easier 
and quicker to resuspend the cells first in the remaining drops (after discarding the 
supernatant) by tapping the tube, and only afterwards to add the required solution 
and mix gently by inversion. 
Transformation: DNA (0.1-1 µg in 1-5 µl) was added to 100-200 µl competent cells 
in 1.5-ml microfuge tube and incubated on ice for 30 min. The tube was then 
incubated at 42 °C for 2 min and cooled down on ice (about 5 min). 1 ml LB medium 
was pipetted into the tube, and the suspension was incubated on a water bath or on 
a shaker (170 rpm) for 1 h at 37 °C. 200 µl of the mixture were spread on a LB agar 
plate containing the appropriate(s) antibiotic(s) and the rest was centrifuged 
(17,000×g, 4 °C, 30 s), resuspended in 200 µl LB and spread on another LB agar 
plate. The plates were incubated at 37 °C. For transformation of E. coli XL1 Blue 
MRF’ cells with a circular plasmid (cccDNA), the incubation on ice might be 
shortened to 10 min and the incubation with LB medium at 37 °C might be omitted, 
since the transformation efficiency is otherwise too high to allow growth of single 
colonies. However, for E. coli ET12567, all the procedure as described above should 
be carried out, as the transformation efficiency of this strain is lower (about 100-fold). 
Blue/white selection: If a lacZa-containing cloning vector was used to prepare the 
recombinant plasmid, blue/white selection can facilitate the identification of the 
expected clones. For this purpose, first 15 µl of IPTG solution (80 mg/ml) in up to 100 
µl H2O (sterile) were pipetted on the top of the plates and spread evenly, and then 60 
µl of X-Gal solution (20 mg/ml in DMF) was plated in the same way. The plates were 
air dried under the laminar flow for 30-45 min in order to evaporate the toxic DMF. 
Colonies containing the recombinant plasmid lack b-galactosidase activity and 
remain white. 
II.7.8.2. Electroporation 
Preparation of electro-competent cells: 50 ml LB-medium was inoculated with 1 ml 
of an overnight culture of E. coli and cultivated at 30 to 37 °C (see note below), 170 
rpm till the OD600 reached 0.6 (2.5-4 h). The cells were harvested by centrifugation 
(3,000×g, 4°C, 5 min), and washed twice with 50 and 25 ml ice-cold 10% (w/v)  
glycerol solution, respectively. The cell pellet was suspended in the remaining drops 
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after discarding the supernatant. Competent cells could be used immediately or 
dispensed in 50-µl aliquots in 1.5-ml microfuge tubes, and stored at -70 °C.  
Electroporation: DNA (about 100 ng in 1-2 µl distilled water) was added to 50 µl 
competent cells in 1.5-ml microfuge tube and incubated on ice for about 1 min. The 
mixture was then carefully transferred to an ice-cold electroporation cuvette (0.2 cm), 
avoiding formation of air bubbles, and electroporation was carried out using a BioRad 
electroporator set to 2.5 kV. The optimal time constant is 4.5 – 5.0 ms. 1 ml LB 
medium was immediately pipetted into the cuvette , and the suspension was 
transferred to a microfuge tube and incubated on a water bath or on a shaker (170 
rpm) for 1 h at 30 to 37 °C. The mixture was spread on LB agar plates containing the 
appropriate(s) antibiotic(s) (no more than 200 µl per plate) and the plates were 
incubated at 30 to 37 °C. 
Note: To maintain plasmid pIJ790 in E. coli BW25113 (REDIRECT© technology kit for 
PCR targeting (Gust et al., 2003)), cells must be cultured at 30 °C, since pIJ790 
contains a temperature sensitive origin of replication. Otherwise, the cultivation 
temperature was 37 °C. 
 
II.7.9. Introduction of DNA in Streptomyces 
II.7.9.1. PEG-mediated protoplast transformation  
Relevant buffers and media are listed in Table II.11 and in section II.4.1.5, 
respectively. 
Preparation of protoplasts:   
- from S. coelicolor and S. lividans: slightly modified from (Kieser et al., 2000). 
Mycelium from a 40 h old culture (50 ml YEME medium containing 0.5% glycine) was 
washed twice with 15 ml of a 10.3% sucrose solution, resuspended in 10 ml of 
lysozyme solution (2 mg/ml in P buffer) and incubated at 30 ºC for 15-60 min with 
gentle agitation. Protoplast formation was monitored using the microscope. After 
most cells became protoplasts, the reaction was stopped by incubation on ice. The 
following steps were carried out on ice. 10 ml of ice-cold P buffer were added and the 
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suspension was drawn in and out of a 10 ml pipette three times and filtered through 
glass wool. Protoplasts were sedimented gently by centrifugation (e.g. 1,000xg, 7 
min). The supernatant was discarded, the pellet was first carefully resuspended in the 
remaining drop of liquid by tapping the tube, and then in 1 ml P buffer. The protoplast 
suspension can be immediately used for transformation or 100 µl aliquots can be 
stored at -70 ºC. To freeze protoplasts for storage, tubes were placed in ice 
contained in a plastic beaker, and the beaker was placed at -70 ºC overnight. To 
assess the protoplast regeneration, dilution series of the protoplast suspension in P 
buffer were prepared and plated on R2YE agar plates (see note below). The plates 
were incubated at 30 °C for 3-7 days. The regenerable protoplasts per ml suspension 
were calculated. To assess the proportion of non-protoplasted units in the 
suspension, samples were also diluted in distilled water and plated on regeneration 
plates (R2YE agar).  
Note: platting of protoplasts was always done by overlaying with R2YE soft agar 
instead of spreading in order to avoid mechanical stress and lysis. 
- from S. roseochromogenes and S. spheroides: as described above with the 
following modifications: mycelium from CRM cultures or TSB cultures containing 10% 
sucrose and 0.4% glycine, respectively; 1 mg lysozyme/ml P buffer for S. 
roseochromogenes. 
 Transformation: The transformation of Streptomyces strains was carried out by a 
modification of the method described by Kieser et al. (2000).  
Before transformation of Streptomyces strains the plasmids were propagated in E. 
coli ET 12567 to bypass methyl-sensing restriction. S. lividans does not carry a 
methyl-sensing restriction system and DNA from common E. coli strains, such as XL1 
Blue MRF’ or DH5a can be used instead. 
1-20 µg DNA (in maximal 10-20 µl TE buffer) were added to 100-200 µl of a 
protoplast suspension, containing at least 108 protoplasts per ml; 400-500 µl T-buffer 
containing PEG 1000 (45% (w/v) for S. roseochromogenes; 25% (w/v) for other 
strains) were immediately added, mixed by pipetting carefully three times and 
incubated at RT for 1 min. Increasing volumes of the resulting suspension (e.g. 10 µl, 
100 µl, 200 µl, rest) were mixed with warm R3 or R2YE soft agar (about 50 °C, 4×3 
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ml) and plated on four R2YE plates. After 16-24 h incubation at 28 °C - 30 °C, the 
plates were overlaid with 3 ml of soft nutrient agar including the required antibiotics 
for selection of mutants, and incubation was continued for further 3-7 days. In order 
to enhance the efficiency of homologous recombination between inactivation 
constructs and the genome of Streptomyces, denatured DNA was used to transform 
S. roseochromogenes during inactivation via the standard method for in frame 
deletion (Kieser et al., 2000). Transformation with multi-copy plasmids and with 
cosmids containing the site specific integration system of fC31 was carried out 
without denaturing the DNA. 
II.7.9.2. Conjugation from E. coli 
The introduction of DNA by conjugative transfer from E. coli was carried out as 
described by (Kieser et al., 2000) with some modifications. For conjugative transfer, 
the vectors must contain oriT (origin of transfer), and transfer functions must be 
supplied in trans by the E. coli donor strain. In this study, the donor strain E. coli 
ET12567 (triple defective in DNA methylation, CmR) carrying the non-transmissible 
plasmid pUZ8002 (containing the transfer functions, KanR) was used. It is important 
to use strain ET12567 in order to bypass the methyl-sensing restriction system of 
some Streptomyces strains, like S. coelicolor. 
The oriT-containing vector to be transferred into Streptomyces was first introduced 
into E. coli ET12567/pUZ8002 by electroporation (high competence is required when 
methylated plasmids are introduced into methylation-deficient strains, therefore, 
electroporation is preferred to the less efficient CaCl2-mediated transformation). 
Selection was with kanamycin (50 µg/ml), chloramphenicol (25 µg/ml), and the 
antibiotic for the incoming vector. A colony was inoculated into 5 ml LB medium 
containing the antibiotics mentioned above and grown overnight at 37 ºC. The 
overnight culture was diluted 1:100 in LB medium plus antibiotics and grown at 37 ºC 
to an OD600 of approximately 0.6 (about 4 h). The cells were harvest by centrifugation 
and washed twice with an equal volume of LB medium (to remove antibiotics) and 
resuspended in 0.1 volume of LB medium. 
Different media (MS, MS supplemented with MgCl2, YMG) and quality of the receptor 
strain (spores, heat-shocked spores, mycelium from a TSB/YEME culture) were 
tested. The optimal conditions were as follows. 
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For S. spheroides: A spore suspension was thawed on ice and an aliquot 
corresponding approximately 108 spores was harvest by centrifugation. The 
supernatant was discarded and 0.5 ml of the E. coli suspension described above 
were mixed gently with the spore pellet. Note that the heat shock treatment described 
by (Kieser et al., 2000) was omitted, which gave the best results. 
For S. roseochromogenes: Fresh mycelium from 50 ml TSB/YEME 1:1 liquid culture 
was used instead of spores. After centrifugation, the mycelium was washed with 
10.3% sucrose solution and resuspended in 5 ml 2´YT broth (Sambrook and Russell, 
2001). 0.5 ml of the Streptomyces suspension was gently mixed with 0.5 ml of the E. 
coli suspension. 
Each mixture was spread on two MS plates (supplemented with 10 mM MgCl2 for S. 
spheroides, and without MgCl2 for S. roseochromogenes), and incubated at 30 ºC for 
about 18 h, then overlaid with 1 ml water containing 0.5 mg nalidixic acid and an 
appropriate amount of the respective antibiotic for the incoming vector (e.g. 1.25 mg 
apramycin for cosmids H10, Z3 and E1). Incubation at 30 °C was continued for about 
a week to allow outgrowth of the exconjugants. Potential exconjugants (resistant 
colonies) were picked off to selective media containing nalidixic acid (25 µg/ml) and 
the antibiotic for the incoming vector, and analysed by Southern blotting . 
 
II.7.10.  DNA sequencing and computer-assisted sequence analysis 
Double-stranded sequencing  of recombinant plasmids was done by the 
dideoxynucleotide chain termination method on a LI-COR automatic sequencer 
(MWG-Biotech AG, Ebersberg, Germany). 
The DNASIS software package (Version 2.1, Hitachi Software Engineering, San 
Bruno, CA, USA) was used for sequence analysis. Amino acid sequence homology 
searches were performed by using the BLAST program (Version 2.0) available on the 
web at www.ncbi.nim.nih.gov/BLAST/. The secondary structure of NovG was 
predicted using the PHD (Profile network prediction Heidelberg) method (Rost, 1996), 
available on the web at http://www.embl-heidelberg.de/predictprotein. 
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II.8. Methods of biochemistry and biology 
II.8.1. Denaturing Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The discontinuous SDS-PAGE was carried out according to the method of Laemmli  
(1970). Probes were mixed with sample buffer in ration 1:1 to 1:4 and incubated for 5 
min in boiling water. 4% and 12% Polyacrylamide gel were used as stocking and 
resolving gel, respectively. Gel electrophoresis was carried out with working voltage 
of 200 V using the Mini-PROTEAN® II Electrophoresis Cell (Bio-Rad, München, 
Germany). Protein bands were stained with Coomassie Brilliant Blue G-250 (s. Table 
II.13): 1-5 min in Fixing buffer, 15 min in Coomassie Brilliant Blue G-250 solution, and 
90 min in Bleaching solution. To determine protein sizes, the Low Molecular Weight 
Calibration Kit for SDS gel electrophoresis (Amersham Biosciences, Freiburg, 
Germany) was used. 
 
II.8.2.  Overexpression and purification of recombinant protein from E. 
coli 
Overexpression and purification of 6×His-tagged NovG protein from E. coli were 
carried out as described by the user manual of Qiagen (Qiagen, Hilden, Germany), “a 
handbook for high level expression and purification of 6×His-tagged proteins”. 
Different conditions for cultivation and purification were tested (e.g. different 
cultivation temperatures, amount of IPTG used for induction, concentration of 
imidazol in the washing buffer, elution; see also Results). The preparative method 
described bellow yielded the best results.  
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II.8.2.1. Cultivation 
Five litres of LB medium containing 50 µg carbenicillin/ml and 35 µg 
chloramphenicol/ml were inoculated with E. coli BL21(DE3)pLysS/pAE-G5 cells; 
sufficient inoculum was used to reach an initial optical density of 0.1 at 600 nm 
(OD600). Cells were then cultured at 30 ºC. When the OD600 reached a value of 0.6, 
IPTG was added to a final concentration of 0.5 mM. After further growth for 1.5 h at 
30 ºC, cells were harvested by centrifugation and frozen at -70 ºC.  
II.8.2.2. Preparation of cell-free extract 
All the following steps were carried out at 4 ºC. After thawing on ice, cells (16 g) were 
suspended in 20 ml ice cold lysis buffer (50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 10 
mM imidazole, 2 mg lysozyme/ml) and incubated on ice for 30 min. The cell 
suspension was sonicated for 7 ´ 30 s with 30 s interva ls between each sonication 
treatment (Branson Sonifier 250). Subsequently, cellular debris was removed by 
centrifugation (17,500´g for 30 min). 
II.8.2.3. Purification by nickel affinity chromatography 
Histidine fusion protein was purified from the soluble cell extract by metal affinity 
chromatography using Ni-nitrilotriacetic acid (Ni-NTA) agarose resin (Qiagen, Hilden, 
Germany) according to the manufacturer´s instructions. 3 ml of Ni-NTA-agarose 
slurry (50% (w/v) Ni-NTA agarose resin suspension in 30% (v/v)  ethanol, precharged 
with Ni2+) were added to 3 ml lysis buffer and stirred gently for about 15 min. The cell 
free extract was added to the Ni-NTA-agarose mixture described above and stirred 
gently for 60 min. 10 ml of washing buffer (50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 
20 mM imidazole) were added and the protein-Ni-NTA-agarose mixture was 
harvested by centrifugation (5,000´g for 10 min at 4 ºC) and washed twice with 30 ml 
washing buffer (5,000´g for 10 min at 4 ºC) to remove unbound proteins. The pellet 
was suspended in washing buffer and loaded into a column. After further washing 
with 3 ´ 4 ml washing buffer containing 50 mM imidazole, unspecifically bound 
proteins were eluted using a stepwise imidazole gradient: 2 ´ 1 ml 100 mM, 1 ´ 1 ml 
150 mM, and 1 ´ 1 ml 200 mM imidazole in washing buffer. The NovG fusion protein 
was subsequently eluted with 4 ml of elution buffer (50 mM NaH2PO4, pH 8.0, 300 
mM NaCl, 250 mM imidazole). 10 µl-aliquots were analysed by SDS-PAGE. 1 ml 
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Eluate fractions containing the NovG fusion protein (38.1 kDa) were applied onto a 
NAP 10 column (Amersham Biosciences) and eluted with 1.2 ml storage buffer (25 
mM Tris-HCl (pH 7.5), 10% (w/v) glycerol, 2 mM DTT). Aliquots of NovG fusion 
protein in storage buffer can be shock frozen in liquid nitrogen and stored at -70 ºC. 
 
II.8.3. Gel mobility-shift assays 
II.8.3.1. Preparation of 3´-end DIG-labeled DNA fragments 
The following DNA fragments were used in gel mobility-shift assays: 
(1) the 325 bp AvaI-fragment obtained from pMS32 (position 4 463 to 4 787 in 
AF170880, i.e. upstream of novE); (2) the 341 bp PvuI-SalI-fragment obtained from 
pMS32 (position 4 231 to 4 571 in AF170880, i.e. upstream of novE); (3) the 272 bp 
PCR product obtained using pMS63 as template and the primer pair Pnov$F_f (5´-
AGG ACC ACT GGC TCG ATT TCG-3´) and Pnov$F_r (5´-GTC ACG CGC GAA 
GCC GTG AG-3´) (position 5 238 to 5 509 in AF170880, i.e. upstream of novF); (4) 
the 265 bp PCR product obtained using pMS33 as template and the primer pair 
Pnov$G_f (5´-GAG CTG GCC CGC CTC TTC GA-3´) and Pnov$G_r (5´-ACT TAA 
TGG TCT GGT CCG GAT CG-3´) (position 6 451 to 6 715 in AF170880, i.e. 
upstream of novG); (5) the 180 bp Van91I-HindIII-fragment obtained from pMS63 
(position 7 725 to 7 904 in AF170880, i.e. upstream of novH); (6) the 209 bp SalI-
EcoRI-fragment obtained from pMS33 (position 7 613 to 7 821 in AF170880, i.e. 
upstream of novH); (7) the 244 bp BamHI-fragment obtained from pMS61 (position 
17 264 to 17 507 in AF170880, i.e. upstream of novO); (8) the 252 bp PCR product 
obtained using pMS61 as template and the primer pair Pnov$O_f (5´-TGT ACG AGC 
TGC TCA CCC ACG-3´) and Pnov$O_r (5´-TGA ATT GAG CCT ACA CGG ACA C-
3´) (position 17 101 to 17 352 in AF170880, i.e. upstream of novO); (9) the 231 bp 
PCR product obtained using pMS62 as template and the primer pair Pgyr$_f (5´-
GCG CAG AGG TGC TCT CGT TCC-3´) and Pgyr$_r (5´-TGC GGG TGT CGT AAG 
AAG TCA C-3´) (position 168 to 398 in AF205854, i.e. upstream of gyrBR); (10) the 
277 bp SmaI-fragment obtained from pMS62 (position 25 608 to 25 617 in AF170880 
and 4 to 270 in AF205854, i.e. upstream of gyrBR); (11) the 235 bp NotI-MluI-
fragment obtained from pAE9 (position 12 654 to 12 888 in AF329398, i.e. upstream 
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of cloY); (12) the 255 bp PCR product obtained using cosmid K1F2 as template and 
the primer pair Pclo$H_1f (5´-GAA CGG CTC CTA TCT GGT CC-3´) and Pclo$H_1r 
(5´-CGG CCT TCG AAC AAC CTT CG-3´) (position 12 946 to 13 200 in AF329398, 
i.e. upstream of cloH); and (13) the 260 bp PCR product obtained using cosmid K1F2 
as template and the primer pair Pclo$H_2f (5´-TGG GTG GCG AGT AGC ATC TG-
3´) and Pclo$H_2r (5´-CTT AAG TCT CCA TGC CAT TGG-3´) (position 13 122 to 13 
381 in AF329398, i.e. upstream of cloH). 
PCR products were obtained using the Expand High Fidelity PCR System (Table 
II.20). Plasmids and cosmids used are described in Tables II.14 and II.15. 
After purification by NuSieve GTG-agarose (FMC BioProducts) gel electrophoresis, 
DNA fragments were 3 -´end labeled with DIG-11-ddUTP using the DIG Gel Shift Kit, 
2nd Generation (Roche) according to the manufacturer’s instructions. 
 
II.8.3.2. Gel mobility-shift assay 
Gel mobility-shift assays were performed using the DIG Gel Shift Kit, 2nd Generation 
(Roche) according to the manufacturer’s instructions. 
The DNA-binding reaction conditions were adapted from (Retzlaff and Distler, 1995). 
It was carried out at 25 ºC in 20 µl of 12.5 mM Tris-HCl (pH 7.5), 5% (w/v) glycerol, 
62.5 mM KCl, 1 mM DTT, 5 mM MgCl2, 50 ng poly [d(I-C)] µl-1, 5 ng poly L-lysine µl-1. 
In general, about 4 ng of DIG-labeled DNA fragment and approximately 0.5 µg of 
purified His6 tagged NovG were used for each assay. 
For testing the specificity of binding, competitor plasmid-DNA or the respective empty 
vector were added in approximately 125-fold molar excess in comparison to the 
labeled fragment. 
After 15 min of incubation, the reaction mixture was applied to a pre-run (20 min at 35 
V) 6% (w/v) native polyacrylamide gel (85 ´ 75 ´ 0.75 mm) with 0.5´TBE as running 
buffer (Table II.14). The gel was run at 35 V for about 3 h, and transferred to a 
positively charged Hybond-N+ nylon membrane (Amersham) by contact blotting. 
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Crosslinking and detection were carried out following the manufacturer’s instructions  
of the DIG Gel Shift kit. 
 
II.8.4. Bioassay with Bacillus subtilis 
Antibacterial activity was determined by a disc diffusion assay using Bacillus subtilis 
ATCC 14893 as the indicator strain. Different amounts of aminocoumarin antibiotics 
dissolved in 5-20 µl of methanol were applied to filter paper disks (Ø 6 mm; MN 440 
B blotting paper, Macherey-Nagel), air dried under the clean bench and placed on 
the top of nutrient agar plates, which were seeded with 2´105 B. subtilis spores per 
ml of agar medium. Plates were cultured overnight at 37 °C, and the diameters of 
growth inhibition zones measured. Novobiocin (Fluka) and clorobiocin (Aventis) were 
used as reference substances. 
 
II.9. Construction of deletion mutants of S. roseochromogenes 
and S. spheroides 
II.9.1. Inactivation of clo-hal in S. roseochromogenes 
clo-hal was inactivated using the PCR targeting system (Gust et al., 2003), which 
takes advantage of the l-Red recombination functions (gam, bet, exo) to promote 
gene replacement. An aac(3)IV (=apramycin resistance gene)/oriT  cassette for 
replacement of clo-hal was generated by PCR (see Table II.22) using the primer pair 
P1-clo-hal (5 -´ ATT GGC GAT TTA TCG TCA GCG GTT GGA GGA AGT AGC GTG 
ATT CCG GGG ATC CGT CGA CC -3´) and P2-clo-hal (5´- AGC CTT CGG GCG 
AGA AGT CCT CGT CAC GTA CCG CGC TTA TGT AGG CTG GAG CTG CTT C-
3´). Underlined letters represent 39 nt homologous extensions to the DNA regions 
immediately upstream and downstream of clo-hal including the putative start and stop 
codons of clo-hal, respectively. This cassette was introduced into E. coli 
BW25113/pIJ790, containing cosmid D1A8 (SuperCos1-based, kanamycin-resistant) 
which included the entire biosynthetic gene cluster of clorobiocin. The gene 
replacement was confirmed by restriction analysis and PCR using test primers TP1-
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clo-hal (5´- GGA ACG GAA GCT TGG CTA TC-3´) and TP2-clo-hal (5´- GAA GTG 
CGA CAG GAT CTG GA-3´). 
The mutated cosmid (termed D1A8-h-773, = H10) was introduced into Streptomyces 
roseochromogenes by conjugation from E. coli ET12567 carrying the non-
transmissible pUZ8002 (see II.7.9.2). Apramycin-resistant, kanamycin-sensitive 
colonies were identified by replica plating and characterised by PCR (using Taq 
polymerase and the test primers mentioned above) and Southern blot analysis. 
II.9.2. Inactivation of cloZ in S. roseochromogenes 
cloZ was inactivated as described for clo-hal. The primer pair used for amplification of 
the aac(3)IV/oriT  cassette was: P1-cloZ (5´-GGC CTG TCA GGC GTT AAC GGC 
GTT GAC TCG TCG ATG ATG ATT CCG GGG ATC CGT CGA CC-3´), P2-cloZ (5´-
CCG GCG TAA CCC TCC GCG GTC GCC AGT CGC GCT GCG TCA TGT AGG 
CTG GAG CTG CTT C-3´). 
The mutated cosmid was termed D1A8-Z-773 (= Z3). 
Test primers were: TP1-cloZ (5´-GAT CCT GAA TTG GCC ATC AAC-3´), TP2-cloZ 
(5´-ATG CGT CAG ACG AGA ACT CAC-3´). 
II.9.3. Inactivation of novE in S. spheroides 
Within cosmid 10-9C (SuperCos1-based) containing the biosynthetic gene cluster of 
novobiocin, novE was inactivated as described for clo-hal. The primer pair used for 
amplification of the aac(3)IV/oriT  cassette was: P1-novE (5´-GCC GGT CCG CTT 
GTC CCG AGG GGA AGA GAG GCA TCG TGA TTC CGG GGA TCC GTC GAC C-
3´); P2-novE (5´-GCC GTG AGG CCG CGA AAT GGA TCG GAG TGC GTC CGG 
TCA TGT AGG CTG GAG CTG CTT C-3´). 
The mutated cosmid was termed 10-9C-E-773 (= E1). 
Test primers were: TP1-novE (5 -´CCG TCA ACA AGT GAA CCC AA-3´) and TP2-
novE (5´-GTC CAT GAG GTA GGA GTC GA-3´). 
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II.10. Heterologous expression of the novobiocin and clorobiocin 
biosynthetic gene clusters 
Plasmid pIJ787 was constructed by Dr. Bertolt Gust (John Innes Centre, Norwich) 
using standard cloning techniques and l-Red-mediated recombination. pIJ787 is a 
SuperCos1 derivative, in which the ampicillin resistance gene (bla) was replaced by a 
cassette containing the integrase gene (int) and attachment site (attP) of phage fC31 
as well as a resistance marker (tet, tetracycline resistance gene). 
The DraI-BsaI-fragment of pIJ787, containing the integrase cassette and flanked by 
about 100 bp bla sequence on one site and about 300 bp bla sequence on the other 
side was used to replace the respective bla gene in the SuperCos1 backbone of 
cosmids 10-9C and D1A8, via l-Red-mediated recombination (Datsenko and Wanner, 
2000; Gust et al., 2003), generating nov-BG1 and clo -BG1, respectively (by Dr. 
Bertolt Gust). 
The modified cosmids nov-BG1 and clo -BG1, still carrying the kanamycin resistance 
gene neo, were then introduced into S. coelicolor M512 and S. lividans TK24 via 
PEG-mediated protoplast transformation (see II.7.9.1). Kanamycin resistant clones 
were checked for site specific integration into the genome by Southern blot analysis. 
II.10.1.  Protocol for single or multiple deletions within the cosmids 
The apramycin resistance cassette (approximately 1 kb) was excised from pUG019 
by digestion with EcoRI and HindIII and amplified by PCR using the forward primer 
5´-(N)39 ATT CCG GGG ATC TCT AGA TCT-3´ and the reverse primer 5´-(N)39 ACT 
AGT CTG GAG CTG CTT C-3´. (N)39 represents 39 nt extensions for l-Red-
mediated recombination, homologous to the regions upstream and downstream of 
the DNA fragment to be deleted; underlined are the XbaI and SpeI restriction sites. 
Amplification was performed using the Expand High Fidelity PCR system as 
described at II.7.6.2. The PCR product was used for gene replacement in cosmids 
via l-Red-mediated recombination, according to the instructions of the REDIRECT© 
technology kit (Gust et al., 2003). The PCR product was introduced into the cells by 
electroporation. Cosmids which had integrated the cassette were isolated and 
analyzed by restriction enzyme digestion. For excision of the resistance cassette, 
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cosmid DNA was isolated from E. coli ET12567, digested with XbaI and SpeI and 
100 ng DNA were religated overnight at 4 °C. CaCl2-competent E. coli XL1 Blue 
MRF’ cells were transformed with the ligation reaction. Apramycin-sensitive 
kanamycin-resistant clones were analyzed by restriction enzyme digestion and gel 
electrophoresis. Correct excision of the cassette was indicated by the absence of 
XbaI and SpeI sites, as well as by the absence of a BglII site internal to the cassette. 
For subsequent gene deletions, the identical procedure was used. 
II.10.2.  Removal of non-essential DNA regions from the cosmid inserts 
Using the procedure described above (II.10.1), cosmids nov-AE6 and nov-AE4 were 
generated (see Fig. III.6). First, the region downstream of gyrBR was removed from 
nov-BG1, using primers PnovgyrB_f (5´-GGT TCC TCC AGC GTG GCC ACG ACC 
ATG ACC GGG AGG TCG ATT CCG GGG ATC TCT AGA TC-3´) and PT3SC1_r 
(5´-GTC TTC AAG AAT TCG CGG CCG CAA TTA ACC CTC ACT AAA ACT AGT 
CTG GAG CTG CTT C-3´) generating cosmid nov-AE2. Underlined letters represent 
the 39 nt extensions homologous to the region downstream of gyrBR and to the T3 
promoter of SuperCos1, respectively. Subsequently, ORF21 was deleted from nov-
AE2 using primers PT7SC1_f (5´-ACA TGA GAA TTC GCG GCC GCA TAA TAC 
GAC TCA CTA TAG ATT CCG GGG ATC TCT AGA TC-3´), and Pnov20_r (5 -´CTT 
CCC GAG GTT CAA TTC CGC CGC GCA CGT CAG CTC CTC ACT AGT CTG 
GAG CTG CTT C-3´) generating cosmid nov-AE6. Underlined are sequences 
homologous to the T7 promoter region of SuperCos1 and to the region downstream 
of ORF20, respectively. Alternatively, the entire region upstream of novE was deleted 
from nov-AE2, using primers PT7SC1_f (see above), and PnovE_r (5´-GCT GGA 
ATG CGC GGC TGC CGT CGC CGG GAC GGT CCC GGC ACT AGT CTG GAG 
CTG CTT C-3´) generating cosmid nov-AE4. Underlined is the sequence 
homologous to the region directly downstream of novD.  
clo-AE2, containing genes from cloE to gyrBR, was generated from clo-BG1 in the 
same way using primers Pcloorf9_f (5´-TAG TAT GGC GAA ATT GGG TGA TCT 
GCT TGC CGC CGT CGA ATT CCG GGG ATC TCT AGA TC-3´) and PT3SC1_r 
(see above). 
See Table II.15 for details about the insert’s sequence of nov-AE4, nov-AE6 and clo-
AE2. 
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II.10.3.  Inactivation of novO in cosmid nov-BG1, and heterologous 
expression of the novO- cosmid 
In cosmid nov-BG1, novO was replaced by the apramycin resistance (aac(3)IV) 
cassette from pUG019 as described at II.10.1 . The cassette for replacement of novO 
was generated by PCR using the primer pair P1-NovO (5´-AGA TCA GCT CAC TGA 
CCC AAC ACG AGG GGC ATC GAG ATG ATT CCG GGG ATC TCT AGA TC-3´) 
and P2-NovO (5´-CGG GTC CAG GCG CTC TGT TCG GGA CAA TTC CGC CGC 
TCA ACT AGT CTG GAG CTG CTT C-3´). Underlined letters represent 39 nt 
homologous extensions to the DNA regions immediately upstream and downstream 
of novO, respectively, including the putative start and stop codons of novO; the XbaI 
and SpeI restriction sites are presented in bold letters. 
The generated DnovO cosmid nov-AE8, carrying the kanamycin resistance gene neo, 
was introduced into S. coelicolor M512 by PEG-mediated protoplast transformation. 
Kanamycin resistant clones were checked for specific genomic integration of cosmid 
nov-AE8 into the fC31 attachment site by Southern blot analysis. 
II.10.4.  Inactivation of novG in cosmid nov-BG1, and heterologous 
expression of the novG- cosmid 
In cosmid nov-BG1, novG was replaced by the apramycin resistance (aac(3)IV) 
cassette from pUG019 as described at II.10.1 . The cassette for replacement of novG 
was generated by PCR using the primer pair P1-novG (5´-GAT CCG GAC CAG ACC 
ATT AAG TCC TAT GGG GGT TAC ATG ATT CCG GGG ATC TCT AGA TC-3´) 
and P2-novG (5 -´CAA CCG AAT GAT TCG AGC AGT TGA ACG TCA GGC GGT 
GTC ACT AGT CTG GAG CTG CTT C-3´). Underlined letters represent 39 nt 
homologous extensions to the DNA regions immediately upstream and downstream 
of novG, including the putative translational start and stop codons of novG, 
respectively; the XbaI and SpeI restriction sites are presented in bold letters. 
The generated DnovG cosmid nov-AE10, carrying the kanamycin resistance gene 
neo, was introduced into S. coelicolor M512 by PEG-mediated protoplast 
transformation. Kanamycin resistant clones were checked for specific genomic 
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integration of cosmid nov-AE10 into the fC31 attachment site by Southern blot 
analysis. 
 
II.11. Analysis and isolation of secondary metabolites 
II.11.1.  HPLC analysis 
II.11.1.1. Analysis of clorobiocin and derivatives 
Constructed mutants, transformants and the wild-type strain of S. roseochromogenes, 
and S. lividans or S. coelicolor carrying the clorobiocin cluster were cultured in 
production medium as described at II.6.2.2. 1-5 ml bacterial culture were acidified 
with HCl to pH 3 and extracted twice with an equal volume of ethyl acetate. After 
evaporation of the solvent, the residue was redissolved in 0.25-1 ml ethanol. After 
centrifugation, 10 to 100 µl of the clear supernatant was analysed by HPLC with a 
Multosphere RP18-5 column (250´4 mm; 5 µm; C+S Chromatographie Service, 
Düren, Germany) at flow rate of 1 ml/min, using a linear gradient from 40 to 100% of 
solvent B in 25 min (solvent A, MeOH : H2O : HCOOH 50:49:1; solvent B, MeOH : 
HCOOH 99:1) with detection at 340 nm. Authentic clorobiocin (Aventis) was used as 
standard.  
II.11.1.2. Analysis of novobiocin and derivatives 
Constructed mutants, transformants and the wild-type strain of S. spheroides, and S. 
lividans or S. coelicolor carrying the novobiocin cluster were cultured in CDM medium 
as described at II.6.2.2. After centrifugation, the clear supernatant was analysed by 
HPLC with a Multosphere RP18-5 column (250 x 4 mm; 5 µm; C+S Chromatographie 
Service, Düren, Germany) with a linear gradient from 60 to 100% methanol in 1% 
aqueous formic acid and detection at 305 nm. Authentic novobiocin (Fluka) was used 
as standard. 
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II.11.2.  Preparative isolation of aminocoumarins 
II.11.2.1. Column chromatography using Sephadex® LH-20 
Column chromatography was used to pre-purify the culture extract. Crude culture 
extract (max. 3 ml) was loaded onto a glass column (100´2.6 cm) with Sephadex LH-
20 (Amersham Biosciences, Freiburg, Germany). The column was eluted with 
degased methanol with a flow rate of 1 ml/min. 15 ml eluates were collected by a 
fraction collector and controlled by HPLC. Fractions containing the expected 
compounds were pooled and the solvent removed in vacuum. The residue was 
dissolved in methanol and used for further purification by HPLC.  
II.11.2.2. Preparative HPLC 
Preparative HPLC was carried out on a Multosphere 120 RP 18-5 column (5 µm, 
250´20 mm; C+S Chromatographie Service, Düren Germany) with a flow rate of 3 ml. 
Solvents were as described at II.11.1. Concentrated culture extract or LH-20 fractions 
were injected and analysed. The expected eluates after HPLC analysis were 
collected and the solvent was evaporated in vacuum. The residues were dried over 
phosphorus pentoxide and subjected to MS and NMR (1H-NMR and 13C-NMR) 
analysis. 
 
II.11.3.  Spectroscopic methods for structural elucidation 
II.11.3.1. Negative-ion FAB mass spectroscopy 
Negative-ion fast atom bombardment (FAB) mass spectra were recorded on a 
TSQ70 spectrometer (Finnigan, Bremen, Germany) using diethanolamine as matrix. 
Negative-ion FAB MS data (m/z (relative intensity in %)) were as follows: 
Clorobiocin: 697 (24, [M-H]-, 37Cl), 696 (28, [M-H]-, 13C), 695 (80, [M-H]-, 35Cl), 661 
(17, [M-HCl]-), 588 (7, [M-C6H7ON, = M-pyrrol unit]-), 507 (23), 473 (9), 413.5 (38), 
379 (32), 283 (31), 226 (100). 
Novclobiocin 101: 661 (50, [M-H]-), 473 (20), 380 (15), 339 (38), 283 (37), 209 (100). 
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Novclobiocin 102: 675 (72, [M-H]-), 661 (6, [M-CH4]-), 568 (7, [M-C6H7ON, = M-
pyrrol unit]-), 487 (28, [M-C12H14O2, = M-ring A]-), 447 (22), 394 (24), 271 (50), 251 
(70), 205 (100). 
Novobiocin: 611 (8, [M-H]-), 568 (7, [M-CONH]-), 395 (7), 378 (6), 281 (10), 255 (24), 
209 (100). 
Novclobiocic acid 106: 380 (18, [M-H]-), 283 (10), 255 (22), 209 (100). 
Novclobiocin 117: 597 (7, [M-H]-), 380 (4), 314 (6), 283 (10), 255 (13), 209 (100). 
Novclobiocin 114: 633 (5, [M-H]-, 37Cl), 632 (5, [M-H]-, 13C), 631 (15, [M-H]-, 35Cl), 
588 (5, [M-CONH]-), 554 (4, [M-CH2ONCl]-), 380 (7), 255 (46), 209 (100). 
Novclobiocin 119: 633 (10, [M-H]-, 37Cl), 632 (11, [M-H]-, 13C), 631 (32, [M-H]-, 35Cl), 
588 (12, [M-CONH]-), 554 (6, [M-CH2ONCl]-), 400 (25), 255 (68), 209 (100). 
II.11.3.2. Nuclear magnetic resonance (NMR) 
1H NMR and 13C NMR spectra were measured on an AC 250, on an AMX 400, or on 
an AMX 600 spectrometer (250, 400, and 600 MHz, respectively; Bruker, Karlsruhe, 
Germany), using CD3OD as solvent. 
For 1H and 13C NMR data of clorobiocin, novclobiocin 101 and novclobiocin 102, see 
Table III.1 and III.2, respectively. For 1H NMR data of novobiocin, novclobiocic acid 
106, novclobiocin 117, 114 and 119, see Table III.4. 
In case of strains harboring nov-BG1, nov-AE6 and nov-AE4 (comprising the 
novobiocin cluster), the isolated compound showed a molecular ion [M-H]- at m/z 611 
(novobiocin = C31H36N2O11; molecular weight, 612). The isolated substance gave the 
following 1H NMR signals: dppm 7.81 (1H, d, J=8.9 Hz, H-5´); 7.75 (1H, br (=broad) s, 
H-2); 7.72 (1H, br d, J=8.3 Hz, H-6); 7.23 (1H, br d, J=8.9 Hz, H-6´); 6.84 (1H, d, 
J=8.3 Hz, H-5); 5.57 (1H, br s, H-1´´); 5.34 (1H, mt, J=7 Hz, H-8, overlapped with H-
3´´, J not exactly determinable); 5.31 (1H, dd, J=3, 10 Hz, H-3´´, overlapped with H-8, 
J not exactly determinable); 4.23 (1H, br s, H-2´´); 3.57 (1H, d,  J=9.9 Hz, H-4´´); 3.55 
(3H, s, H-8´´); 3.34 (2H, d, J=7.3 Hz, H-7); 2.31 (3H, s, H-11´); 1.75 (3H, s, H-11); 
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1.74 (3H, s, H-10); 1.34 (3H, s, H-7´´); 1.14 (3H, s, H-6´´). These signals 
corresponded to those obtained from authentic novobiocin. 
Strains harboring clo-BG1 and clo -AE2 (comprising the clorobiocin cluster), showed 
four peaks in the HPLC analysis (Fig. III.8D). The first peak (1), with the shortest 
retention time, showed a molecular ion [M-H]- at m/z 661 and the following isotopic 
pattern: mass (intensity): 661 (100.0%), 662 (39.9%), 663 (11.9%). Furthermore, this 
compound gave the following 1H NMR signals: dppm 7.93 (1H, d, J=9.3 Hz, H-5´); 7.77 
(1H, d, J=2.0 Hz, H-2); 7.72 (1H, br d, J=8.5 Hz, H-6); 7.06 (2H, complex signal, H-6´ 
and H-8´); 6.90 (1H, d, J=3.8 Hz, H-3´´´); 6.83 (1H, d, J=8.3 Hz, H-5); 5.94 (1H, d, 
J=3.8 Hz, H-4´´´); 5.61 (1H, d, J=2.6 Hz, H-1´´); 5.59 (1H, dd, J=3.3, 9.9 Hz, H-3´´, 
overlapped with H-1´´); 5.35 (1H, mt, J not determinable, H-8); 4.23 (1H, t, J=2.7 Hz, 
H-2´´); 3.69 (1H, d, J=9.8 Hz, H-4´´); 3.51 (3H, s, H-8´´); 3.34 (2H, d, J not 
determinable, overlapped with solvent signal, H-7); 2.29 (3H, s, H-6´´´); 1.74 (6H, br s, 
H-11 and H-10); 1.37 (3H, s, H-7´´); 1.20 (3H, s, H-6´´). The MS and 1H NMR data 
corresponded to those obtained for C-8´-deschloro-clorobiocin (=novclobiocin 101, 
Table III.1). The second peak (2) showed a molecula r ion [M-H]- at m/z 695 and the 
typical isotopic pattern caused by the chlorine isotopes 35Cl and 37Cl: mass (intensity): 
695 (100.0%), 696 (36.1%), 697 (39.5%), 698 (14.6%). This compound gave the 
following 1H NMR signals: dppm 7.91 (1H, d, J=9.0 Hz, H-5´); 7.76 (1H, br s, H-2); 7.73 
(1H, dd, J=2.4, 10 Hz, H-6, overlapped with H-2, J not exactly determinable); 7.35 
(1H, d, J=9.1 Hz, H-6´); 6.90 (1H, d, J=3.7 Hz, H-3´´´); 6.85 (1H, d, J=8.3 Hz, H-5); 
5.94 (1H, br d, J=3.7 Hz, H-4´´´); 5.72 (1H, d, J=3.3 Hz, H-1´´); 5.70 (1H, dd, J=3.2, 
7.0 Hz, H-3´´, overlapped with H-1´´, J not exactly determinable); 5.35 (1H, mt, J not 
determinable, H-8); 4.32 (1H, t, J=2.8 Hz, H-2´´); 3.72 (1H, d,  J=10.2 Hz, H-4´´); 3.52 
(3H, s, H-8´´); 3.35 (2H, d, J=6.8 Hz, H-7); 2.29 (3H, s, H-6´´´); 1.75 (3H, s, H-11); 
1.74 (3H, s, H-10); 1.35 (3H, s, H-7´´); 1.18 (3H, s, H-6´´). The MS and 1H NMR data 
corresponded to those obtained for clorobiocin (Table III.1). The third peak (3) had 
the same mass as the first one, molecular ion [M-H]- at m/z 661, and showed the 
same isotopic pattern (mass (intensity): 661 (100.0%), 662 (30.2%), 663 (17.5%)), 
indicating absence of a chlorine atom. The fourth peak (4) had the same mass as 
clorobiocin, molecular ion [M-H]- at m/z 695, and the isotopic pattern caused by the 
chlorine isotopes 35Cl and 37Cl: mass (intensity): 695 (100.0%), 696 (37.6%), 697 
(36.0%), 698 (14.6%). Substances (3) and (4) are therefore likely to represent 
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structural isomers of (1) and (2) which carry the acyl group at 2-OH rather than 3-OH 
of the deoxysugar, as identified previously (Galm et al., 2004a). 
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III. RESULTS 
III.1. Identification of the gene responsible for the halogenation 
reaction in clorobiocin biosynthesis 
The characteristic aminocoumarin moiety of the aminocoumarin antibiotics is 
substituted at position 8 in novobiocin and coumermycin A1 with a methyl group and 
in clorobiocin with a chlorine atom (Fig. I.1). This structural difference is perfectly 
reflected in the organization of the gene clusters: the novobiocin and coumermycin A1 
clusters contain a C-methyltransferase gene, i.e. novO and  couO, respectively, 
whereas the clorobiocin cluster contains the gene clo-hal, which shows sequence 
similarity to the recently discovered class of FADH2-dependent halogenases (van 
Pée, 2001), at the corresponding position (Fig. I.3). In addition, the clorobiocin cluster 
also contains the ORF cloZ, which shows no sequence similarity to known genes. For 
all genes of the clorobiocin cluster, with the exception of clo-hal and cloZ, 
homologues exist in the novobiocin and/or coumermycin cluster. Since the halogen 
atom represents the only structural characteristic of clorobiocin absent from both 
novobiocin and coumermycin, it can be questioned whether cloZ, together with clo-
hal, may play a role in the halogenation of clorobiocin. 
 
III.1.1.  Sequence analysis of clo-hal and cloZ 
The predicted gene product of clo-hal comprises 525 amino acids and resembles 
FADH2-dependent halogenases which use phenols or pyrrole derivatives as 
substrates, such as BhaA of the balhimycin gene cluster  (Pelzer et al., 1999; Puk et 
al., 2002), ComH of the complestatin gene cluster  (Chiu et al., 2001), and PltA of the 
pyoluteorin gene cluster  (Nowak-Thompson et al., 1999). The sequence identity of 
Clo-hal to those three proteins is 36%, 35% and 31%, respectively. 
The predicted gene product of cloZ comprises 254 amino acids and shows no 
homology to known proteins. 
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III.1.2.  Inactivation of clo-hal and cloZ in S. roseochromogenes 
It was first attempted to inactivate clo-hal and cloZ by conventional methods reported 
for in frame gene deletion (D) in Streptomyces (Kieser et al., 2000). For this purpose, 
a Dclo-hal and a DcloZ allele was constructed by cloning two non-contiguous 
fragments of about 1 kb, carrying the 5´ and 3´ ends of the target gene, in a suitable 
vector (non-replicative in Streptomyces), which finally led to plasmids pAE-ha3 (ThioR)  
and pAE-Z3 (ThioR) (s. Table II.15 and Figs. III.1 and III.2). These plasmids were 
then independently transformed into S. roseochromogenes by PEG-mediated 
protoplast transformation. Selection for thiostrepton allowed the isolation of mutants 
in which a single crossover event had occurred, due to homologous recombination 
between one fragment of the plasmid and the respective DNA region of the S. 
roseochromogenes genome, as shown by Southern blot analysis (Figs. III.1 and III.2). 
Note that homologous recombination may have occurred upstream or downstream of 
clo-hal and cloZ, respectively, since the used probes do not distinguish between 
these two crossover events. 
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Fig. III.1: Single crossover mutants of clo-hal in S. roseochromogenes. 
(A) Schematic presentation of a single crossover event. The DNA fragment used as probe is 
indicated as a black bar. tsr: thiostrepton resistance gene. Restriction sites marked with an 
asterisk are not presented in the original sequence, but only in pAE-ha3 (introduced by PCR). 
Out of scale. (B) Southern blot analysis of wild-type (WT) and clo-hal single crossover 
mutants (SCO) of S. roseochromogenes. Genomic and plasmid DNA were digested with 
PvuII and EcoRV. M: DIG-labeled DNA Molecular Weight Marker VII (Roche). 
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Fig. III.2: Single crossover mutants of cloZ in S. roseochromogenes. 
(A) Schematic presentation of a single crossover event. The DNA fragment used as probe is 
indicated as a black bar. tsr: thiostrepton resistance gene. Restriction sites marked with an 
asterisk are not presented in the original sequence, but only in pAE-Z3 (introduced by PCR). 
Out of scale. (B) Southern blot analysis of wild-type (WT) and cloZ single crossover mutants 
(SCO) of S. roseochromogenes. Genomic and plasmid DNA were digested with KpnI and 
BglII. M: DIG-labeled DNA Molecular Weight Marker VII (Roche). 
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Single crossover mutants were then cultured without addition of antibiotics to allow 
selection for another crossover event in which the vector was lost (thiostrepton-
sensitive mutants). These second crossover events may either lead to a reversion to 
the wild-type or to the desired gene replacement mutant (Kieser et al., 2000). To 
select for double crossover mutants, it is necessary to grow the single crossover 
mutants non-selectively for several generations, and to screen single colonies (often 
thousands) by replica plating (sporulation is here desirable). It is therefore a very 
time-consuming method, especially for S. roseochromogenes, which sporulates (if at 
all) only very slowly (Mancy et al., 1974).  
During the selection for double crossover events, we became acquainted with a new 
approach, the PCR targeting system (Gust et al., 2003), which allows gene 
inactivation experiments to be carried out much more simply and quickly than by 
previous methods (Kieser et al., 2000). Datsenko and Wanner (2000) have 
developed a rapid method to disrupt chromosomal genes in Escherichia coli by 
replacement with a selectable marker. The marker is generated by PCR, using 
primers with 36-50 nt extensions which are homologous to the targeted gene. 
Recombination of these short homologous sequences with chromosomal DNA is 
promoted by the l-Red functions (gam, bet, exo). This strategy was adapted for use 
in Streptomyces coelicolor by (Gust et al., 2003).  
We have therefore abandoned the experiments described above and decided to use 
this PCR targeting system to inactivate clo-hal and cloZ in S. roseochromogenes.  
Within cosmid D1A8, which contained the biosynthetic gene cluster of clorobiocin in 
the SuperCos1 vector (carrying a kanamycin resistance gene), clo-hal was replaced 
by an apramycin resistance/oriT cassette using l-Red-mediated recombination in E. 
coli (see Methods). The modified cosmid (named D1A8-h-773, = H10) was 
introduced into S. roseochromogenes by conjugation from E. coli. Apramycin-resitant, 
kanamycin-sensitive colonies, resulting from double crossover events, were selected. 
From the 17 obtained ex-conjugants, 15 were Apramycin-resitant, kanamycin-
sensitive, representing therefore potential double crossover mutants. Southern blot 
analysis of three candidates confirmed that in these mutants clo-hal was replaced by 
the apramycin resistance/oriT cassette (Fig. III.3A and B). 
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cloZ was inactivated in the same way, and the correct genotype of the resulting 
double crossover mutants was confirmed by Southern blot analysis (Fig. III.3C and 
D).   
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Fig. III.3:  Inactivation of clo-hal and cloZ in S. roseochromogenes. See next page for details. 
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(A) Schematic presentation of the clo-hal inactivation experiment. The DNA fragment used 
as probe is indicated as a black bar. aac(3)IV: apramycin resistance gene, Paac: promoter of 
the apramycin resistance gene, FRT: FLP recognition target, oriT: origin of transfer from RK2, 
neo: kanamycin resistance gene. Out of scale. (B) Southern blot analysis of wild-type and 
clo-hal- mutants. Genomic DNA was restricted by Eco0109I. M: DIG-labeled DNA Molecular 
Weight Marker VII (Roche); WT: S. roseochromogenes var. oscitans wild-type; 1-3: clo-hal- 
mutants (strains AE h2, AE h10, and AE h11). (C) Schematic presentation of the cloZ 
inactivation experiment. The DNA fragment used as probe is indicated as a black bar. Out of 
scale. (D) Southern blot analysis of wild-type and cloZ- mutants. Genomic DNA was 
restricted by BamH1. M: DIG-labeled DNA Molecular Weight Marker VII (Roche); WT: S. 
roseochromogenes var. oscitans wild-type; 1-3: cloZ- mutants (strains AE-Z4, AE-Z25, and 
AE-Z40). 
 
With some modifications of the conjugation procedure (see Methods), the PCR 
targeting system could therefore be used successfully in S. roseochromogenes, 
allowing gene inactivation experiments to be indeed carried out much more simply 
and quickly than by previous methods (Kieser et al., 2000). 
 
III.1.3.  Characterization of secondary metabolites  
Three independent clo-hal- mutants (AE-h2, AE-h10, and AE-h11) and three 
independent cloZ- mutants (AE-Z4, AE-Z25, and AE-Z40) as well as the wild-type 
were cultured in clorobiocin production medium (see Methods). After extraction of the 
cultures with ethyl acetate, secondary metabolites were analysed by HPLC in 
comparison with clorobiocin standard. 
The production of clorobiocin was abolished in all clo-hal- mutants (Fig. III.4B). These 
mutants produced, instead, a new substance with a shorter retention time than 
clorobiocin. This compound was isolated on a preparative scale. Negative-ion FAB 
MS analysis showed a molecular ion [M-H]- at m/z 661, consistent with the loss of a 
chlorine atom in comparison to clorobiocin ([M-H]- at m/z 695). Clorobiocin shows the 
typical isotopic pattern caused by the chlorine isotopes 35Cl and 37Cl (mass [intensity]: 
695 [100.0%], 696 [32.6%], 697 [31.8%], 698 [11.1%]), whereas the negative-ion 
FAB MS of the new substance did not show this pattern, indicating the absence of 
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chlorine (mass [intensity]: 661 [100.0%], 662 [25.9%], 663 [9.5%]). 1H NMR (Table 
III.1) and 13C NMR (Table III.2) unequivocally confirmed that the new substance was 
a clorobiocin derivative containing an hydrogen instead of a chlorine atom at C-8´ of 
the aminocoumarin moiety. In the 1H NMR spectrum of the new compound, the signal 
at 7.33 ppm corresponding to H-6´ of clorobiocin had disappeared. Instead, a signal 
at 7.06 ppm for two protons was observed as a broad singlet, which could be 
assigned to H-6´ and H-8´ by correlated spectroscopy (COSY). The coincidence of 
the signals of H-6´ and H-8´ as a broad singlet is in accordance with the spectrum 
reported from a naturally occurring novobiocin derivative lacking the 8´-methyl group 
(Sasaki et al., 2001). In the 13C NMR spectrum, the signal corresponding to C-8´ was 
found at 104.0 ppm (instead of 110.7 ppm as for clorobiocin), and the signal 
corresponding to C-6´, at 115.0 ppm (clorobiocin: 112.5 ppm). This is also in 
accordance with literature data (Sasaki et al., 2001). 
 
Fig. III.4: HPLC analysis of secondary metabolites. 
(A) S. roseochromogenes var. oscitans wild-type. (B) clo-hal- mutant. (C) cloZ- mutant. (D) 
clo-hal- mutant transformed with the novO expression construct (pTLO5). 
The new compound was named novclobiocin 101. The clo-hal- mutants produced 35-
45 µg novclobiocin 101 per ml medium, which exceeded the clorobiocin production of 
the wild-type (25 µg/ml). 
 III. RESULTS 91 
TABLE III.1: 1H NMR data of clorobiocin, novclobiocin 101, and novclobiocin 102 in 
d4-methanol 
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Compound  
Clorobiocin Novclobiocin 101 Novclobiocin 102 
Position d, Multiplicity (J/Hz) d, Multiplicity (J/Hz) d, Multiplicity (J/Hz) 
2-H 7.76 d (2.5) 7.77 d (2.1) 7.76 br s 
5-H 6.84 d (8.4) 6.84 d (8.4) 6.84 d (8.3) 
6-H 7.72 dd (8.4; 2.5) 7.72 br d (8.0) 7.72 br d (8.5) 
7-H2 3.34 d (7.1) 3.34 d (7.0)  3.34 d (7.2) 
8-H 5.35 bra t (7.1) 5.35 br t (7.3) 5.35 br t (7.2) 
10-H3 1.74 s 1.74 s 1.74 s 
11-H3 1.75 s 1.75 s 1.75 s 
5´-H 7.90 d (9.2) 7.92 d (9.4) 7.82 d (8.8) 
6´-H 7.33 d (9.2) 7.06b 7.24 d (8.7) 
8´-H - 7.06b - 
11´-CH3 - - 2.34 s 
1´´-H 5.73 d (1.8) 5.63 d (2.0) 5.63 d (1.6) 
2´´-H 4.34 t (2.7) 4.24 t (2.6) 4.29 br s 
3´´-H 5.71 dd (10.3; 2.9) 5.59 dd (9.8; 3.2) 5.67 dd (9.9; 3.1) 
4´´-H 3.72 d (10.3) 3.70 d (9.8) 3.71 d (9.9) 
6´´-H3 1.18 s 1.20 s 1.18 s 
7´´-H3 1.35 s 1.37 s 1.36 s 
8´´-OCH3 3.52 s 3.51 s 3.52 s 
3´´´-H 6.90 d (3.6) 6.90 d (3.6) 6.90 d (3.6) 
4´´´-H 5.94 br d (3.6) 5.94 d (3.6) 5.94 br d (3.4) 
6´´´-H3 2.29 s 2.29 s 2.29 s                        
d is given in ppm. The solvent signal (3.30 ppm) was used as reference. Spectra 
were obtained at 400 MHz (clorobiocin and novclobiocin 102) or at 600 MHz 
(novclobiocin 101). 
abr = broad signal. 
bComplex, overlapping signals; J not determinable. 
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TABLE III.2: 13C NMR data of clorobiocin, novclobiocin 101, and 
novclobiocin 102 in d4-methanol at 100 MHz 
Compound  
Clorobiocin Novclobiocin 101 Novclobiocin 102 
Position d (ppm) d (ppm) d (ppm) 
1 124.2 124.3 124.3 
2 130.9 130.8 130.8 
3 129.9 129.8 129.8 
4 161.0 160.9 160.9 
5 115.6 115.6 115.6 
6 128.5 128.5 128.4 
7 29.2 29.2 29.2 
8 123.2 123.2 123.2 
9 133.8 133.8 133.8 
10 17.9 17.9 17.9 
11 26.0 26.0 26.0 
12 170.0 169.8 169.7 
2´ 162.4a 163.3a 163.5a 
3´ 103.7 103.4 103.3 
4´ 157.8a 158.7a 158.8a 
5´ 123.9 126.4 123.2 
6´ 112.5 115.0 111.7 
7´ 161.8a 161.3a 158.8a 
8´ 110.7 104.0 114.9 
9´ 156.5 154.1 151.7 
10´ 113.3 112.4 112.4 
11´ --- --- 8.7 
1´´ 100.4 100.1 100.0 
2´´ 71.0 70.9 71.0 
3´´ 71.6 71.6 71.8 
4´´ 82.7 82.7 82.7 
5´´ 80.5 80.15 80.1 
6´´ 22.9 23.4 23.2 
7´´ 29.3 29.0 29.2 
8´´ 62.1 62.0 62.0 
2´´´ 121.8 121.8 121.8 
3´´´ 118.33 118.4 118.4 
4´´´ 109.8 109.8 109.8 
5´´´ 136.3 136.4 136.3 
6´´´ 12.9 12.9 12.9 
7´´´ 161.8a 161.9a 161.9a 
The signal of the solvent (49.0 ppm) was used as reference. Assignments 
were made with the help of 1H, 13C COSY and of the litreature  (Chadwick, 
1990; Sasaki et al., 2001). 
aSignal of carbon 2´, 4´, 7´, and 7´´´ showed similar chemical shift (157.8-
163.5 ppm), and their assignment may be interchanged.  
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In contrast to the clo-hal- mutants, all cloZ- mutants produced clorobiocin (Fig. III.4C). 
The production level was similar to that of the wild-type strain (25 µg/ml). The identity 
of the clorobiocin produced by the cloZ- mutants was confirmed by negative-ion FAB 
MS (molecular ion [M-H]- at m/z 695) and 1H NMR analysis (the spectrum obtained 
was identical to that of authentic clorobiocin, Table III.1).  
Although the presence of cloZ within the clorobiocin cluster is suggestive of a 
function related to the formation of this antibiotic, the above experiments show that 
cloZ is clearly not essential for clorobiocin biosynthesis under the present culture 
conditions, and apparently not involved in the halogenation reaction.  
 
III.1.4.  Complementation of the clo-hal- mutation 
To prove that only the inactivation of clo-hal was responsible for the loss of the 
chlorine atom, the clo-hal- mutant was complemented by expression of an intact copy 
of clo-hal under the control of the constitutive ermE* promoter, using the expression 
vector pUWL201 (plasmid pAE-ha7, Table II.15). HPLC analysis showed a 
chromatogram identical to that of the wild-type, i.e. clorobiocin production could be 
fully restored by expression of clo-hal. The authenticity of the obtained peak was 
confirmed by negative-ion FAB MS analysis (mass [intensity]: 695 [100.0%], 696 
[36.5%], 697 [30.2%], 698 [10.5%]). 
 
III.2. Generation of a hybrid antibiotic by metabolic engineering 
III.2.1.  Expression of novO in the clo-hal- mutant 
novO encodes a putative methyltransferase (Steffensky et al., 2000b). A very similar 
gene, couO, in the coumermycin A1 biosynthetic cluster (Wang et al., 2000) (Fig. I.3) 
has been experimentally confirmed to determine the methylation of C-8´ of the 
aminocoumarin ring (Li et al., 2002). NovO shows 84% identity to CouO, and both 
proteins are of equal size (230 aa). The conserved motif III 
[LL(R/K)PGG(R/I/L)(L/I)(L/F/I/V)(I/L)] for S-adenosyl-methionine-dependent 
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methyltransferases (Kagan and Clarke, 1994) is found in both gene products from 
amino acid 135 to 144 (CouO: LVKPGGAILN, NovO: LAKPGGAVLN). 
In order to produce a hybrid antibiotic, the putative methyltransferase gene novO was 
expressed in the clo-hal- mutant. For this purpose, plasmid pTLO5 – which was 
previously constructed by T. Luft by cloning novO into the replicative expression 
vector pUWL201 (Table II.14), placing it under the control of the constitutive ermE* 
promoter – was introduced into the clo-hal- mutant by protoplast transformation. As 
control, the clo-hal- mutant was transformed with the empty vector pUWL201.  
Culture extracts of the two strains were analysed by HPLC. In each case, three 
independent transformants were examined. While transformants containing the 
empty vector still produced novclobiocin 101 (data not shown), transformants 
containing the novO construct showed instead a new compound (Fig. III.4D) with a 
longer retention time than novclobiocin 101. Negative-ion FAB MS analysis of the 
isolated substance showed a molecular ion [M-H]- at m/z 675, corresponding to the 
addition of a methyl group to the molecule of novclobiocin 101. 1H NMR (Table III.1) 
and 13C NMR (Table III.2) analysis unequivocally confirmed that this substance was a 
clorobiocin derivative in which the chlorine atom at C-8´ of the aminocoumarin ring is 
replaced with a methyl group. In comparison to the 1H NMR spectrum of clorobiocin 
(Table III.1), an additional singlet at 2.34 ppm corresponding to three protons was 
detected, which could be assigned to 8´-CH3, based on literature data (Sasaki et al., 
2001). In comparison to novclobiocin 101, the signal of H-8´ had disappeared, and 
the signal of H-6´ was found as doublet at 7.24 ppm, as reported in the literature 
(Sasaki et al., 2001). In the 13C NMR spectrum (Table III.2) a new signal at 8.7 ppm 
was observed, which could be assigned to C-11´, using 1H, 13C correlated 
spectroscopy (COSY). This was also in accordance with the literature (Sasaki et al., 
2001). 
The new compound was named novclobiocin 102. It was produced in an amount of 
28-58 µg per ml medium (data of three independent transformants), exceeding the 
amount of clorobiocin produced in the wild-type (25 µg/ml). 
In the wild-type and in all mutant strains, an additional peak with a slightly longer 
retention time than the respective main product was observed (Fig. III.4A-D). 
Negative-ion FAB MS analysis of these minor peaks showed the same molecular ion 
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as the corresponding main product. These compounds are likely to represent isomers 
of the main products, possibly carrying the pyrrole carboxylic acid moiety in position 2 
instead of position 3 of the deoxysugar (Galm et al., 2004a; Westrich et al., 2003). 
 
III.2.2.  Antibiotic activity of clorobiocin and derivatives against B. 
subtilis 
Authentic clorobiocin (Aventis), novclobiocin 101 (from the clo-hal- mutant) and 
novclobiocin 102 (from the clo-hal- mutant transformed with novO) were assayed for 
antibiotic activity against Bacillus subtilis (Fig. III.5). Clorobiocin showed the highest 
antibacterial activity, followed by novclobiocin 102 (approximately half as active as 
clorobiocin) and novclobiocin 101 (approximately eight times less active than 
clorobiocin). The results show that a substitution at C-8´ of the aminocoumarin unit 
strongly enhances the activity of the aminocoumarin antibiotics against this test 
organism. A chlorine atom at this position appears to be superior to a methyl group, 
although the difference is moderate. 
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Fig. III.5: Antibacterial activity of clorobiocin and derivatives. 
(A) clorobiocin, (B) novclobiocin 101, (C) novclobiocin 102. Bioassay with Bacillus subtilis. 0: 
methanol, 1-5: 0.5 µg, 1 µg, 2 µg, 4 µg, and 8 µg of the respective substance. For structures 
see Table III.1. 
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III.3. Heterologous expression of the novobiocin and clorobiocin 
biosynthetic gene clusters 
III.3.1.  Integration into the genome of host strains and analysis of 
secondary metabolites 
Cosmids containing the entire biosynthetic gene clusters of novobiocin and 
clorobiocin have been obtained previously (Pojer et al., 2002; Steffensky et al., 
2000b), employing the widely used cosmid vector, SuperCos1 (Stratagene), which 
contains an ampicillin (bla) and a neomycin/kanamycin (neo) resistance gene. 
The bla gene within the SuperCos1 backbone of cosmids 10-9C and D1A8 
(containing the novobiocin and clorobiocin cluster, respectively) was replaced with a 
cassette containing the integrase gene (int) and the attachment site (attP) of phage 
fC31, as well as a selectable marker (tetracycline resistance), using l-Red-mediated 
recombination in E. coli. This one-step procedure yielded the desired modified 
cosmids termed nov-BG1 and clo-BG1, respectively (constructed by Dr. Bertolt Gust, 
John Innes Centre, Norwich, UK; presently at Prof. Dr. Heide’s department). 
Cosmids nov-BG1 and clo-BG1 were introduced into S. coelicolor M512 and into S. 
lividans TK24 by protoplast transformation. Selection for kanamycin resistance 
resulted in the desired integration mutants (approximately 103 mutants per microgram 
cosmid DNA for S. coelicolor and 105 mutants for S. lividans). Southern blot analysis 
showed that the entire cosmids had integrated site-specifically into the attB site of the 
chromosome in both Streptomyces strains (Figs. III.6C and III.7C; only results for S. 
coelicolor strains are shown). 
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Fig. III.6: Cosmid constructs containing the novobiocin biosynthetic gene cluster and their 
integration into the S. coelicolor chromosome. See details on next page. 
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(A) Cosmid constructs nov-BG1, nov-AE6 and nov-AE4. P = PstI restriction site. T3, T7 = T3 
and T7 promoter of the SuperCos1 vector. tet = tetracycline resistance gene; neo = 
neomycin/kanamycin resistance gene; int, attP = integrase gene and attachment site of 
phage fC31. Fragment sizes resulting from digestion with PstI are indicated. Cosmid 
backbone out of scale. (B) Schematic presentation of site specific integration of constructs 
nov-BG1, nov-AE6 or nov-AE4. The integrase, int, derived from Streptomyces phage fC31 
catalyses integration via recombination between attP (from phage or vector) and attB (from 
Streptomyces genome) sites generating the hybrid sites attL and attR (Thorpe et al., 2000). 
Junction fragments which prove specific integration into the fC31 attachment site of the S. 
coelicolor genome are indicated. Out of scale. (C) Southern blot analysis of S. coelicolor (= S. 
c.) M512 parental strain, of S. coelicolor M512 integration mutants harboring nov-BG1, nov-
AE6 or nov-AE4, and of the respective cosmid constructs. M = DIG-labeled DNA Molecular 
Weight Marker VII (Roche). Genomic and cosmid DNA were digested with PstI. The DIG-
labeled cosmid nov-BG1 was used as probe. The 14.0 kb band resulting from site specific 
integration overlaps with the 13.8 kb band from the cosmid inserts.  
 
Integration mutants and parental host strains were cultured in production media. The 
analysis of secondary metabolites by HPLC (Fig. III.8) showed that, in contrast to the 
untransformed host strains, the integration mutants accumulated novobiocin and 
clorobiocin, respectively. The identity of these substances was confirmed, after 
preparative isolation, by negative-ion FAB MS and 1H NMR analysis (see Methods). 
S. coelicolor strains expressing the clorobiocin cluster additionally accumulated three 
clorobiocin analogs (Fig. III.8D), identical to those observed in the natural clorobiocin 
producer S. roseochromogenes (see Methods).  
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Fig. III.7: Cosmid constructs containing the clorobiocin biosynthetic gene cluster and their 
integration into the S. coelicolor chromosome. See details on next page. 
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 (A) Cosmid constructs clo-BG1 and clo-AE2. B = BglII restriction site. T3, T7 = T3 and T7 
promoter of the SuperCos1 vector. Fragment sizes resulting from digestion with BglII are 
indicated. Cosmid backbone out of scale.  (B) Schematic presentation of site specific 
integration of constructs clo-BG1 and clo-AE2. See Fig. III.6 for details of the integration 
mechanism. (C) Southern blot analysis of S. coelicolor (= S. c.) M512 parental strain, of S. 
coelicolor M512 integration mutants harboring clo-BG1 or clo-AE2, and of the respective 
cosmid constructs. M = DIG-labeled DNA Molecular Weight Marker VII (Roche). Genomic 
and cosmid DNA were digested with BglII. The DIG-labeled cosmid clo-BG1 was used as 
probe. 
 
 
 
Fig. III.8: HPLC analysis of secondary metabolites. 
(A) S. coelicolor M512 parental strain (detection at 305 nm). (B) S. coelicolor harboring nov-
BG1 (C) S. coelicolor M512 parental strain (detection at 340 nm). (D) S. coelicolor harboring 
clo-BG1. 
 
The productivity of the integration mutants of S. coelicolor was comparable to that of 
the original producers S. spheroides and S. roseochromogenes (Table III.3). S. 
lividans as host was much less productive. Therefore, S. coelicolor was used in the 
subsequent experiments. 
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TABLE III.3: Novobiocin and clorobiocin production by S. coelicolor and S. 
lividans strains 
Strain Novobiocina (mg/l) Clorobiocina, b (mg/l) 
Parental strains 
S. spheroides 35 (30-40) --- 
S. roseochromogenes --- 25 (20-30) 
S. coelicolor M512 --- --- 
S. lividans TK24 --- --- 
Strains carrying full length cosmids 
S. coelicolor (nov-BG1) 31 (20-42) --- 
S. lividans (nov-BG1) <1 --- 
S. coelicolor (clo-BG1) --- 26 (18-34) 
S. lividans (clo-BG1) --- 5 (4-6) 
Strains carrying shortened cosmids 
S. coelicolor (nov-AE6)  24 (23-25) --- 
S. coelicolor (nov-AE4) 1.5 (0.8-2.2) --- 
S. coelicolor (clo-AE2) --- 14 (8-19) 
amean values (range) from at least two independent experiments. 
btotal amount of clorobiocin and the three major analogs (see Fig. III.8D). 
 
III.3.2.  Removal of non-essential DNA regions from the cosmid inserts 
III.3.2.1. Orientation of inserts in cosmids nov-BG1 and clo-BG1 
Removal of putative non-essential DNA regions in the SuperCos1-derived cosmids 
nov-BG1 and clo-BG1 was carried out using gene deletion via PCR targeting (Gust et 
al., 2003). For this purpose, the sequence of the inserts’ extremities or the orientation 
of the inserts must be known. Therefore, cosmids nov-BG1 and clo-BG1 were short-
sequenced using T3 and/or T7 primers. The sequencing results allowed the following 
conclusions about the orientation of the inserts: 
- nov-BG1: (T7) ORF21 incomplete (682 bp of 1 485 bp, start at position 4 927 
of AY227005), ORF20, novA to ORF6, unknown sequence (T3). See Fig. III.6.  
- clo-BG1: (T3) unknown sequence (the sequence data with T3 primer showed 
no homology to the known sequence of the clorobiocin cluster), ORF1 to 
gyrBR, parYR incomplete (123 bp of 2.1 kb, till position 2 238 in AY136281) (T7) 
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(the sequence data with T7 were identical to the reverse-complementary 
sequence of AY136281, position 2 238 – 1 968). See Fig. III.7. 
III.3.2.2. Removal of non-essential DNA regions 
The apramycin resistance cassette from the previously described plasmid pIJ773 of 
the REDIRECT© technology kit for PCR targeting  (Gust et al., 2003) is flanked by 
FLP recognition targets (FRT). After gene replacement, this cassette can be 
conveniently removed by action of FLP recombinase, leading to the excision of the 
DNA region in between the FRT sites and leaving an 81 bp “scar” sequence. 
However, the presence of this scar sequence makes further knock-outs in the same 
cosmid difficult, because it represents a functional FRT site as well as a target for l-
Red-mediated recombination.  
To overcome this problem, Ute Galm (Pharmazeutische Biologie, Universität 
Tübingen) has generated an apramycin resistance cassette by PCR using primers 
with either an XbaI or a SpeI recognition site between the apramycin resistance 
marker and the 39 bp flanking sequence for l-Red-mediated recombination, leading 
to plasmid pUG019 (Table II.14).  XbaI and SpeI sites are rare in the GC-rich 
Streptomyces genome. After gene replacement, this cassette can be removed by 
digestion with XbaI and SpeI and religation of the resulting compatible ends (Fig. 
III.9). This procedure leaves a minimal in frame “scar” of 18 nucleotides, which does 
not interfere with further gene deletions or replacements. 
gene(s) of
interest
Cosmid
XbaI SpeI
1) I/ I digestion
2) religation
Xba Spe
l-Red-mediated
recombination
D
aac(3)IV
In-frame deletion
in cosmid
Gene replacement 
in cosmid with 
cassette from pUG019
P
 
 
 
 
 
Figure III.9 Gene deletion using the 
apramycin resistance cassette from 
pUG019 containing flanking XbaI 
and SpeI recognition sites. 
aac(3)IV = apramycin resistance 
gene; P = promoter of the 
apramycin resistance gene. 
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The biosynthetic gene cluster of clorobiocin is flanked on one side by the two 
resistance genes gyrBR and parYR (Fig. I.3). Of the latter 2.1 kb gene, only 123 bp 
are contained in cosmid clo-BG1 (Fig. III.7A, right-hand side of the insert). On the 
opposite end, the gene cloE may represent the border of the cluster (Eustáquio et al., 
2003b; Schmutz et al., 2003a) (Fig. I.3 and Fig. III.7A). 
In order to prove that the genes upstream of cloE are indeed non-essential for 
clorobiocin biosynthesis, these were deleted from cosmid clo-BG1 using the cassette 
from pUG019 (see also Methods). The insert of the resulting cosmid, clo-AE2, starts 
148 bp upstream of the start codon of cloE (Fig. III.7). 
This cosmid was trans formed into S. coelicolor M512, and integration mutants were 
selected. Site specific integration of the entire cosmid was confirmed by Southern 
blot analysis (Fig. III.7C, lanes 5 and 6). When these mutants were cultured in 
production medium, HPLC analysis clearly showed that clorobiocin was still produced 
in significant amounts (Table III.3), proving that the 34 kb sequence from cloE to 
gyrBR contains all genes required for clorobiocin biosynthesis. 
A similar experiment was performed with the novobiocin cluster, contained in cosmid 
nov-BG1. It has been suggested previously that novE and gyrBR (Fig. III.6A) may 
delineate the left and right border of this cluster, respectively (Eustáquio et al., 2003b; 
Schmutz et al., 2003a). However, novA which is located outside of this region shows 
sequence similarity to ABC transporters and has been suggested to be involved in 
novobiocin transport (Méndez and Salas, 2001; Schmutz et al., 2003a). Therefore, 
two different shortened cosmids were produced: nov-AE4, containing only the genes 
from novE to gyrBR; and nov-AE6, containing additionally the genes novABCD and 
ORF20 (Fig. III.6A). ORF20 shows sequence similarity to transcriptional regulators of 
the MarR-type (MarR is a transcriptional repressor of the mar, multiple antibiotic 
resistance, operon of E. coli), and may encode a regulator of novA, as suggested by 
sequence comparison with database entries. 
Cosmids nov-AE4 and nov-AE6 were transformed into S. coelicolor M512, and site  
specific integration of the entire cosmids was confirmed by Southern blot analysis 
(Fig. III.6). Cultivation in production medium and HPLC analysis revealed that 
integration mutants containing the larger cosmid, i.e. nov-AE6, produced still two 
thirds of the novobiocin amount found in the parental strain S. spheroides. In contrast, 
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mutants containing the smaller cosmid nov-AE4 produced only 6% of that amount 
(Table III.3). This proves that the DNA region from novE to gyrBR contains all genes 
which are essential for novobiocin biosynthesis, but also that the DNA region from 
ORF20 to novD contains elements which are required for a high productivity of 
novobiocin. 
 
III.4. Production of 8´-halogenated and 8 -´unsubstituted novobiocin 
derivatives in genetically engineered S. coelicolor strains 
III.4.1.  Heterologous expression of a modified novobiocin cluster (novO-) 
Since heterologous expression of the intact novobiocin biosynthetic gene cluster was 
successful, the generation of a modified (8´-unsubstituted) antibiotic by inactivation of 
the methyltransferase gene novO in cosmid nov-BG1 and introduction of this 
modified cosmid into the genome of S. coelicolor was attempted. 
Therefore, novO was replaced by the apramycin resistance cassette from pUG019 
(Fig. III.9) via l-Red-mediated recombination (Gust et al., 2003). The cassette was 
then removed by digestion with XbaI and SpeI and religation. As explained above, 
this procedure leaves a minimal in frame “scar” of 18 nucleotides inside the targeted 
sequence. The modified cosmid (named nov-AE8) was then introduced into S. 
coelicolor by transformation. Southern blot analysis confirmed the integration into the 
genome, and the deletion of novO was clearly shown by the shortening of the 
relevant BglII restriction fragment (Fig. III.10). 
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Fig. III.10: Inactivation of novO. See next page for details. 
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(A) Schematic presentation of cosmids nov-BG1, containing the intact novobiocin 
biosynthetic gene cluster, and nov-AE8 in which novO was deleted. The novobiocin cluster is 
presented in grey, the flanking regions in white, and novO in black. B = BglII restriction site. 
Cosmid backbone out of scale. (B) Schematic presentation of site specific integration. 
Junction fragments which prove specific integration into the fC31 attachment site of the S. 
coelicolor genome are indicated. Out of scale. (C) Schematic presentation of the novO 
inactivation. novO (693 bp) was first replaced by an apramycin resistance (aac(3)IV) cassette. 
Afterwards, the cassette was excised by digestion with XbaI and SpeI and religated, leaving 
an in frame “scar” of 18 nucleotides between the start and stop codons of novO. Out of scale. 
(D) Southern blot analysis of S. coelicolor M512 (lane 1), and M512-derived integration 
mutants bearing cosmid nov-BG1 (lane 2), or the novO- cosmid nov-AE8 (lane 3). M = DIG-
labeled DNA Molecular Weight Marker VII (Roche). Genomic DNA was digested with BglII. 
The DIG-labeled cosmid nov-BG1 was used as probe. The novO inactivation is confirmed by 
the 3.1 kb band (lane 3) instead of a 3.8 kb band (lane 2); otherwise the band pattern should 
be identical. See Fig. III.6 for further details. 
 
The analysis of secondary metabolites by HPLC (Fig. III.11C) showed complete 
absence of novobiocin. Instead, the novobiocin derivati ve novclobiocin 117 
accumulated, carrying a hydrogen instead of a methyl group at C-8´.  The structure 
was confirmed by negative-ion FAB MS (molecular ion [M-H]- at m/z 597 
corresponding to the loss of a methyl group in comparison to novobiocin) and by 1H 
NMR analysis (Table III.4) of the isolated compound, which clearly showed the 
absence of the signal for 8´-CH3. These spectroscopic data are in accordance with 
the litreature (Sasaki et al., 2001; Xu et al., 2004). The novO mutant also produced a 
minor product (= novclobiocic acid 106) with shorter retention time than novclobiocin 
117. This compound lacked the entire deoxysugar moiety, as shown by a molecular 
ion [M-H]-  at m/z 380 in MS analysis and by the absence of sugar protons in 1H NMR 
analysis (Table III.4). In addition, a third compound was detected with a slightly 
higher retention time than novclobiocin 117. This substance showed a molecular ion 
[M-H]- at m/z 597, i.e. identical to novclobiocin 117. As explained below, this 
compound is likely to represent an isomer of novclobiocin 117, carrying the 
carbamoyl moiety in position 2 instead of 3 of the deoxysugar. The production of 
such 2´ -´acylated isomers has previously been observed in strains of S. 
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roseochromogenes, the clorobiocin producer (Galm et al., 2004a; Westrich et al., 
2003). 
 
Fig. III.11: HPLC analysis of secondary metabolites. 
(A) S. coelicolor M512 parental strain. (B) S. coelicolor (nov-BG1), carrying the novobiocin 
biosynthetic gene cluster. (C) S. coelicolor (nov-AE8), novO- mutant. (D) S. coelicolor (nov-
AE8)/pAE-ha7, novO- mutant transformed with the clo-hal expression construct (pAE-ha7). 
Detection at 305 nm. 
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TABLE III.4: 1H NMR data of novobiocin, novclobiocic acid 106, novclobiocin 117, 
novclobiocin 114, and novclobiocin 119 in d4-methanol. 
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Compound  
Novobiocin Novclobiocic 
acid 106 
Novclobiocin 
117 
Novclobiocin 
114 
Novclobiocin 
119 
Position d, Multiplicity 
(J/Hz) 
d, Multiplicity 
(J/Hz) 
d, Multiplicity 
(J/Hz) 
d, Multiplicity    
(J/Hz) 
d, Multiplicity    
(J/Hz) 
2-H 7.75 bra s 7.76 br s 7.76 br s 7.75 br s 7.76 br s 
5-H 6.84 d (8.3) 6.83 d (8.4) 6.82 d (8.2) 6.84 d (8.3) 6.82 d (8.3) 
6-H 7.72 br d (8.3) 7.72 br d (8.4) 7.72 br d (8.2) 7.72 br d (8.3) 7.72 br d (8.3) 
7-H2 3.34 d (7.3) 3.34 d (7.5) 3.33
c 3.33 d (7.1) 3.33 d (6.9) 
8-H 5.34 mt (7)b  5.35 br t (7.5) 5.35 mt (7)d 5.35 mt (7)b 5.35 br t (7)d 
10-H3 1.74 s 1.74 br s 1.74 br s 1.74 s 1.74 br s 
11-H3 1.75 s 1.74 br s 1.74 br s 1.75 s 1.74 br s 
5´-H 7.81 d (8.9) 7.81 br d (8.0) 7.91 br d (7.5) 7.88 d (8.9) 7.88 d (8.8) 
6´-H 7.23 br d (8.9) 6.78 br d (8.3) 7.00 br d (7.6)b 7.29 d (8.9) 7.26 d (9.1) 
8´-H - 6.68 s 7.00 s - - 
11´-H3 2.31 s - - - - 
1´´-H 5.57 br s - 5.55 d (2.3) 5.67 br s 5.74 br s 
2´´-H 4.23 tc - 4.18 t (2.8) 4.28 tc 5.10 tc 
3´´-H 5.31 dd (3; 10)b - 5.25 dd (3.1; 
9.6) 
5.36 dd (2.8;  
10.0)b 
4.35 dd (3.4; 
9.9) 
4´´-H 3.57 d (9.9)  - 3.54 d (10.2) 3.58 d (10.0)  3.40 d (9.9) 
6´´-H3 1.14 s - 1.17 s 1.15 s 1.14 s 
7´´-H3 1.34 s - 1.35 s 1.32 s 1.32 s 
8´´-H3 3.55 s - 3.53 s 3.55 s 3.60 s 
d is given in ppm. The solvent signal (3.30 ppm) was used as reference. Spectra were obtained at 
400 MHz. 
abr = broad signal. 
bComplex, overlapping signals; J not exactly determinable. 
cJ not determinable. 
dComplex signal; J not exactly determinable.  
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The S. coelicolor strain harboring the novO-defective cluster produced 30 mg/l 
novclobiocin 117 and 10 mg/l novclobiocic acid 106. Its productivity was therefore 
similar to that of the S. coelicolor strains carrying the intact novobiocin biosynthetic 
gene cluster (31 mg/l on average).  
III.4.2.  Complementation of the novO mutation 
To prove that only the inactivation of novO was responsible for the loss of the methyl 
group, we complemented the mutant by expressing an intact copy of novO. For this 
purpose, plasmid pTLO5 was used, a derivative of the replicative vector pUWL201, in 
which novO was placed under the control of the constitutive ermE* promoter (Table 
II.14). After pTLO5 was used to transform the novO mutant, HPLC analysis showed 
that the novobiocin production was restored to about 80% of the productivity 
observed before novO inactivation (data not shown). The identity of novobiocin was 
confirmed by negative-ion FAB MS analysis (molecular ion [M-H]- at m/z 611). 
III.4.3.  Production of the hybrid antibiotic novclobiocin 114 
In order to obtain the desired novobiocin analog carrying a chlorine atom instead of a 
methyl group at C-8´, the halogenase gene clo-hal from the clorobiocin biosynthetic 
gene cluster was expressed in the S. coelicolor strain harboring the novO-defective 
cluster, using the replicative plasmid pAE-ha7 in which clo-hal was under the control 
of the constitutive ermE* promoter (Table II.15). As shown by HPLC (Fig. III.11D), the 
resulting clo-hal transformants produced a substance which was absent from 
transformants carrying the empty replicative vector pUWL201 (data not shown). 
Negative-ion FAB MS of the isolated compound showed a molecular ion [M-H]-  at m/z 
631, corresponding to the substitution of a hydrogen by a chlorine atom in the 
molecule of novclobiocin 117. The typical isotopic pattern caused by the chlorine 
isotopes 35Cl and 37Cl was clearly visible (mass [intensity]: 631 [100.0%], 632 [30.6%], 
633 [31.9%], 634 [11.2%]). 1H NMR analysis (Table III.4) unequivocally confirmed 
that the chlorine atom was attached at C-8´ of the aminocoumarin core: the signal at 
7.00 ppm corresponding to the two protons H-6´ and H-8´ of novclobiocin 117 had 
disappeared, and instead a signal at 7.27 ppm (doublet, 1H) was observed, which 
could be assigned to H-6´. In comparison, the H-6´ signal of novobiocin was seen as 
doublet (1H) at 7.23 ppm (Table III.4). As observed previously (Table III.1 and (Xu et 
 III. RESULTS 110 
al., 2004)), the chlorine atom at C-8´ in clorobiocin causes a slightly different 
magnetic shift of the H-6´ signal  than a methyl group at the same position. The 
accumulated substance was therefore unequivocally identified as novclobiocin 114 
(Fig. III.11D). The three independent clo-hal transformants tested produced on 
average 14 mg novclobiocin 114 per litre medium. The minor peak with slightly longer 
retention time represents the  isomer of novclobiocin 114, i.e. novclobiocin 119, which 
carries the carbamoyl moiety in position 2 instead of 3 of the deoxysugar. In the 
negative-ion FAB MS, it showed the same molecular ion [M-H]- at m/z 631 and 
similar isotopic pattern (mass [intensity]: 631 [100.0%], 632 [34.7%], 633 [32.1%], 
634 [12.5%]) as novclobiocin 114. Furthermore, in the 1H NMR analysis (Table III.4), 
the signal of H-2´´ was seen at 5.10 ppm instead of 4.28 ppm and the signal of H-3´´ 
at 4.35 instead of 5.36 ppm. Therefore, the chemical shift of the sugar protons 
demonstrates the presence of the carbamoyl moiety in position 2 instead of 3, in 
accordance with published data on novobiocin and isonovobiocin (Crow et al., 1999). 
The minor peaks with shorter retention times than novclobiocin 114 (Fig. III.11D) 
represent remaining non-halogenated compounds, i.e. novclobiocin 117 and 
novclobiocic acid 106. 
III.4.4.  Antibacterial activity of novobiocin and derivatives 
The obtained novclobiocins (i.e. novclobiocin 114, 119, 117, and novclobiocic acid 
106; see Table III.4 for structures) were assayed for antibiotic activity against Bacillus 
subtilis in comparison to authentic novobiocin (Fig. III.12). In accordance with results 
obtained previously (see III.2.2 and (Galm et al., 2004b; Xu et al., 2004)), substitution 
at C-8´ with either –CH3 or –Cl  was important for biological activity: novclobiocin 117 
(8´-H) showed only 4% of the activity of novobiocin, while novclobiocin 114 (8´-Cl) 
was half as active as novobiocin (8´-CH3). Further investigations of the structure-
activity relationships of these compounds are in progress. 
As reported for clorobiocin derivatives (Galm et al., 2004b), the transfer of the acyl 
group from 3´´-OH to 2´´-OH resulted in a reduction but not in a complete loss of 
activity: novclobiocin 119 still showed approximately 20% of the activity of 
novclobiocin 114. In contrast, the removal of the deoxysugar moiety and the 8´-
substituent (= novclobiocic acid 106) resulted in 99% loss of activity. 
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Fig. III.12: Antibacterial activity of novobiocin and derivatives. 
Bioassay against Bacillus subtilis. Activities are expressed relative to novobiocin (100%). For 
structures see Table III.4. 
 
III.5. Are the halogenases of clorobiocin and balhimycin 
biosynthesis interchangeable? 
The glycopeptide antibiotic balhimycin (Fig. III.13) and the aminocoumarin antibiotic 
clorobiocin both contain 3-chloro-b-hydroxy-tyrosyl-derived moieties. In both 
compounds, the biosynthesis of these moieties starts from L-tyrosine, which forms a 
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thioester bond with an activating enzyme, i.e. BpsD or CloH, respectively. 
Subsequently, the cytochrome P450 enzymes OxyD or Clo I, respectively, introduce 
the b-hydroxy group (Fig. III.13) (Chen and Walsh, 2001; Süssmuth and Wohlleben, 
2004). The predicted protein sequences of CloH and CloI show clear sequence 
similarity to BpsD and OxyD. The introduction of the chlorine atom into position 3 of 
the aromatic nucleus of the b-hydroxy-tyrosyl-derived moieties is catalyzed by 
enzymes with sequence similarity to FADH2-dependent halogenases (van Pée, 2001). 
The predicted amino acid sequence of BhaA of the balhimycin cluster (Puk et al., 
2002) shows 36% identity to Clo-Hal of the clorobiocin cluster (Pojer et al., 2002). In 
the biosynthesis of both antibiotics, it is unknown which exact intermediate serves as 
substrate for the halogenation. 
In order to verify whether bhaA could functionally replace clo-hal, we placed bhaA 
under the control of the constitutive ermE* promoter using the same expression 
vector, pUWL201, as employed for the experiments with clo-hal described above. 
The resulting plasmid was termed pAE-B3. pAE-B3 was constructed by cloning a 
BamHI-XbaI fragment of plasmid pSETbhaA, containing the bhaA gene and its 
natural ribosome binding site (Puk et al., 2002) into the same sites of pUWL201. 
pSETbhaA has been successfully used previously for complementation of a bhaA- 
mutant of Amycolatopsis balhimycina (Puk et al., 2002). 
pAE-B3 was introduced by protoplast transformation into the S. coelicolor strain 
containing the novO defective novobiocin cluster. In three independent transformants, 
the presence of the intact plasmid was confirmed by plasmid isolation and restriction 
analysis. However, HPLC analysis of the three transformants showed no changes in 
comparison to the untransformed control, or to controls transformed with the empty 
vector pUWL201. The detected compounds still showed the same molecular ions in 
the negative-ion FAB MS analysis as those seen in the S. coelicolor strain with the 
novO- cluster ([M-H]- at m/z 597, corresponding to novclobiocin 117; and [M-H]-  at 
m/z 380, corresponding to novclobiocic acid 106). Therefore, no chlorinated products 
could be observed after expression of bhaA in the novO- mutant. 
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Fig. III.13: Biosynthesis of the 3-chloro-b-hydroxy-tyrosyl moieties of clorobiocin and 
balhimycin. 
In both pathways, it is unknown at which exact step during the biosynthesis the halogenation 
takes place (see text). The 3-chloro-b-hydroxy-tyrosyl-derived moieties of clorobiocin and 
balhimycin are emphasized by larger font size. 
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In order to confirm this result, the bhaA expression plasmid pAE-B3 was also 
introduced into the clo-hal- mutant of the clorobiocin producer S. roseochromogenes 
(see III.1.2). Again, bhaA was unable to complement the mutant. HPLC analysis of 
three independent transformants, as well as FAB MS analysis of the isolated 
compounds, showed only the same metabolites as detected in the clo-hal- mutants 
prior to  transformation. The dominant product was a clorobiocin derivative with a 
hydrogen instead of a chlorine atom at C-8´ ([M-H]- at m/z 661). If, however, the clo-
hal- mutant was transformed with plasmid pAE-ha7, which contains clo-hal rather 
than bhaA and is otherwise identical to pAE-B3, clorobiocin production was readily 
restored. The resulting chromatogram corresponded to that of the wild-type S. 
roseochromogenes, and the identity of clorobiocin was confirmed by negative -ion 
FAB MS analysis (mass [intensity]: 695 [100.0%, [M-H]-], 696 [36.5%], 697 [30.2%], 
698 [10.5%]). These experiments provide clear evidence that clo-hal cannot be 
functionally replaced by bhaA. 
 
III.6. Regulation of novobiocin production 
III.6.1.  NovG, a positive regulator of novobiocin biosynthesis 
III.6.1.1. Sequence analysis of novG  
novG codes for a protein which comprises 318 amino acids and shows 41% identity 
on the amino acid level to StrR, a pathway-specific transcriptional activator of 
streptomycin biosynthesis in Streptomyces griseus and S. glaucescens (Retzlaff and 
Distler, 1995; Thamm and Distler, 1997). 
The predicted amino acid sequence of NovG shows a putative helix-turn-helix (HTH) 
motif in the central region of the protein, which is typical for a family of bacterial and 
phage DNA-binding proteins (Pabo and Sauer, 1992). This motif is also found in StrR 
(Retzlaff and Distler, 1995; Thamm and Distler, 1997). Prediction of the secondary 
structure of NovG using the PHD (Profile network prediction Heidelberg) method 
confirmed the presence of an HTH motif (Fig. III.14). 
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Fig. III.14: Putative helix-turn-helix (HTH) motif of NovG. 
The most highly conserved residues in the HTH motif are underlined and include a glycine (G) 
in the turn and several hydrophobic residues (I, A, L, V) (Pabo and Sauer, 1992). The 
secondary structure was predicted using the PHD (Profile network prediction Heidelberg) 
method (Rost, 1996) (available on the web at http://www.embl-heidelberg.de/predictprotein). 
 
novG contains the rare TTA leucine codon (as codon 182) which indicates its 
dependence of bldA, the structural gene for tRNA UUA. This may represent a further 
indication for a regulatory role of NovG in novobiocin biosynthesis, since most of the 
known TTA-containing genes specify regulatory or resistance proteins associated 
with biosynthetic gene clusters for antibiotics (Leskiw et al., 1991). 
Orthologues of novG are found in the biosynthetic gene clusters of the 
aminocoumarin antibiotics clorobiocin and coumermycin (Pojer et al., 2002). They are 
termed cloG and couG and code both for proteins of 319 amino acids, which share 
on average 78% sequence identity with novG. Just as novG, both show the putative 
HTH motif in their central region. cloG contains three TTA codons (as codon 28, 83, 
and 149), whereas couG contains none. 
III.6.1.2. Inactivation of novG 
In order to investigate the function of novG, the effects of its inactivation and its 
overexpression were first examined. Using the method described above to 
circumvent genetic manipulation in the novobiocin producer S. spheroides, a DnovG 
strain was generated by deletion of novG in cosmid nov-BG1 and introduction of this 
modified cosmid into the genome of S. coelicolor (Fig. III.15). 
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Fig. III.15: Inactivation of novG. See next page for details. 
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(A) Schematic presentation of cosmids nov-BG1, containing the intact novobiocin 
biosynthetic gene cluster, and nov-AE10 in which novG was deleted. The novobiocin cluster 
is presented in grey, the flanking regions in white, and novG in black. P = PstI restriction site. 
For further details see Fig. III.6. Cosmid backbone out of scale. (B) Schematic presentation 
of site specific integration. Junction fragments which prove specific integration into the fC31 
attachment site of the S. coelicolor genome are indicated. For details about the integration 
system see Fig. III.6. Out of scale. (C) Schematic presentation of the novG inactivation. novG 
(957 bp) was first replaced by an apramycin resistance (aac(3)IV) cassette. Afterwards, the 
cassette was excised by digestion with XbaI and SpeI and religated, leaving an in frame 
“scar” of 18 nucleotides between the start and stop codons of novG. Out of scale. (D) 
Southern blot analysis of S. coelicolor M512 (lane 1), and M512-derived integration mutants 
bearing cosmid nov-BG1 (lane 2), or the novG- cosmid nov-AE10 (lane 3 and 4). M = DIG-
labeled DNA Molecular Weight Marker VII (Roche). Genomic DNA was digested with PstI. 
The DIG-labeled cosmid nov-BG1 was used as probe. The novG inactivation is confirmed by 
the 7.2 kb band (lane 3 and 4) instead of an 8.1 kb band (lane 2); otherwise the band pattern 
should be identical. 
For this purpose, novG was replaced by the apramycin resistance cassette from 
pUG019. The cassette was then removed by digestion with XbaI and SpeI, and 
subsequent religation of the outer ends lead to excision of the cassette (Fig. III.15C). 
The modified cosmid (named nov-AE10) was then introduced into S. coelicolor by 
protoplast transformation. Southern blot analysis confirmed the site  specific 
integration into the genome, and the deletion of novG was clearly shown by the 
smaller size of the relevant PstI restriction fragment in comparison to nov-BG1 strains 
(Fig. III.15D, lanes 2, 3 and 4). 
Analysis of secondary metabolites by HPLC showed that the resulting DnovG strains 
still produced novobiocin, which was identified by negative-ion FAB MS analysis in 
comparison to an authentic standard (molecular ion [M-H]-  at m/z 611; novobiocin, 
C31H36N2O11, has a molecular weight of 612). However, the amount of novobiocin 
produced by the DnovG mutants was reduced by 98% in comparison to S. coelicolor 
strains carrying the intact novobiocin cluster (Table III.5). 
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TABLE III.5: Effect of novG inactivation or expression on novobiocin production by 
recombinant S. coelicolor strains carrying the novobiocin cluster 
Novobiocin 
productiona 
Strain Expression  
plasmid 
mg/l (%) 
S. coelicolor M512 --- 0 0 
S. coelicolor(nov-BG1), complete cluster pWHM3 (empty vector) 20 100 
S. coelicolor(nov-AE10), DnovG pWHM3 (empty vector) 0.4 2 
S. coelicolor(nov-AE10), DnovG pAE-G2_1 (novG with 100 bp 
upstream sequence, opposite 
orientation to lacZa) 
0.4 2 
S. coelicolor(nov-AE10), DnovG pAE-G2_2 (novG with 100 bp 
upstream sequence) 
3 15 
S. coelicolor(nov-AE10), DnovG pAE8 (novG with 336 bp 
upstream sequence) 
16 79 
S. coelicolor(nov-BG1), complete cluster pAE-G2_2 (novG with 100 bp 
upstream sequence) 
38 190 
S. coelicolor(nov-BG1), complete cluster pAE8 (novG with 336 bp 
upstream sequence) 
54 270 
aValues are means from two to four independent mutants with two determinations each. 
 
III.6.1.3. Complementation of the novG mutation 
To prove that indeed the inactivation of novG was responsible for the low productivity 
of the DnovG strains, we attempted to complement one of these strains by 
expressing novG under control of its own promotor. For this purpose, we used a 
derivative of the promoterless, replicative shuttle vector pWHM3 (Vara et al., 1989), 
into which novG and 336 bp of the upstream DNA region (from the putative 
translational start point) was cloned, resulting in pAE8. 
Transformants of the DnovG strain carrying pAE8 produced on average 79% of the 
novobiocin amount accumulated by S. coelicolor strains bearing the intact novobiocin 
cluster (Table III.5). Therefore, complementation was successful, establishing that 
the low productivity of DnovG strains was due to lack of novG and not to possible 
polar effects of the deletion on downstream genes. 
Notably, a pWHM3 construct containing novG with only 100 bp of the upstream DNA 
region (termed pAE-G2_2) was much less effective in restoration of novobiocin 
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biosynthesis (Table III.5). If the orientation of its insert was reversed (i.e. placed 
against the lacZa orientation), the resulting plasmid pAE-G2_1 was completely 
unable to restore novobiocin production. Apparently, these constructs did not contain 
a functional promoter upstream of novG, and the low increase of productivity 
observed in pAE-G2_2 transformants may be due to a slight activity of the lacZa 
promoter in the Streptomyces host. 
III.6.1.4. Overexpression of novG in S. coelicolor(nov-BG1) leads to 
overproduction of novobiocin 
The results presented above indicate that NovG could act as a positive regulator in 
novobiocin biosynthesis. It has been reported that overexpression of pathway-
specific activators can lead to overproduction of the respective antibiotic (Gramajo et 
al., 1993; Stutzman-Engwall et al., 1992). Therefore, the multicopy plasmids pAE-
G2_2 and pAE8 were introduced into S. coelicolor(nov-BG1) by protoplast 
transformation. As presented in Table III.5, pAE-G2_2 led to 1.9-fold and pAE8 to 
2.7-fold increase in novobiocin biosynthesis in comparison to strains carrying only the 
empty vector pWHM3. 
III.6.1.5. Overexpression and purification of NovG as a His6 fusion protein 
For further investigation of the function of novG, its gene product was expressed as 
an N-terminal His6 fusion protein in E. coli (see Methods). When cultivating at 30 ºC 
and inducing with 1 mM IPTG for 5 h, most of the protein was insoluble. The amount 
of soluble protein did not improve significantly when the growth temperature was 
reduced to 15 ºC and the IPTG concentration to 0.25 mM. However, useful amounts 
of soluble protein could be obtained reproducibly when the induction period was 
shortened to only 1.5 h, using 0.5 mM IPTG at 30 ºC (see Methods). The His6 tagged 
NovG protein was purified from the soluble fraction by nickel affinity chromatography. 
SDS-PAGE analysis showed a band of about 40 kDa (calculated mass 38.1 kDa) in 
the eluate (Fig. III.16). The protein yield of purified NovG was about 15 µg/g cells 
(fresh weight), determined by SDS-PAGE. 
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Fig. III.16: Purification of NovG after overexpression as a fusion protein with a N-terminal 
His6 tag in E. coli BL21(DE3)pLysS. 
SDS/12% PAGE. Lane 1, soluble protein before induction; lane 2, soluble protein after 
induction with 0.5 mM IPTG for 1.5 h; lane 3, eluate from nickel affinity chromatography; M, 
molecular weight (MW) marker. The molecular weights (kDa) of the marker proteins are 
indicated. 
 
III.6.1.6. DNA-binding activity 
NovG may act as a positive regulator of novobiocin biosynthesis by binding at or near 
the promoter region of biosynthetic genes and thereby activating their transcription 
(see Introduction). In order to verify whether NovG has indeed DNA-binding activity, 
gel mobility-shift assays were carried out using the purified His6 tagged NovG and 
selected DNA fragments from the novobiocin biosynthetic gene cluster. 
In the novobiocin cluster, the intergenic regions between most genes are very short, 
and often the coding regions even overlap indicating a possible translational coupling  
(Steffensky et al., 2000b). Only six of the intergenic regions are larger than 70 bp (Fig. 
III.17A), and those we chosen for gel mobility-shift experiments, which are based on 
the differential mobility of free DNA and DNA-protein complexes in a gel matrix. As 
shown in Fig. III.17B, also DNA fragments extending into the coding sequences 
upstream of these intergenic regions were investigated. The NovG fusion protein 
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showed very clear binding activity for one of the two fragments obtained from the 
novG-novH intergenic region (Fig. III.17), but not for any other of the investigated ten 
DNA fragments. 
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Fig. III.17: Gel mobility-shift assays with DNA fragments from the novobiocin biosynthetic 
gene cluster. See next page for details. 
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(A) Schematic presentation of the novobiocin biosynthetic gene cluster. All intergenic regions 
larger than 70 bp are shown and their exact size is given. (B) Autoradiogram of gel mobility-
shift assays using purified His6 tagged NovG. The DNA-binding activity was analysed as 
described in the Methods section, using about 4 ng of the indicated DIG-end-labelled 
fragment and no protein (-) or 0.5 µg of purified His6 tagged NovG protein (+). A map 
showing the location of the DNA fragments used is indicated above each autoradiogram (out 
of scale, the intergenic regions are oversized in comparison to the ORFs). The fragments 
were obtained by digestion of appropriate plasmids or by PCR amplification (see Methods). 
For fragments obtained by digestion, restriction sites are indicated (P = PvuI, S = SalI, A = 
AvaI, V = Van91I, E = EcoRI, H = HindIII, B = BamHI, Sm = SmaI). 
 
The novobiocin and the clorobiocin clusters show very high similarity between each 
other. For most of the nov genes, orthologues exist in the clorobiocin cluster, which 
show 75-80% sequence identity to the genes of the novobiocin cluster on the amino 
acid level (Pojer et al., 2002). This is also the case for both novG and novH. However, 
in the novobiocin cluster the gene novH (coding for a biosynthetic enzyme (Chen and 
Walsh, 2001)) is situated directly downstream of the regulatory gene novG, whereas 
in the clorobiocin cluster their orthologues cloG and cloH are separated by a small 
open reading frame of unknown function, i.e. cloY. As shown in Fig. III.18, we tested 
whether NovG could also bind to the DNA regions upstream of cloY and/or cloH. 
Very clearly, NovG did bind to the DNA region upstream of cloY, but not to those 
upstream of cloH. 
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Fig. III.18: Gel mobility-shift assays with DNA fragments from the clorobiocin biosynthetic 
gene cluster. 
The fragments were obtained by digestion of pAE9 (fragment 1) or by PCR amplification from 
cosmid K1F2 (fragments 2 and 3, see Methods). N = NotI, M = MluI. See legend of Fig. III.17 
for further explanations. 
 
III.6.1.7. NovG binds specifically to the novG-novH and cloG-cloY intergenic 
regions 
To provide proof that binding of NovG to the novG-novH and cloG-cloY intergenic 
regions is specific, a gel mobility-shift assay was carried out in which a competitor 
plasmid containing the respective binding site was added in approximately 125-fold 
molar excess. As negative control, the same amount of empty vector was used. As 
shown in Fig. III.19, the presence of the specific competitor plasmid indeed strongly 
reduced the intensity of the band caused by the NovG-DNA complex, while the empty 
vector caused no significant effect. 
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Fig. III.19: Specifity of His6 tagged NovG binding to DNA. 
Approximately 4 ng of DIG-end-labelled fragment (novH: fragment 6 of Fig. III.17, cloY: 
fragment 1 of Fig. III.18) and no protein (-) or 0.5 µg purified His6 tagged NovG protein (+) 
were used in each lane for a standard DNA-binding assay (see Methods). When indicated (+), 
an additional 125-fold molar excess of specific competitor plasmid DNA (pAE7 or pAE9, 
respectively) or of the non-specific empty vector-DNA (pBluescript SK(-) or pSPORT1, 
respectively) was added. 
 
III.6.1.8. In silico analysis of the NovG binding DNA fragments 
When the DNA sequences of the novG-novH and cloG-cloY intergenic regions were 
compared, similar palindromic structures could be found in both fragments (Fig. 
III.20). Notably, similar inverted repeats were identified as the binding site for StrR by 
DNase I footprinting assay (Retzlaff and Distler, 1995). The putative NovG-binding 
sites and the StrR-binding sites all possess a conserved palindromic structure with 
the consensus sequence GTTCRACTG(N)11CRGTYGAAC. 
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putative NovG binding site (novH) CTGACGTTCAACTGCTCGAATCATTCGGTTGAACACCA 
putative NovG binding site (cloY) GGGAT GTTCAACTGCTCGAACCATACGGTTGAACATGG 
StrR binding site (consensus sequence)           GTTCGACTGNNNNNNNNNNNCAG TCGAAC 
Consensus sequence              GTTCRACTGNNNNNNNNNNNCRG TYGAAC 
 
Fig. III.20: Sequences of putative NovG-binding sites of S. spheroides (upstream of novH) 
and S. roseochromogenes (upstream of cloY) in comparison to the consensus sequence of 
StrR-binding sites of S. griseus and S. glaucescens (see (Retzlaff and Distler, 1995)). 
Nucleotides conserved in at least two of the sequences are written in bold. Nucleotides 
conserved in all three sequences are underlined. The inverted repeats are indicated with 
arrows. A putative consensus sequence for NovG- and StrR-binding sites is indicated. 
 
III.6.2.  Inactivation of novE in S. spheroides 
novE, cloE and couE show, on average, 82% sequence identity with each other on 
the amino acid level. The predicted gene product of novE comprises 217 amino acids 
and shows 45% identity to the gene product of lmbU of the lincomycin biosynthetic 
gene cluster. Lincomycin, like the aminocoumarin moiety of novobiocin, is formed 
from tyrosine, but the reaction sequence is unknown. Peschke et al. (1995) 
speculated that lmbU may encode a regulatory protein, but a catalytic function for 
LmbU could not be excluded. 
novE contains the rare TTA leucine codon (as codon 189) which may represent an 
indication for a regulatory role of NovE in novobiocin biosynthesis, since most of the 
known TTA-containing genes specify regulatory or resistance proteins associated 
with biosynthetic gene clusters for antibiotics (Leskiw et al., 1991). 
In order to gain more insights into the role of novE in novobiocin biosynthesis, it was 
inactivated in S. spheroides NCIMB 11891. Within cosmid 10-9C, which contained 
the biosynthetic gene cluster of novobiocin in the SuperCos1 vector (KanR), novE 
was replaced by an apramycin resistance/oriT cassette using the PCR targeting 
system (Gust et al., 2003). The modified cosmid (named 10-9C-E-773, = E1) was 
then introduced into S. spheroides by conjugation. Apramycin-resistant, kanamycin-
sensitive colonies, resulting from double crossover events, were selected. Southern 
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blot analysis confirmed that in these mutants novE was replaced by the ApraR/oriT 
cassette (Fig. III.21). 
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Fig. III.21: Inactivation of novE of the novobiocin biosynthetic gene cluster. 
(A) Schematic presentation of the gene inactivation experiment. The DNA fragment used as 
probe is indicated as a black bar. aac(3)IV: apramycin resistance gene; Paac: promoter of 
the apramycin resistance gene; FRT: FLP recognition target; oriT: origin of transfer from RK2; 
neo: kanamycin resistance gene. (B) Southern blot analysis of wild-type and mutants. 
Genomic DNA was restricted by BamHI. M: DIG-labeled DNA Molecular Weight Marker VII 
(Roche); WT: S. spheroides wild-type; 1-3: novE mutants (strains S. spheroides AE-E2, AE-
E3, and AE-E4). 
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The secondary product formation of three independent novE mutants (named AE-E2, 
AE-E3, and AE-E4) and the wild-type strain of S. spheroides were analysed by HPLC. 
All three mutants, as well as the wild-type strain, produced novobiocin, which was 
identified by 1H NMR and negative-ion FAB MS analysis in comparison to an 
authentic standard. However, the level of production in the mutants was significantly 
lower than in the wild -type (average 1.5 mg/l in the mutants, compared to 37 mg/l in 
the wild-type). This finding rules out the possibility that NovE has an essential 
catalytic function. Rather, NovE may act as a positive regulator in novobiocin 
biosynthesis.
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IV. DISCUSSION 
IV.1. Clorobiocin biosynthesis in S. roseochromogenes: 
Identification of the halogenase and generation of structural 
analogues 
The results presented in this thesis demonstrate that the gene clo-hal is responsible 
for halogenation of position 8 of the aminocoumarin ring of clorobiocin, while novO is 
responsible for methylation of the corresponding position of novobiocin. cloZ is not 
involved in the halogenation, nor is it essential for clorobiocin biosynthesis under the 
present culture conditions. 
The clo-hal gene product is responsible for the introduction of the halogen atom of 
clorobiocin. The mechanism of halogenation reactions, which are involved in the 
biosynthesis of at least 3000 natural halometabolites (Gribble, 1998), is not yet 
completely understood. Clo-hal shows sequence similarity to the recently discovered 
class of FADH2-dependent halogenases (van Pée, 2001), such as are involved in the 
biosynthesis of chlortetracycline  (Dairi et al., 1995), the glycopeptide antibiotic 
balhimycin (Puk et al., 2002), and pyoluteorin (Nowak-Thompson et al., 1999). It has 
been speculated that the reactions catalysed by these enzymes may proceed via an 
epoxide intermediate (van Pée, 2001). In vitro, these enzymes require the presence 
of an unspecific flavin reductase generating FADH2. This reductase appears not to be 
encoded within the gene clusters of the above mentioned secondary metabolites, 
similar to the finding for the clorobiocin cluster (Pojer et al., 2002). The functional 
identification of clo-hal reinforces the importance of this new class of halogenases for 
natural product biosynthesis. 
Moreover, expression of novO from the novobiocin cluster in the clo-hal- mutant led 
to the very efficient formation of an 8 -´methylated compound, i.e. novclobiocin 102. 
Together with the previously published inactivation of the very similar gene couO 
from the coumermycin cluster (Li et al., 2002), this result provides conclusive 
evidence that NovO and CouO catalyse the C-methylation reaction in the 
biosynthesis of the aminocoumarin rings of novobiocin and coumermycin. 
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It is not clear at present at which step of aminocoumarin biosynthesis the methylation 
or halogenation reactions takes place. For novobiocin biosynthesis, Chen and Walsh 
(Chen and Walsh, 2001) provided evidence that the methylation occurs after 
activation of tyrosine, which is the first step in aminocoumarin formation (Fig. I.4), and 
an inactivation experiment by Steffensky et al. (Steffensky et al., 2000b) 
demonstrated that methylation takes place before glycosylation of novobiocic acid. In 
any case, for the assembly of the entire novobiocin or clorobiocin molecule, several 
enzymatic steps are required to take place after the methylation or halogenation, 
respectively (Fig. I.4). It is remarkable that the yields of novclobiocin 101 (8´-H), 
produced by the clo-hal- mutant, and 102 (8´-CH3), produced by the clo-hal- mutant 
expressing novO, were at least as high as that of clorobiocin (8´-Cl) in the wild-type. 
This indicates a low specificity of the subsequent biosynthetic enzymes for the 
substituent at the 8´ position, a very useful feature for the development of new 
aminocoumarin antibiotics by genetic approaches. 
In the present study, this allowed the production of the two clorobiocin analogues 
mentioned above, and a first comparison of these compounds with clorobiocin 
regarding their antibacterial activity (see IV.4). 
Moreover, with some modifications of the conjugation procedure (see Methods), the 
PCR targeting system could be used successfully in S. roseochromogenes, allowing 
gene inactivation experiments to be carried out much more simply and quickly than 
by previous methods (Kieser et al., 2000). The modified cosmid can be introduced in 
Streptomyces by conjugation from E. coli, which represents usually a more efficient 
method than transformation, since restriction barriers may be reduced by the transfer 
of single-stranded concatemers of DNA (Kieser et al., 2000). Furthermore, by using 
the cosmid as vector, the flanking DNA region of the inactivated allele is much bigger 
than 1 kb (e.g. for clo-hal about 20 kb on either side). Since the frequency of 
homologous recombination is proportional to the lengths of the DNA fragments used 
(Kieser et al., 2000), the frequency of desired double crossover events is also 
proportionally higher. Indeed, by omitting the selection for the vector backbone (in 
this case, by overlaying the conjugation plates only with apramycin), colonies 
carrying the desired double crossover events grew already on these plates, making 
time-consuming non-selective growth and screenings unnecessary. 
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IV.2. Heterologous expression of the novobiocin and clorobiocin 
gene clusters 
The expression of biosynthetic genes in heterologous hosts which are more 
amenable for genetic manipulation can be used to circumvent the challenge 
associated with developing suitable protocols for the genetic manipulation of natural 
producers (Eppelmann et al., 2001; Sánchez et al., 2002; Tang et al., 2000). 
Furthermore, the successful heterologous expression of a biosynthetic cluster proves 
that all genes essential for antibiotic biosynthesis are included in that cluster. In this 
study, the clusters for novobiocin and clorobiocin were expressed in S. coelicolor and 
S. lividans, phylogenetically very near species which have been extensively studied 
and for which well established genetic tools are available  (Kieser et al., 2000). 
The complete genome sequence of strain M145 of S. coelicolor has been published 
(Bentley et al., 2002). S. coelicolor M145 is able to produce three antibiotics, i.e. 
prodiginines, actinorhodin and calcium-dependent antibiotic (CDA). To avoid 
interference in the chemical and biological analysis of antibiotic formation, the 
novobiocin and clorobiocin biosynthetic gene clusters were expressed in S. coelicolor 
M512, which is derived from M145 but which is unable to produce prodiginines and 
actinorhodin, since the activator genes redD and actIIORF4 were deleted in this 
strain (Floriano and Bibb, 1996). For the heterologous expression of clorobiocin, a 
prodiginine-deficient strain offers the additional advantage that any competition for 
proline or proline derivatives, which are precursors of both prodiginines and 
clorobiocin (Thomas et al., 2002), is avoided. 
Historically, S. lividans has been distinguished phenotypically from S. coelicolor by 
the inability of the former to normally produce actinorhodin, which lends the 
characteristic blue color of S. coelicolor colonies responsible for its name. Yet, a 
functional biosynthetic actinorhodin gene  cluster is present in S. lividans, suggesting 
different regulation of the onset of secondary metabolism in the two species (Kim et 
al., 2001; Shima et al., 1996). Kim et al. (2001) reported that actinorhodin 
biosynthesis in S. lividans is repressed by glucose in the media and that a change of 
the carbon source (glycerol instead of glucose) promotes production of the antibiotic. 
Furthermore, a strain of S. lividans, TK24 (str-6, SLP1-, SLP2-), was found to produce 
actinorhodin under “normal” culture conditions (which are described for S. coelicolor), 
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while the parental strain TK21 (SLP1-, SLP2-) and the wild-type isolate, strain 66, do 
not. It has been suggested that the streptomycin-resistant mutation str-6 
(representing a point mutation in the rpsL gene encoding ribosomal protein S12, 
changing Lys-88 to Glu) may be responsible for induction of antibiotic synthesis 
(Shima et al., 1996). Shima et al. (1996) proposed that this mutation leads to a 
change in the ribosomal structure which may give rise to initiation of the onset of 
secondary metabolism (by an unknown mechanism). 
Therefore, to test S. lividans as host, strain TK24 was chosen. However, S. coelicolor 
M512 showed at least five times higher productivity than S. lividans TK24 (Table III.3), 
under the present culture conditions, and was therefore used for subsequent 
experiments. 
Since heterologous expression of cosmid clo-AE2 (Fig. III.7) led to significant 
production of clorobiocin, it could be proven, for the first time, that the DNA region 
from cloE to gyrBR contains all genes necessary for clorobiocin production. This 
finding is of special interest since no candidate gene has been identified which may 
code for the enzyme responsible for the introduction of the ring oxygen of the 
coumarin moiety of the aminocoumarin antibiotics (see also Introduction) (Chen and 
Walsh, 2001; Eustáquio et al., 2003b; Holzenkämpfer and Zeeck, 2002). Unless this 
oxygenation is carried out by primary metabolic enzymes of S. coelicolor (a rather 
unlikely scenario), this catalytic function will have to be identified in one of the 
proteins encoded in cosmid clo-AE2. 
The principal resistance gene of the novobiocin producer S. spheroides is gyrBR, 
encoding for an aminocoumarin-resistant gyrase B subunit (Schmutz et al., 2003a; 
Schmutz et al., 2004; Thiara and Cundliffe, 1988). Since this gene is contained within 
the novobiocin cluster (Fig. III.6), the S. coelicolor mutants generated in this study 
were able to tolerate the accumulation of the antibiotic.  
The clorobiocin producer S. roseochromogenes contains, besides gyrBR, an 
additional resistance gene, parYR, which encodes an aminocoumarin-resistant 
topoisomerase IV subunit (Schmutz et al., 2003a; Schmutz et al., 2004). Only 123 bp 
of the 2.1 kb parYR gene were contained in the cosmids clo-BG1 and clo-AE2 (Fig. 
III.7). Nevertheless, clorobiocin was produced in good yield by the mutants 
expressing these cosmids, consistent with the previous finding that gyrBR alone is 
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sufficient to provide resistance against aminocoumarin antibiotics (Schmutz et al., 
2003a). 
Vectors containing the integrase gene and the attP site of fC31 can integrate not 
only as a single copy, but also in tandem (Combes et al., 2002). Tandem integration 
of cosmids was observed in approximately 90% of all integration mutants obtained in 
this study, as identified in Southern blot analysis by a hybridizing fragment containing 
the unchanged attP site (e.g. 3.9 kb in Fig. III.6C). This 3.9 kb band may in principle 
also indicate the presence of the cosmid as covalently closed circular DNA. However, 
since the SuperCos1-derived cosmids are non-replicative in Streptomyces, their 
presence after extended sub-culturing is unlikely. Mutants with tandem integration 
showed somewhat higher antibiotic production than mutants with single copy 
integration, but the difference, and the number of available strains, was not large 
enough to draw unequivocal conclusions. 
In contrast, the 16-fold higher productivity of strains bearing cosmid nov-AE6, 
compared to strains harboring nov-AE4 (Table III.3 and Fig. III.6) was observed in 
more than ten independent mutants each and clearly proves that the DNA sequence 
from ORF20 to novD contains elements required for a high novobiocin production. 
The gene novA which codes for an ABC transporter may be responsible for this effect. 
Alternatively, two other hypotheses could explain this finding. First, genes between 
ORF20 and novD could have a regulatory function. Second, even though the used 
cosmid contained all intergenic region between novD and novE (180 bp), it is 
possible that it does not include all necessary regulatory regions for the normal 
transcription of novE, which likely codes for a positive regulator in novobiocin 
biosynthesis (see IV.6.2), leading to the drop in novobiocin production. Further 
experiments are necessary to identify which part of the sequence between ORF20 
and novD is responsible for the observed effect. 
 
IV.3. Production of 8´-halogenated and 8 -´unsubstituted novobiocin 
derivatives in genetically engineered S. coelicolor strains 
In this study, a strategy was developed for the production of a hybrid antibiotic, 
novclobiocin 114, which carries a chlorine atom instead of a methyl group at position 
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8´ of the aminocoumarin unit of novobiocin. This compound could not be produced by 
gene inactivation and heterologous gene expression experiments in the novobiocin 
producer S. spheroides, because of difficulties in the genetic manipulation of this 
strain (Pojer and Heide, unpublished results). Yet, through heterologous expression 
of the entire novobiocin biosynthetic gene cluster in S. coelicolor, novobiocin and, 
after appropriate modification of the cluster, both the 8 -´H compound (novclobiocin 
117) and the 8´ -Cl compound (novclobiocin 114) were readily obtained from the 
resulting strains. 
An accumulation of truncated intermediates, lacking the deoxysugar moiety, was 
observed in mutants carrying modified biosynthetic pathways, i.e. in the novO- mutant 
(Fig. III.11C), and in the novO- mutant complemented with clo-hal (Fig. III.11D). This 
may indicate that the remaining biosynthetic machinery does not accept the modified 
substrates as efficiently as the genuine intermediates. Notably, this was not the case 
for modified clorobiocin pathways (see III.1 and III.2). 
The development of suitable protocols for the genetic manipulation of Streptomyces 
strains which produce useful antibiotics is time-consuming and often, e.g. for the 
novobiocin producer S. spheroides, gives unsatisfactory results. This problem 
presents a severe limitation for basic research on microbial secondary metabolism 
and for drug discovery programs from streptomycetes. 
The modification of cosmids in E. coli followed by heterologous expression of the 
modified cosmid in the well-studied S. coelicolor offers an alternative approach of 
unprecedented speed and versatility in comparison to the manipulation of natural 
producers. It may also allow the exploitation of biosynthetic gene clusters from 
organisms which are difficult to cultivate, using heterologous expression in culturable 
hosts. 
 
IV.4. Structure-activity relationships 
Structurally, clorobiocin differs from novobiocin in the substitution at C-8´ of the 
aminocoumarin ring and at the C-3´´ of the deoxysugar moiety (Fig. I.5). Clorobiocin 
has been reported to show a six times higher antibacterial activity than novobiocin in 
 IV. DISCUSSION 134 
vitro (Hooper et al., 1982), and to bind more efficiently to isolated gyrase (Lafitte et al., 
2002; Lewis et al., 1996a; Tsai et al., 1997). Most authors have attributed the higher 
activity of clorobiocin primarily to the pyrrole moiety at C-3´´ (Berger and Batcho, 
1978; Tsai et al., 1997). Interestingly, however, clorobiocic acid (Fig. I.4), but not 
novobiocic acid, was found to inhibit both DNA synthesis in vivo and gyrase activity in 
vitro (Althaus et al., 1988; Reusser and Dolak, 1986), suggesting that the chlorine 
atom makes an important contribution to the biological activity of this molecule.  
The substances produced in this study (novobiocin and clorobiocin analogs with –
CH3, –H, or –Cl at C-8´) will allow a detailed investigation of the structure-activity 
relationships of such aminocoumarin compounds, using both antibacterial assays 
and in vitro investigations with purified gyrase. In a first comparison using a bioassay 
with Bacillus subtilis (Fig. III.5), clorobiocin (8´-Cl) was twice as active as novclobiocin 
102 (8´-CH3), and eight times more active than novclobiocin 101 (8 -´H); whereas Fig. 
III.12 shows that novobiocin (8 -´CH3) was twice as active as novclobiocin 114 (8´-Cl), 
and 25 times more active than novclobiocin 117 (8´-H). Therefore, in both cases, 
substitution at C-8´ with either –Cl or –CH3 was important for biological activity; –CH3 
or –Cl leading to comparable activity, and –H causing eight- to 25-fold loss in activity. 
Notably, the difference between substitution with –CH3 or –Cl, though moderate, 
depended upon the compound being a novobiocin or a clorobiocin derivative, i.e. 
depended upon the substitution at 3´ -´OH of the deoxysugar. Further experiments 
are necessary to identify the cause for this observation. 
As reported for clorobiocin derivatives (Galm et al., 2004b), the transfer of the acyl 
group from 3´´-OH to 2´´-OH resulted in a reduction but not in a complete loss of 
activity: novclobiocin 119 still showed approximately 20% of the activity of 
novclobiocin 114. In contrast, the removal of the deoxysugar moiety and the 8´-
substituent (= novclobiocic acid 106) resulted in 99% loss of activity. These results 
are in accordance with X-ray data, which showed that the carbamoyl group of 
novobiocin forms important hydrogen bonds with E. coli GyrB (directly with Ala47 and 
Asp73 and through ordered water molecules to different residues) (Lewis et al., 
1996a). Lewis et al.  (1996a) speculated that the reduced affinity of isonovobiocin (in 
which the carbamoyl group is presented at 2´´-OH instead of 3´´-OH of the 
deoxysugar) to gyrase is probably a consequence of steric clashes. In addition to 
further hydrogen bonding network (involving the 2´ -´OH and the 4´ -´OCH3), there are 
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a number of hydrophobic contacts between gyrase and the deoxysugar, which 
explains the importance of this moiety for activity. Yet, the substituted deoxysugar 
alone has shown no antibacterial or anti-gyrase activity (Althaus et al., 1988), 
showing also the relevance of the aminocoumarin unit (which forms two hydrogen 
bonds with Arg136) (Lewis et al., 1996a) and of the 3-dimethyl-allyl-4-
hydroxybenzoate moiety (Galm et al., 2004b) for activity. 
 
IV.5. Are the halogenases of clorobiocin and balhimycin 
biosynthesis interchangeable? 
The aminocoumarin antibiotic clorobiocin and the glycopeptide antibiotic balhimycin 
both contain 3-chloro-b-hydroxy-tyrosyl-derived moieties, and the biosynthesis of 
these moieties show striking similarities (see Fig. III.13). It is not clear at present at 
which step of clorobiocin biosynthesis the halogenation reaction takes place. In 
novobiocin biosynthesis, the methylation at C-8´ (corresponding to the chlorination at 
C-8´ in clorobiocin biosynthesis) occurs only after activation of tyrosine (Fig. III.13) 
(Chen and Walsh, 2001), and before glycosylation of novobiocic acid  (Steffensky et 
al., 2000b). Possible substrates of Clo-hal include therefore b-hydroxy-tyrosyl-CloH, 
3-amino-4,7-dihydroxycoumarin, and the amide of this aminocoumarin unit with 3-
dimethylallyl-4-hydroxybenzoic acid. 
Likewise, the substrate of the halogenase BhaA of balhimycin biosynthesis is still 
elusive. Possible candidates are tyrosine, b-hydroxytyrosine in either free or enzyme-
bound form, or substrates derived from later stages of peptide assembly (Süssmuth 
and Wohlleben, 2004). 
The present study clearly showed that BhaA was unable to functionally replace Clo-
hal. The structural genes for both halogenases have been cloned into the same 
expression vector, which contains the constitutive promoter ermE*. Furthermore, the 
identical bhaA gene under control of this promoter has been used successfully for 
complementation of a bhaA-defective mutant (Puk et al., 2002). However, only 
expression of clo-hal resulted in the formation of halogenated aminocoumarins in this 
thesis. 
 IV. DISCUSSION 136 
To date, three different halogenating enzymes are known: haloperoxidases, 
perhydrolases and FADH2-dependent halogenases. Clo-hal and BhaA shows 
sequence similarity to the recently discovered class of FADH2-dependent 
halogenases, which in contrast to haloperoxidases and perhydrolases show 
substrate specificity and regioselectivity. The mechanism of halogenation catalyzed 
by FADH2-dependent halogenases is not yet completely understood (see also IV.1). 
In vitro, these enzymes require the presence of an unspecific flavin reductase 
generating FADH2 (van Pée, 2001). Recently, the co-crystallization of tryptophan 7-
halogenase with tryptophan and FAD was described, representing an important step 
towards understanding the reaction mechanism of such enzymes (Dong et al., 2004). 
Therefore, the inability of BhaA to functionally replace Clo -hal is unlikely to result 
from the specificity of the flavin reductase. Rather, the results presented here 
suggest that the genuine substrates for the halogenation reactions catalyzed by 
BhaA and Clo-hal are different. This is in accordance with recent evidence showing 
that in balhimycin biosynthesis halogenation apparently takes place during the 
formation of the oligopeptide backbone (Puk et al., 2004). 
 
IV.6. Regulation of novobiocin biosynthesis 
IV.6.1.  NovG, a positive regulator of novobiocin biosynthesis 
The present work provides experimental proof for the function of NovG as a DNA-
binding protein which acts as a positive regulator of novobiocin biosynthesis. 
Inactivation of novG led to a 98% reduction of the novobiocin productivity of the 
heterologous producer strain. Since DnovG strains still produced some novobiocin, a 
catalytic role for novG can be ruled out. By complementation with novG under control 
of its own promoter, the novobiocin production could be restored nearly to the same 
level as observed before novG inactivation, indicating that the observed phenotype of 
DnovG strains was indeed caused by lack of novG. 
Expression of novG from a multicopy plasmid in a S. coelicolor strain carrying the 
intact novobiocin cluster led to almost three-fold overproduction of the antibiotic, 
suggesting that novobiocin biosynthesis in the investigated heterologous expression 
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host is limited by the availability of enough of the activator protein, as has been 
shown for other pathway-specific activators in the respective natural antibiotic 
producers (Gramajo et al., 1993; Stutzman-Engwall et al., 1992). 
Furthermore, it was demonstrated that His6 tagged NovG protein binds specifically to 
the novG-novH intergenic region and, in so doing, probably activates the transcription 
of novH, just as described for StrR which activates transcription of streptomycin 
biosynthetic genes by binding to their promoter regions (Retzlaff and Distler, 1995). 
The putative binding site of NovG is located directly downstream of the translational 
stop codon of novG, i.e. between positions -165 and -194 upstream of the putative 
translational start codon of novH. Since nickel affinity purified protein, generated in E. 
coli, was used for the DNA-binding assays, it is very likely that NovG can bind to DNA 
with no further macromolecular factor involved. However, our results do not 
completely rule out the possibility that other proteins may be required for activating 
the transcription of novH. 
The novobiocin and the clorobiocin clusters show very high similarity between each 
other. Indeed, NovG could also bind to a DNA region of the clorobiocin cluster, i.e. 
the cloG-cloY intergenic region; the putative binding site is located between positions 
-160 and -189 upstream of the putative translational start of cloY. The function of the 
small ORF cloY remains to be elucidated. Genes with obvious similarity to cloY have 
been found in many other clusters, such as those for coumermycin A1 (Wang et al., 
2000), teicoplanin (Sosio et al., 2004), complestatin (Chiu et al., 2001), CDA (Hojati 
et al., 2002), and balhimycin (Pelzer et al., 1999), but not in the novobiocin cluster. 
The in silico analysis of the DNA fragments from the novobiocin and the clorobiocin 
cluster which bind NovG showed the presence of a perfectly conserved 9 bp inverted 
repeat, separated by a somewhat less conserved (two mismatches) 11 bp spacer 
sequence (Fig. III.20). Notably, the previously identified StrR binding sites in S. 
griseus and S. glaucescens contain a similar palindromic structure, i.e. conserved 
inverted repeats of 9 bp each separated by a non-conserved 11 bp spacer (Retzlaff 
and Distler, 1995). The same putati ve NovG binding site, with exactly the same 
inverted repeat and spacer sequences as found upstream of cloY, is also present in 
the coumermycin A1 cluster, in between of the genes couG and couY. The strict 
similarity of the putative NovG/CloG/CouG binding sites in the novobiocin, clorobiocin 
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and coumermycin A1 clusters further indicates a common evolutionary origin for 
these clusters (Eustáquio et al., 2003b). 
The consensus sequence GTTCRACTG(N)11CRGTYGAAC could be found nowhere 
else  in the gene clusters of novobiocin or clorobiocin except in the mentioned 
regions upstream of novH and cloY, respectively. This is in accordance with the 
experimental results of the gel shift assays with the novobiocin cluster depicted in 
Fig. III.17. In contrast, four StrR binding sites had been identified in the streptomycin 
biosynthetic gene cluster in Streptomyces griseus, and three in the 5´-OH-
streptomycin cluster in S. glaucescens (Retzlaff and Distler, 1995). Comparatively, it 
cannot be completely excluded that NovG may also bind to additional sequences 
which are different from the motif shown above. However, the possibility should also 
be considered that only a single transcription unit is expressed under control of novG. 
In the novobiocin and clorobiocin clusters, all genes are orientated in the same 
direction, and may in principle be transcribed as a single mRNA from novH to novW 
or from cloY to cloZ, respectively. In contrast, previous results suggest that the 
resistance gene gyrBR, at the right border of the cluster depicted in Fig. III.17, is 
under control of its own promoter and may be regulated by changes in DNA 
superhelical density (Thiara and Cundliffe, 1989). NovG was not required for 
expression of gyrBR in S. lividans (Thiara and Cundliffe, 1988), and correspondingly 
binding of NovG to the promoter sequence of gyrBR was not observed in the gel shift 
assays. 
Analysis of different gene clusters encoding biosynthetic pathways for antibiotics has 
revealed the existence of distinct families of pathway-specific regulatory proteins. 
One of these families comprises the strR-like genes and includes, besides novG, 
cloG and couG, also dbv4 of the glycopeptide antibiotic A40926 (Sosio et al., 2003), 
bbr of the balhimycin (Pelzer et al., 1999), and tcp28 of the teicoplanin (Sosio et al., 
2004) cluster. Another family comprises the SARPs, i.e. ActII-ORF4 and DnrI (see 
Introduction) and SnoA of the nogalamycin, RedD of the undecylprodigiosin, and 
CcaR of the cephamycin cluster, respectively (Wietzorrek and Bibb, 1997). However, 
no genes with sequence similarity to this family have been found in the gene clusters 
of the aminocoumarin antibiotics. 
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An understanding of the complex regulatory mechanisms that determine the onset of 
antibiotic biosynthesis in actinomycetes is only just beginning to emerge (Wietzorrek 
and Bibb, 1997). Activation of any particular pathway of any particular organism 
might be expected to require its own combination of signals  (Chater and Bibb, 1997). 
Therefore, analysis of regulatory genes from different species is crucial to build a 
comprehensive picture of these processes. 
The aminocoumarin antibiotics may provide useful model systems for such studies, 
due to their very stringent genetic organization (Pojer et al., 2002) and due to the 
availability  of detailed data on the function of most genes contained therein. The fact 
that they can be successfully expressed in Streptomyces coelicolor, the genome 
sequence of which is available (Bentley et al., 2002), makes them even more 
attractive for investigating the regulation cascades for improved antibiotic production 
in streptomycetes. 
 
IV.6.2.  Inactivation of novE in S. spheroides 
In this study, it was shown that novE- mutants of S. spheroides are still able to 
produce novobiocin, although in significantly lower amounts in comparison to the 
wild-type. 
This finding rules out the possibility that NovE has an essential catalytic function. 
Rather, NovE may act as a positive regulator in novobiocin biosynthesis. This 
hypothesis is supported by the presence of a TTA codon in novE. Many of the known 
TTA-containing genes specify regulatory or resistance proteins associated with 
biosynthetic gene clusters for antibiotics (Leskiw et al., 1991). 
Since novE was inactivated by replacement with a resistance cassette , it cannot be 
excluded that the observed down-regulation of novobiocin biosynthesis was due to 
polar effects, i.e. the transcription of downstream genes could be affected by the 
presence of the resistance marker. However, such effects were not observed during 
inactivation of clo-hal and cloZ using the same cassette. Yet, complementation 
experiments are necessary to confirm that the observed phenotype is only dependent 
on the absence of novE. 
 IV. DISCUSSION 140 
Indeed, it was attempted to complement the novE- mutant by expressing an intact 
copy of novE using plasmid pAE-E4 (a multi-copy plasmid, see Table II.15). Such 
experiments were however unsuccessful, due to difficulties in the genetic 
manipulation of S. spheroides, i.e. the presence of the plasmid in potential 
transformants could not be demonstrated. 
If S. spheroides is so difficult to manipulate, how could a novE- mutant be at all 
constructed? There are several answers: (1) the PCR targeting method developed by 
Gust et al. (2003) allows gene inactivation experiments to be carried out much more 
simply and efficiently than by previous methods; (2) the modified cosmid can be 
introduced in Streptomyces by conjugation from E. coli, which represents usually a 
more efficient method than transformation, since restriction barriers may be reduced 
by the transfer of single-stranded concatemers of DNA (Kieser et al., 2000); (3) yet 
the efficiency for S. spheroides was very low and poorly reproducible (only six ex-
conjugants were obtained in one of several experiments). 
Further experiments are necessary to determine a  possible role for novE in the 
regulation of novobiocin biosynthesis.The successful heterologous expression of the 
novobiocin cluster in S. coelicolor reported here offers a much simpler and easier 
way for functional investigation of biosynthetic genes and may help reaching this goal.  
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